var title_f38_26_39328="Potential symptoms and signs of anaphylaxis during pregnancy";
var content_f38_26_39328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F87183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F87183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential symptoms and signs of anaphylaxis during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Potential symptoms and signs of anaphylaxis during pregnancy. Sudden onset of multisystem symptoms and signs is characteristic; most symptoms and signs are similar to those in nonpregnant patients with anaphylaxis. Itching in the vulvar/vaginal areas, low back pain, uterine cramps, fetal distress, and preterm labor can occur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Simons FER, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39328=[""].join("\n");
var outline_f38_26_39328=null;
var title_f38_26_39329="Pap test liquid-based";
var content_f38_26_39329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liquid-based cervical cytology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Obtaining endocervical portion of Pap test. B) Placement of specimens in liquid collection medium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beckmann CRB, Ling FW, Barzansky BM, et al. Obstetrics and Gynecology, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy;2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39329=[""].join("\n");
var outline_f38_26_39329=null;
var title_f38_26_39330="Patient information: Clavicle fracture (The Basics)";
var content_f38_26_39330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82809\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/19/6453\">",
"         Clavicle (collarbone)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Clavicle fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/clavicle-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12160762\">",
"      <span class=\"h1\">",
"       What is a clavicle fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A &ldquo;fracture&rdquo; is another word for a broken bone. The clavicle, also called the &ldquo;collarbone,&rdquo; connects the breastbone to the shoulder blade (",
"      <a class=\"graphic graphic_figure graphicRef82791 \" href=\"mobipreview.htm?6/19/6453\">",
"       figure 1",
"      </a>",
"      ). A clavicle fracture is when a person breaks their clavicle.",
"     </p>",
"     <p>",
"      There are different types of clavicle fractures. The type of fracture depends on the part of the clavicle that breaks and how it breaks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160777\">",
"      <span class=\"h1\">",
"       What are the symptoms of a clavicle fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a clavicle fracture can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the area of the clavicle, especially when moving the arm",
"       </li>",
"       <li>",
"        Swelling over the injured area",
"       </li>",
"       <li>",
"        Bruising over the injured area",
"       </li>",
"       <li>",
"        Feeling the bone snap or crack (when the fracture happens)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A clavicle fracture can also make the clavicle look like it&rsquo;s out of position or crooked.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160792\">",
"      <span class=\"h1\">",
"       Is there a test for a clavicle fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your injury and symptoms, do an exam, and order an X-ray.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160807\">",
"      <span class=\"h1\">",
"       How are clavicle fractures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of clavicle fracture you have and how severe it is.",
"     </p>",
"     <p>",
"      Your doctor will treat your pain. If you have a lot of pain or a severe fracture, he or she will prescribe a strong pain medicine. If you have a mild fracture, he or she will recommend that you take an over-the-counter medicine for your pain. Over-the counter medicines include",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      Severe clavicle fractures are treated with surgery. During surgery, the doctor will put the clavicle back in the correct position.",
"     </p>",
"     <p>",
"      Clavicle fractures that are not severe are usually treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Ice &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. You should put a thin towel between the ice (or other cold object) and your skin. You should use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"       <li>",
"        A sling or bandage &ndash; The main part of treatment involves keeping your clavicle from moving too much so that your fracture can heal. To hold your clavicle in place, your doctor will probably recommend that you wear a sling. A sling holds the arm bent and close to the body. Some people might wear a bandage that goes around the shoulders and upper back instead of a sling.",
"        <br/>",
"        <br/>",
"        The main downside of wearing a sling is that it keeps you from using your shoulder, elbow, and arm. Not using these parts of the body can make them stiff or weak. To prevent these problems, your doctor will show you exercises and stretches to do. He or she will tell you when to start them and how often to do them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your fracture heals, your doctor might recommend that you work with a physical therapist (exercise expert). He or she can show you other exercises and stretches for your shoulder, elbow, and arm.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160822\">",
"      <span class=\"h1\">",
"       How long do clavicle fractures take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Clavicle fractures take weeks to months to heal, depending on the type of fracture.",
"     </p>",
"     <p>",
"      Healing time also depends on the person. Healthy children usually heal much more quickly than older adults or adults with other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160837\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your clavicle fracture is healing. He or she will probably recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid certain activities.",
"       </li>",
"       <li>",
"        Eat a healthy diet that includes getting enough calcium, vitamin D, and protein (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"mobipreview.htm?18/13/18647\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Stop smoking. A fracture can take longer to heal if you smoke.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160852\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call him or her if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have severe pain, or your pain or swelling gets worse.",
"       </li>",
"       <li>",
"        You have numbness or tingling in your fingers, or your fingers look blue or purple.",
"       </li>",
"       <li>",
"        You have weakness or swelling in the hand or arm.",
"       </li>",
"       <li>",
"        Pus drains from the injury.",
"       </li>",
"       <li>",
"        The skin around the injury changes color, is irritated and thin, or is raised up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12160867\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/26/39330?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82809 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39330=[""].join("\n");
var outline_f38_26_39330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160762\">",
"      What is a clavicle fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160777\">",
"      What are the symptoms of a clavicle fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160792\">",
"      Is there a test for a clavicle fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160807\">",
"      How are clavicle fractures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160822\">",
"      How long do clavicle fractures take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160837\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160852\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160867\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/19/6453\">",
"      Clavicle (collarbone)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39331="Patient information: Checking your childs blood sugar level (The Basics)";
var content_f38_26_39331=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16601\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/52/2880\">",
"         Where to give a child a glucagon shot",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/36/35394\">",
"          Fingertip testing",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/23/20848\">",
"           Glucagon kit",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/57/18322\">",
"            Glucagon shot",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/3/4155\">",
"             Quick sources of sugar to treat low blood sugar",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/52/37699\">",
"         Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/40/36483\">",
"         Patient information: Diabetes and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/33/5651\">",
"         Patient information: Giving your child insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/14/227\">",
"         Patient information: Hemoglobin A1C tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/25/36243\">",
"         Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/11/38066\">",
"         Patient information: Managing diabetes in school (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/48/18179\">",
"         Patient information: My child has diabetes: How will we manage? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/40/22144\">",
"         Patient information: The ABCs of diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/58/28579\">",
"         Patient information: Using insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/31/35317\">",
"         Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/43/39603\">",
"         Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/20/3397\">",
"         Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/checking-your-childs-blood-sugar-level-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2059498\">",
"      <span class=\"h1\">",
"       Why is it important to check my child&rsquo;s blood sugar level?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to check your child&rsquo;s blood sugar level so that you know:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If the level gets too low or too high &ndash; Blood sugar levels that are very low or very high can cause serious problems. If you check your child&rsquo;s blood sugar levels often, you can treat low or high blood sugar before it becomes an emergency.",
"       </li>",
"       <li>",
"        What changes to make in your child&rsquo;s next insulin dose &ndash; Knowing your child&rsquo;s blood sugar level will help you choose his or her next insulin dose.",
"       </li>",
"       <li>",
"        How well-controlled your child&rsquo;s diabetes is &ndash; Keeping your child&rsquo;s blood sugar under control helps prevent health problems later in life.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059513\">",
"      <span class=\"h1\">",
"       How do I check my child&rsquo;s blood sugar level?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To check your child&rsquo;s blood sugar level, you use a device called a &ldquo;blood glucose meter.&rdquo; Your child&rsquo;s doctor or diabetes nurse will show you how to use yours. You will need to prick your child&rsquo;s fingertip to get a drop of blood (",
"      <a class=\"graphic graphic_picture graphicRef57918 \" href=\"mobipreview.htm?34/36/35394\">",
"       picture 1",
"      </a>",
"      ). Try not to use the same finger each time.",
"     </p>",
"     <p>",
"      You will put the drop of blood on a special glucose test strip that fits into the meter. After a few seconds, the meter will show your child&rsquo;s blood sugar level. Be sure to record your child&rsquo;s blood sugar levels and show the record to your child&rsquo;s doctor or nurse. He or she will use this information to make changes to your child&rsquo;s treatment plan.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059528\">",
"      <span class=\"h1\">",
"       How often should I check my child&rsquo;s blood sugar level?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child uses insulin, you need to check his or her blood sugar level 4 or more times each day. That will probably mean checking blood sugar levels before meals and snacks, and at bedtime. At least once a week, you might also need to check your child&rsquo;s blood sugar at night (between midnight and 4 AM). Plus, you might need to do overnight checks more often if your child&rsquo;s overnight insulin dose changes. Teenagers should check their blood sugar anytime they plan to drive.",
"     </p>",
"     <p>",
"      Certain conditions can affect your child&rsquo;s blood sugar. You might need to check your child&rsquo;s blood sugar more often when he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Is sick",
"       </li>",
"       <li>",
"        Travels, especially to another time zone",
"       </li>",
"       <li>",
"        Eats or exercises more or less than planned",
"       </li>",
"       <li>",
"        Is under extra stress",
"       </li>",
"       <li>",
"        Gets vaccines &ndash; Vaccines are treatments that prevent infections.",
"       </li>",
"       <li>",
"        Has symptoms of low or high blood sugar &ndash; These symptoms can be different, depending on the child and his or her age.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Common symptoms of low blood sugar can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Acting cranky, tired, or not eating (especially in babies and toddlers)",
"       </li>",
"       <li>",
"        Shaking",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Feeling weak, tired, nervous, or hungry",
"       </li>",
"       <li>",
"        Having nightmares or not sleeping well",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Common symptoms of high blood sugar can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Urinating more than usual",
"       </li>",
"       <li>",
"        Feeling thirsty and drinking more than usual",
"       </li>",
"       <li>",
"        Feeling tired or having no energy",
"       </li>",
"       <li>",
"        Breathing fast or having a &ldquo;fruity-smelling&rdquo; breath &ndash; This can be a sign of a medical emergency called &ldquo;diabetic ketoacidosis.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059543\">",
"      <span class=\"h1\">",
"       What should I do if my child&rsquo;s blood sugar is low?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child&rsquo;s doctor or nurse will tell you how to treat low blood sugar. It depends on the level, your child&rsquo;s age, symptoms, and the time of day.",
"     </p>",
"     <p>",
"      In general, low blood sugar is treated with either:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A quick source of sugar &ndash; Your child can eat or drink a quick source of sugar (",
"        <a class=\"graphic graphic_table graphicRef71872 \" href=\"mobipreview.htm?4/3/4155\">",
"         table 1",
"        </a>",
"        ). Foods that have fat, such as chocolate or cheese, do not raise low blood sugar levels as quickly. You should carry a quick source of sugar for your child at all times. You should also leave quick sources of sugar at your child&rsquo;s school, and with babysitters and coaches.",
"       </li>",
"       <li>",
"        A glucagon shot &ndash; Glucagon is a hormone that can quickly raise blood sugar levels. It comes in the form of a shot. If your child&rsquo;s doctor recommends that you carry a glucagon shot for your child, he or she will tell you when and how to use it (",
"        <a class=\"graphic graphic_figure graphicRef64557 \" href=\"mobipreview.htm?2/52/2880\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_picture graphicRef50427 \" href=\"mobipreview.htm?20/23/20848\">",
"         picture 2",
"        </a>",
"        and",
"        <a class=\"graphic graphic_picture graphicRef61722 \" href=\"mobipreview.htm?17/57/18322\">",
"         picture 3",
"        </a>",
"        ). Your child&rsquo;s doctor might also recommend that you leave a glucagon shot with a staff member at your child&rsquo;s school.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059558\">",
"      <span class=\"h1\">",
"       What should I do if my child&rsquo;s blood sugar is high?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child&rsquo;s doctor or nurse will tell you how to treat high blood sugar. It depends on the blood sugar level, your child&rsquo;s age, and his or her symptoms. Episodes of high blood sugar are usually treated with insulin and extra fluids. To check how serious the high blood sugar is, you might need to test your child&rsquo;s urine. Your child&rsquo;s doctor or nurse will show you how to do this.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059573\">",
"      <span class=\"h1\">",
"       Should my child&rsquo;s blood sugar be checked at school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You, your child&rsquo;s diabetes team, and the school should make a plan to manage your child&rsquo;s diabetes in school. This plan will list when your child&rsquo;s blood sugar should be checked and who will check it. Most children check their blood sugar before gym class, before lunch, and any time they do not feel well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059588\">",
"      <span class=\"h1\">",
"       When can my child check his or her own blood sugar?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends, in part, on your child&rsquo;s age. Have your young child help with blood sugar testing as much as possible so that he or she learns how to do it. Many children are able to check their own blood sugar by ages 8 to 11. But they usually still need help using the results to choose insulin doses. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2059603\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"       Patient information: My child has diabetes: How will we manage? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/11/38066?source=see_link\">",
"       Patient information: Managing diabetes in school (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"       Patient information: Giving your child insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=see_link\">",
"       Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=see_link\">",
"       Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/40/36483?source=see_link\">",
"       Patient information: Diabetes and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=see_link\">",
"       Patient information: The ABCs of diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=see_link\">",
"       Patient information: Using insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/14/227?source=see_link\">",
"       Patient information: Hemoglobin A1C tests (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=see_link\">",
"       Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=see_link\">",
"       Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/26/39331?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16601 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39331=[""].join("\n");
var outline_f38_26_39331=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059498\">",
"      Why is it important to check my child&rsquo;s blood sugar level?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059513\">",
"      How do I check my child&rsquo;s blood sugar level?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059528\">",
"      How often should I check my child&rsquo;s blood sugar level?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059543\">",
"      What should I do if my child&rsquo;s blood sugar is low?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059558\">",
"      What should I do if my child&rsquo;s blood sugar is high?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059573\">",
"      Should my child&rsquo;s blood sugar be checked at school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059588\">",
"      When can my child check his or her own blood sugar?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2059603\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/52/2880\">",
"      Where to give a child a glucagon shot",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/36/35394\">",
"       Fingertip testing",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/23/20848\">",
"        Glucagon kit",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/57/18322\">",
"         Glucagon shot",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/3/4155\">",
"          Quick sources of sugar to treat low blood sugar",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/14/227?source=related_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/20/3397?source=related_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39332="Electrolyte disturbances with HIV infection";
var content_f38_26_39332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrolyte disturbances with HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39332/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39332/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39332/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39332/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39332/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39332/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/26/39332/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia and hyperkalemia are the two major electrolyte disorders that may be associated with HIV infection. They are more likely to occur in sicker patients, with the highest rates in those who are hospitalized. In addition, lactic acidosis, hypophosphatemia have been described.",
"   </p>",
"   <p>",
"    The major electrolyte disorders that occur in patients with HIV infection will be reviewed here. A discussion of the endocrine changes seen in these patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=see_link\">",
"     \"Pituitary and adrenal gland dysfunction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPONATREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia occurs in as many as 35 to 55 percent of hospitalized HIV-infected patients, but can also be seen in ambulatory patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The hyponatremia is usually due to one or more of three disorders, each of which is associated with an impaired ability to excrete water due to increased release of antidiuretic hormone (ADH): syndrome of inappropriate ADH secretion, volume depletion, and adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Syndrome of inappropriate ADH secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of inappropriate ADH secretion (SIADH) is usually due to pneumonia (with Pneumocystis carinii or other organisms), malignancy, or occult or symptomatic infection of the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Among patients treated with intravenous trimethroprim-sulfamethoxazole, the fluid required to dilute the drug may contribute to the development of hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion in HIV-infected patients is most often caused by gastrointestinal fluid losses, primarily from diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Hypovolemia can be distinguished from the SIADH by a low urine sodium concentration (usually below 15",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and correction of the hyponatremia with volume repletion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is a much less common cause of hyponatremia than the SIADH or hypovolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In general, the fall in the plasma sodium concentration is due to cortisol deficiency (which appears to directly enhance hypothalamic ADH release), while the frequently associated hyperkalemia is due to aldosterone deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adrenal insufficiency seen in AIDS is often due to adrenalitis that may be induced by infection with cytomegalovirus, Mycobacterium avium intracellulare, or HIV itself. Adrenal hemorrhage and infiltration with Kaposi's sarcoma also may be seen. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia has been described in up to 15 to 20 percent of hospitalized patients with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The major causes include adrenal insufficiency, hyporeninemic hypoaldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/4\">",
"     4",
"    </a>",
"    ], the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], and impaired renal function due to HIV-induced renal disease or other disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism responsible for the low renin release in HIV infected patients is not known, nor are the relative roles of hyporeninemia and direct adrenal injury in the decreased aldosterone release. Mineralocorticoid replacement (starting with 0.05 to 0.10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    per day) will usually correct the hyperkalemia induced by hypoaldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trimethoprim and pentamidine as potassium-sparing diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     Trimethoprim",
"    </a>",
"    is an important cause of hyperkalemia in patients with AIDS. Trimethoprim, which is usually given in combination with sulfamethoxazole or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    for Pneumocystis carinii pneumonia, causes an average rise in the plasma potassium concentration of 0.5 to 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with occasional cases of severe hyperkalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Trimethoprim is cationic, like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    , and appears to act as a potassium-sparing diuretic, decreasing the number of open sodium channels in the luminal membrane of the cortical collecting tubule cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. The ensuing reduction in sodium reabsorption then minimizes potassium secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Reduced urinary potassium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    doses in HIV-infected patients that are often five to 10 times higher than that given for conventional infections probably explains the more frequent development of hyperkalemia among HIV-infected patients. However, conventional doses of trimethoprim can also raise the plasma potassium concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevation in the plasma potassium concentration is also a common complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Pentamidine appears to act by the same mechanism as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , blocking distal potassium secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=see_link&amp;anchor=H15534424#H15534424\">",
"     \"Overview of kidney disease in HIV-infected patients\", section on 'Electrolyte disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LACTIC ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increased propensity to serious infection, sepsis-induced lactic acidosis can occur in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, there are cases in which lactic acidosis appears to result from drug-induced mitochondrial dysfunction in the absence of sepsis or hypoperfusion (type B lactic acidosis). This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link&amp;anchor=H12#H12\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\", section on 'Hyperlactatemia and lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia and hypophosphatemia have been described with increased frequency in the era of highly active antiretroviral therapy (HAART). In a single center study from France of 1232 consecutive HIV patients, hyperuricemia was present in 41 percent and hypophosphatemia in 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39332/abstract/13\">",
"     13",
"    </a>",
"    ]. Protease inhibitor and non-nucleoside reverse transcriptase inhibitor therapy were significantly associated with hyperuricemia and hypophosphatemia, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22944343\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia (35 to 55 percent of patients), hyperkalemia (15 to 20 percent), hyperuricemia (41 percent), and hypophosphatemia (17 percent) are commonly observed among hospitalized patients with HIV infection.",
"     </li>",
"     <li>",
"      Hyponatremia may be caused by one of three mechanisms: the SIADH, usually resulting from Pneumocystis or other pneumonia or CNS disease; adrenal insufficiency; or hypovolemia resulting from infectious diarrhea.",
"     </li>",
"     <li>",
"      Hyperkalemia may be caused by adrenal insufficiency, hyporeninemic hypoaldosteronism or the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      ; mineralocorticoid replacement (starting with 0.05 to 0.10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      per day) will usually correct the hyperkalemia induced by hypoaldosteronism.",
"     </li>",
"     <li>",
"      Lactic acidosis can occur in HIV infected patients as a complication of sepsis or from drug-induced mitochondrial dysfunction in the absence of sepsis or hypoperfusion.",
"     </li>",
"     <li>",
"      Protease inhibitor and non-nucleoside reverse transcriptase inhibitor therapies are significantly associated with hyperuricemia and hypophosphatemia respectively.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/1\">",
"      Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 1990; 112:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/2\">",
"      Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA 1990; 263:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/3\">",
"      Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med 1993; 94:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/4\">",
"      Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987; 82:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/5\">",
"      Guy RJ, Turberg Y, Davidson RN, et al. Mineralocorticoid deficiency in HIV infection. BMJ 1989; 298:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/6\">",
"      Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/7\">",
"      Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/8\">",
"      Vel&aacute;zquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/9\">",
"      Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med 1989; 87:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/10\">",
"      Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/11\">",
"      Preston RA, Hirsh MJ MD, Oster MD Jr, Oster HR MD. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther 1998; 5:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/12\">",
"      Chattha G, Arieff AI, Cummings C, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39332/abstract/13\">",
"      Isnard Bagnis, C, Du Montcel, ST, Fonfrede, M, et al. Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol 2006; 103:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2375 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39332=[""].join("\n");
var outline_f38_26_39332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22944343\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPONATREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Syndrome of inappropriate ADH secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Volume depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trimethoprim and pentamidine as potassium-sparing diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LACTIC ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22944343\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39333="Allis clamps on myometrium";
var content_f38_26_39333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Placement of allis clamps for traction on the myometrium during myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 375px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF3AdIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKfi34h8V6H4i0xrC110eExbPJd3Wg2kN1dibJAVllVgsYGDkLnrzxWOnxsXyLGz8OWF34uvn09tReWK3mhZk8wqIwkUUuHBG0ltqZH3hnFen+IPCOka/cm41GO7E5h+ztJa309qzxZJ2MYnXcuWPByOaoXPw48KzNp7R6WbOWwgNrbS6fczWciRHJKb4nViuSTgk8knuaAOSh+LuoXPiq50m28G3ht7K0tr6/nmu1hktIZYxI5eF1DFkzjaCSSD0pdA+ML6hc+HzfeHJre08Q211c6W1tdfaJpPIBJR49ihWYDjDNyQOOcdxo3gvw/o2p3WoabpyxXdzaxWczGR3DwxqFRNrMRwABnGT3zVLSPhv4V0e6W503TZIJo4ZYICLuci2SQkuIAXxDnJ5j2nmgDjPDvxstdW0LVNRuI9C0ySyiEjWd5qsyToTIFAlT7Nleo5TzOSo75rlPGXxXvvEfh+a3sYL3QtS0vxBp9vcG3nmQTRTFyAC8cUmCFOVZB2616vc/CzwfeQ36ahpct819GkU817fXFxMyKwZVEskhdQGAOFI6Ui/CvwePtZfS5pXu7mC8uJJr+4leWaHd5bszSEkjc3fnPOaAMf42anf6dqHw8XT726tVuvE9pb3AglZBNE27KPg/Mp7g8VRtvjKk3jSw0KPTbO7g1C5ntLa+sbuaSLzYwCFZnt0Q5yM+W8m3POeM+ja/wCHNK8QS6ZJq9r9ofTbtL60PmOnlzJ91/lIzjPQ5HtWBp3wt8H6dqVlf2WlSRT2Vw91aj7ZOY4JX+8yRl9i57gDHA4oA4yw+PNncxQl9EljmtrO8vNZhFxubThAxQJ9z52d8AZ24yDTX+N1/D4a1PWrrwVqEVnb6fFf285adIJw8iJ5Rlkt0AcBw3yh1IBwxrq/Dfw80zw5qPjbWNSMOoHxDM81ygs8BIMHMO0Fi+csSRjcT0qPRfAPgHWvDTxaZC+oaJdQG2EY1O5liSPermNAZD5XzIuQu0/Lg+lAHSeCNa1PX9EF/rGhvoskj5hge6S4LxFQVkJTgZyfl6jFdBUVrbx2lrDb267IYUEaLknCgYAyfapaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArltZ8IRy6hJq3h67fRdbfmSeFA0VyfSeLgSf73DjswrqaKAOQsfF8lhdw6b4ytE0i+kYRw3SuWsrpuwjlIG1j/wA83w3puxmuvqC+s7a/s5rS+t4rm1mUpJDMgdHU9QQeCK4/+w9b8KfP4TlOpaSvXRb2bDRj/p3nbJX2jfK9gyCgDt6KxPDfifTfEHnR2jyw31vgXNjdIYriA/7aHnB7MMqexNbdABRRRQAUVm67rml6Dai41m/trKJjtQzOFLt/dUdWPsMmuZ1Dx5Kjumn+HtScDkTX5WyjYccgOTIev/POgDuKK8c1vx74xt4zJa2WmCPkkrayyqijqd7SR7sdztA681U8LfFTWPEKWxsrvQ3lcN5sD2U0Trt6lT5pDjkc8DBzntQB7dRXB2Xjm+E6Q3uiiRmA/wCPW4G9vdUlCBgcH7rtXRWvifS57iO2lnazu5Blbe8jaBz7DcAGP+7mgDaooooAKKKKACiiigAooooAKKKq39/a6eiPdzLHvYIi8lnYnACqOWPsBQBapAQc4IJHB9qzdPmv75jNcQNY2wOY4mIMsgweX7J1HAJPHJHIrRG1AoJAzwMnkn+tADqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKo3d3cWitI9o9xEGAzbfM4BJ5KnHQY6Ek88Vbnj86CSLe8e9Su9DhlyOoPY1lCDWbIKLe5g1CJVPF0PKlJ7fOg2+v8NAGhY3lvf24ntJlljJIyvYjqCOoI7g8irFcfeSW325bvUbe60HU+B9sjIaGXj7ruPlZeMfvAp9Mda2pNX+y26T3SGa0bpd2amVMY6soywHuNwHcigDWoqK2uIbqIS200c0R4DxsGB/EVLQAUUUUAYniTwxpviDyZLtJYb63yba+tXMVxAf8AYcc4PdTlT3BrD/tzW/CnyeLIjqWkr01qyhw0Y/6eIFyV95Eyvcqgrt6xPE3iO10KGJDHJd6lckpaWFuN01w/oB2Ud3OFUckigC1NrmlQ6IdZk1G0GkiPzftnmqYinZg2cEVwupeNNX1lmXw1CmnabkJ/aN/EfNm3dPJhPTPYvkntGwrlrnwBeXl4mtC5tLTVzcfaTpiwsdLjkPbYAGaYj/louHzzhRgHc0bxDFPexaXrdodA1Nl2KZJVaO4HVkt5lwpHqq7WGMsRQB0/hnw9o2kyxX95KNQ19/ke/vHM1xnGdikjKAA8qoUeoFXPGGs6b4bs5tR1m7jtLbG1ViTM87f3F7nJwMD8xXPeIPFOleHrWWGzhF5fEBI4yh2cjILhRlVJ6LgZPPA+avO1t9d1rVRruuX3llP78mwRxkfdWJlGXGBgxuRknDE0AZniq48SeJxMdR05Leyji8+y0iK4UJCqjJmvpGbB2gjIIxz8hJ67nhXwh/b3gu3vNLEUJcJLKtnKEBmUACVYwgML4GcqzHnlWHy1leIdPsZ9NbT9V1D+y9IgYz63qXlxE5wSlqhRsNgMBtCepOWNdh8MNY8O+MrOR/DV7cPPpwVG0r7VNH5KZO2SMkJgt1zgjoDjNAFjTp77TbyXT9eVDCuGSdxhiS2FM6DgEngSocN0PPyV166Ha6vpwjnV5URjm3mAbZz2DZUjI6EFeOiniovEWiWeuW8GleKVY7m/0DUY8JKrkfdJwQsnt91/TsOQg1jxD8O54tG8TzW1/oE8vkWWpOpDKpACxynOF54BPA4BIU5QA6CPTtU8NXckekXkwt84S1uN09vzz8nO9MDPyA8DkBwMDo9C8T2+oXCWN5H9h1RgStu0gdZlABLxSDiRcEHswHVRWDblLlSJGAdEBLEMWCjpkg5dV45z5iEZyQdxr6ppSXaMk0W5twfKsQd+CVdWXBDjkh1xnkrhtyMAejUVxXh7xDd2M8Nh4gkEtvKQlrqTFVLMekU4GAsh52sMK/TCt8p7WgAooooAKQkKCWIAHJJ7VnatrNtprJEwkuLyT/VWsC7pX6847Dg/McAdzXMatqEEs0cPiSd57ljlNC0wNOW4yPO2jLf8C2x+uetAG4+rz6kRF4eSOZCcPfyAmBBkg7enmnjoDj1bsUVNN0S5jm1C7a41S5/drJL880nU7Y0UcL7KAPX1psCa1qSgME0Sw2YSOPbJc49zykfGOBv+orS0zSrPTQxtYsSP9+Z2LyPzn5nbLH8TQBUjudV1F1a3t1061zkvdLumceyA4TtyxJ/2RWuqAHJ+Zsk5PUc9KdRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFIzBVLMQFAySeABQAtFYieLfDb6PJq6eINIbSo5PKe9F7GYFfj5TJu2g8jjPcVsxSJNEkkTq8bgMrqchgehB7igB1FFFABRRRQAUUUUAFFFFABWJP4ctBKZ9Mkm0u5J3F7MhVc/7UZBRsnqSM+9bdFAHIXmm6hay/amhL3AHzXml4jlc5H34Xyjjj1J9AM1Y0zxFK52zIt4iAiSS1RlmjIODvtm+dfw3E+ldPVLUtLstTVBewK7J9yQEo6f7rqQy9B0IoAms7u3vI99rNHKvfac49iOx9jU9clqPh+7hzPbu1/Mi7Y5Gk8i7ReQQJlGHxnhXGPU1Dpuu6ik32RWW/ulO5rK7C2l6qdyOfLlxx8y7V96ANXxd4hXQbSFYYkudSu38q0tmk2b26szHnaij5mbB44GSQDnaTpcejW82o3F2mpeINRx514AE8wDkRx8ny4VBPrjkncxyfP4tcR/EN1c+L4pNH1a6YIsV8fJRYAfkgjlOUKjO92Q8nc3GxBXe6z4p0rQ9E+3asiJaWcIbz3UIA2AQqqM4wAGx2+UctxQBK8f2aF3n2II49zIcxqIx/ez9xO5GQT1Y/wANcB4912z10Poqx27wIU883SbVYYGNgbGSMjBHzDJ2hThjjza5qXjS4guEuF03RZMuILhZAXPZ3kxsyRkZLFQMYUY3Vo6JZyrcxpa6TeXGnQXDOgWFBFkn7zAv8qjqMYZiMnpQBHoemWlpZxiGOW4vAA6wTW3nXAK4+YyBDhDyTuAJJJO5skpquu2q2F1eazc2Vvp2m/vJTYJtRCT8ohy0ZkmO084+XPyjJzVy+NmumXF3fXENhosUpS7aKR3a6k53Isp8wueAONucYHqPNNcvIvHd+b9LS5s/ClmFWKySNpdjEDe7DJ2SEHG4KcbDjPzNQBzM8GpfEC9h1LWIv7J8KxT+XaWs8zJAqnJJDsWw7YJZyG6noOvUtat4b1mHWfDf7nxBY/LFFbFFtJoS+Xj2DJZMHpvJH3uOAO90TTEuPDyaTDMLBr6HbEkMY8q73odp84gls9CpCOQATkDNao8KwalpH2aSK4snknktp4biXfA8oThRsUfLkMAQFJ4zlsLQBveFPGlh4y0x7toWWDCw6nptwVY2bEArIOPmQ+v44UhhW1qNtazWd5ousRrqWkSIEdJ+ZI424BJP3wD0cfMCB1PNeC3mj+KNH1m+u7JLuLxFbLssWeeMxPEgwUYcK6u2Ad2Tl0+6fmrvfh54mtvF1rPp9sY9P1uwZy2mXLGVIyDhjA4GXgboY+2cfLgUAdHEh0K9Oj6msy2e0fYr4Pj7o+UFudu0+vTPdCQvTxWJntlt3RY5lBYO6ZRw2Mjbkjae654PTsay5zFcaRMyu3kRlUm065kCPBJxtEcjY2tnG3PynIwVBrN0TxBcaeYLZD59lvaNEaMrIhBA8oDjawP8HbgD5WUgA3pdAjvMwahbebbzI0UgkPmK6ngo4/iBwCDwcgEgHk0fDesrpep/8I9f3clzEHMdjey53ORk+RKSP9YoBw38YU9WVqTV/ENxCDPNNHa2cbL6ETI4+U/3ucfwgnDHA3IRWHe6fqWrWF5JcmLR9HMB83UdRkIlwMFZVQEbGUqp3sy/MofaMkUAej6hf2unW5nvriOCId3bGT1wB3PsOa5XV/Es80i2sJm0/wA9cwosXmX1wOeY4TxGvB+eTgHqB1rmfC+rx+KNduYvCkz3UlrEvmeI9VXfIwYkf6LDhRtOGG8BUyOj16Poui2WjpJ9kjZp5iDNcSsZJZj6u55PfA6DsAKAMKw8OXkkbiSZ9Ktpm3zx20m+6uDnrLcHkcdkxjoGxXQ6RpOn6Na/Z9Ls4bWEsWZYlxuY9WY9Sfc81eooAKKKKAOEu/ij4ftPifb+BJRd/wBsTICJQi+QrFC4Rm3bgxUDHy45HNYGofGP7JqF7bf2Fv8As3iWDw7u+2Y3eYGPnY2cY2/d75+8K5a9+CfiW8tdS1p9dtY/GM+trrECIQbNSjfIrSeT53yoWHB29OO9aF/8JfEF3qF7dG50pPtPi228QbfOkO2CNWDJny/v5bjt7igD0+38Z6KbfVLi/vbTTbXTr1rGWe6vbcJ5g91kbYT/AHX2v6qK2dN1Kx1TT47/AEy9tryxkBKXFvKskbAEg4ZSQcEEfga8WvPhDqssevM6WU93d+JLjW7C5g1aWyltA4AQ7hBJlweoxgYHJrurLwnrt78Jbjwx4o137XrV1ZzW02oxLjBfdt7AsACBk4Jx70AVvG3xW0LQtCkv9FvNM1+eK6ht5ba01CMtH5j7dzbdxGD2I5rqV8V+HW1k6QuvaSdWD+WbIXkfn7v7vl53Z9sV5nrXgDxZrHwv0vwhLB4etDprWnl3MN7KyzLCRklPIGwkDPBbkn61neKPhd411/xhBqN9rFld2dr4gi1O1aW/uF8i0Qk+QtuEMYcZ+/kk46jJyAesJ408LPO0KeJdEaZd+YxfxFhs+/xu/h7+nenT+MPDMFja3s/iLRo7O63m3ne+iWObb97YxbDY746V5Po/wg1yyk8ONNc6U39neJrjWptsjndDJt2hfk5cbehwOnNc9L8PvFPhbWfAUNvYw6rLb69qF9ugaX7NBHIIyglkEZ8vkHnaRnpmgD3u68XeG7TTLXUrrxDo8GnXRIt7qS9jWKYjqEcthuh6GtBtTsE0sam17arpxiE4uzKoiMZGQ+/ONpBBznFeCxfBXxBY6HYnTbmzh8TQS3VzHqVtqk1qtm8zAmNI/IfzIwBzkoTuYcda7n4p+FNS134LzaJfam0+qxwW5nuktZJBcyxspbMUSs5DEHhVOOuOKAOqh8c+E57W4uofFGhSW1vsE0qahCUi3HC7iGwMkcZ60XPjnwnapE9z4o0KFZSwjaTUIlDlTtYDLc4PB9DXgMvw/wDFPxEb4jXP9nQaN/a82mrai8WeGJxbrh9oeJZNuAMZjXOa7z4lfDLXdXY6d4Rm0zTvCz6bNbHSYp5dPiW6cticrAhEowRlGwMjJzzQB6Xq/irw9ozW41jXtJsDcJ5kIuryOLzV9V3EZHuKZ/wl/hv+1Bpv/CQ6P/aRmNuLX7bF5plBwU2bs7uRxjNeQzfCXxTa2+gy+HL600fX7LTLXT59Wg1OUrIsYG5WtjAVdeOMuvQEjjBxLH4eeJfEur+NNNktY9N06fxUuoNqN2skcrxxkkNbps2vnP3t4A980AfStFFFABRRRQAUUUUAFFFFABUGoKWsblVBLGNgAByTg1PRQB8cWvwf1lvgI2oFNajv/LaV/Dv2Nw8l0LlkScr97IhbG3byAGzxXb+Lj4v0/wAZaL4V0fVNSht/FtjZci5dZNLNvt+0GMZzGDGOcYySfSvpCqb6Xp8mqx6nJY2ralHGYUu2hUzKhOSofGQuSeM4oA8Bv08fR+ItRSI+Jzry+Io104o07ab/AGWB/Gf9Sfl+8X/eZx3zVbULXx3/AGpeXcMni4OfHTWyKslz5Y0twcsE+75XTD4wvYivpOigD5tS58bWun3ukXWn+J57MeKLqC31KV9RkktbIBfLciCRJZ0OW2kvtyOvTHpPwIufEp+GUTeLodUl1aCadFS9jMdxIit8gPmEEkjoWP1PevSaKAORPj7TLfjWbHWtIPdrzT5fLH1lQNGP++q2dG8R6Jrgzo2r6ff/APXtcpIR9QpOK1ax9a8L6Drh3axo2nXzjo89ujsPQhiMg/SgDYorkh4EsbYf8SbVNd0k9hbahJJGv0im3xj8FpP7L8Y2P/Hn4jsNRQfwalp+1z/20hZVH/fs0AddRXJNrnimyP8AxMfCQu0HV9I1GOU49dswiP4An8aD4/0W3H/E3TU9II6nULCaKMf9tdpj/JqAOtorP0jW9K1qLzdH1Oxv4uu+1uElH5qTWhQAVweqQJ4z8Z/2e7KdC0MlrkKSDcXbp8sYYcgRowY4Odzp/dNbXxA1+Tw34Xuby1jWbUJGS1sYWPEtzKwSNT7bmBPsDWBpHg6705YIFlkmkgtzG94z7WnmkYNPK3rvMjnHqo9BQBs3On6hp1rJE6/8JBpR62t0Fa4Re4Vm+WX2DYP+0a4+++FvgXxnbtdab9ptQtwWlhgldYhKrZKS20mVHIBK7VzxntXTP4f1p7prpL4QmWAo8aSsMOTuPI9CT0r5o+IGqeJ9D+MqTaXq8w1i10+JpmjJkjmVQGwy4y4wzZBGQB1BoA9tX4Z63pYaTSdWs7ucEsq3iyJEPQbCZFAA4BCjjHpXP/EDW/G3hXSXvNV8OWH9nvKsMs9jqWeXIRBl1TylYkKWCkgHsea2/hp8bdP8Q3NnpHiWD+ytcnIjjdfmtbqQkALG+SQxyPlb14J4qv8AtDayGvvDPh57aW4sZLpdR1AJH5gMUZ/dxsMHO9+gwSdmPXAB5RPqGoeKbp7rxjcRWMcFtnyorhLZRHuULBHGdzMW8yNsgDdtwWwRWzpEEd7N9i+y6veLpyRCKG8newVZ5UwCeSxJ3lUBZUYgkNzUN7bTtcxSeHZNGhkDm9ur0Rq8V3GjtjYrEGUr97HVNuBgjA7SxvLWwll/4SdItIG97aC8tZ2a3+YLuDyMA0c25Q2Jxg8jJHAALWgaMdTtbWQrpEMkVwbcSW9jvmRtuAtwowrsdyEuVUAN1XPN6y0LUdPvYYNafRZLHzpIo5zZ4jXG7aPvNlwRwr85wQxORW1pXhm3SAiwvIr/AM1TIJWUmF1PWPauV8v75UhsqeBkcVuparqUDW97YwfZ5Rt+xylWaNDETiUbcgbh2PU5J5wADmdR8MSGFkEljG+Cm62gmWMNI7gLsBbDgEguCG5528GvO/EnhXUFna7t5Yk1j7seoyFxNFIWVVdXXZyAjMRhgd5BJGBXqWtWusaUl7Jptrb3+nrIjQWcivC8ZZsnY2/58MFJXAz0X+7XLW0mrX5D2cVoyONs1siSKQ/lrI6McswVXB+8mSzhSMLigDlfDfjnxPe6rHot14fm1jXJrJbiDU7ERrDew/d/0qNj5ezPG8EHptAzivT08D6lrOlQxaxdRaUdo3RWBM0qcghPOccheVX5cgHhq880Key8M/EDQtUcNaW9xPJaYj2+QUuNoPz55ImCcnB2jpwTXVfE/wCKdzZXmoeHvAsS32u2cXmXtzs8yKxXv8o5d8AnHQd/SgDqrx/D/gswRx27XutT7niDuJbqXklnaRz8qAkksSFGcDkgGrZ2Ntrt/wDb/F+q2V4YcSQaVDLmzt87irnOPPfCsQzDAwSqjrXlngLQNW0X4n3un+K79tWi1aISX1xKcN5ojaQYOPu7DtwOh5GOK9wsfCuiCNZreAskiqysZGIKjaVA56YRR9MjucgFDx/JDoi2nitGKvpSv9oVFz51m2PNX/gOBIP+uZHQmuvjkSWNJInV43AZWU5DA9CDXnWv+FLqxitI9L1K4niguormOwuG+WSIHy5oi5OCHSY8EYyFyeppfglqEg0LUPDd3JuuvDt21ku4ncbc/NATn0Q7PrGaAPRqKKKACvIfG/xjm8Max4ttx4eS7svDZsmup/t/lvIlztwUTyyMqWHBYAjnI6V69XJ638OvC2tya7Jqml+e2uCBdQP2iVfPEOPK+6w242j7uM980AcZqHxjudPi8W/afDW648NyWjXUcN9vDW04yJVPlj5lBGUx6/Nxml/4XOt1ffZ9H0RbyO71j+xtLuTe7Irt1UGWVm2Eoi5ABActnjpXX6t4B0me18UtpkMdnqfiGzFndXcgedSqxmNCY2cL8qnoMZ75qtovwy8P2HgbQ/DV3b/a4dKKyxXKM8EouASTMjowZGLEnhuM4yaAOXtfjLLeXWl6fa+Hk/te51i60S4hlvtsUE8KgkiQRkuh3DnaCOeDUXhz44Jqb+GZb7QfsVjrU11bect55rwSwDLZTyxuU5GGyD1+XjnubL4d+FrL+yTa6UsbaXcyXlq/nyFhM/DyOxbMjHA5fd0qPTvhp4S04aQLPSfLGk3Et3Z/6RK3lSyY3ty53ZwOGyB2oA4TTvjJqviLTpJ9D8JXyWV1aXUtpqTifyoWiVtpmY2/ljdtONjyDOAcVn+Gvi54ntPBXgaTUtBi1/WPEZnjgaC+S3eUx9CymJUQknGAcADOSTivQo/B3gfwrcW0zJDpkc9w0dvbz6jKls00qspWOBpPK3spYYVc9cVPpvwz8Kaa+kNaadMo0iZ57BXvriRbZ3ADbFZyADj7uMZ5xk0AcDefF++0O98VvqOkXUk2nXWmWrWMt9F5cD3MZLBGSEH5SMHcz7sZBUcVo658Zm0y/wDENqmgCZtJ1e00oE3u3zjOG+f/AFZ2429Oc56iuo8R+DfAzyamPEFvZxv4luLeO4+0Xjxm7njBESx5cYcc4CYJ96q6b4D8A6tFqL6fDDqKyX8c15LHqc1wxuoAdu9/MJDru5BPOeQaAObb41T20066h4ciijs9fTQbx4tQMmx2J2yRgxDevynIO09OuTjU+O/ijxF4Yt/CLeGZLeM3+uQWVwZWA8xWDYi5jfCtg5cfMuBgHJxLF4f+Hes+JNa0KGykutSTUE1bUFjN0Y0uwCVZpQfLVsMfk3Dv8vFdn4p8M6T4q0+Ky121NzBDOlzFtleJ45UztdXQhlIyeQe9AHnWufGSXSTr9xJ4fWXS/Dtxb2mq3CX3zpJKQG8mMx/vFVjjLFCfTrib9oDV9R0zTvBMujXtzbPc+JLOFxBO0PnRsHzG5HVTgZByPaunvPhp4Svb43d3pbTTOYXmD3cxS5aIYjaZN+2Zh/ecMfU1s+JPDWk+JU09dbtPtK2F3HfWw8x08uZM7X+UjOMng5HtQB5nL8b47ewvEutCca1BrraCtnBO88ckq/xh1iLlfYRlumAaytW8d63rXif4evLp2seHDJrVza3NnK00SXcaxqVcb0jLxnPG5AQQeBXcal4S+HoOuabewWRuJ5m16+t/tbm4Vx1uVUP5kfXAKYHOB1qTwz4a8GeIdM0bXtGjuL+FJ3vrK9uLq5kkMjKI2djK29uEAw+QAOBQBzXgr4zz+IH8JS33h2OxsPEk1xbW0seoee8csRIIdDEvynsQT7ivYq81+GHwi0fwVp+ki6lfV9W0zzvs95K0ipEJGJby4TIyIcHBKjJr0qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorlvE3jvQ/D87Ws9w91qPays0MsxOMgEDhSewJGaALmreD/AA5q83naloem3Fx1E7W6+ap9Q4G4H3BrO/4QeK2OdF17xDpZHIWO+Nyg+iXAkUD2AFcvP4o8ba7rX9maPpB0oiNZZJZVR/IVunmOxwrdwgjc98gcmh448N6ta6PFa3evNqmq3u+K0gmRwofaS0rlpCipGPmLbBwAMZYCgDm/El/4m1b4paTpttrVlqWneH7oy+ZcweQJbzCp5beXnJRZvvBRgs3Bxx64PEHiOzH/ABNfCE8oHWTSb6K4Ue+JfKbH0UmuC+Evh7TbLWrq00+c3dtp0kMVrOx5kRI1klmJ/vPNcH8B9K9eF063rRybfLaQRR4652Fzn8qAObf4ieH4Eb+05bzSJAucapZy2i/9/JFCH6hiK8K1mFL/AOJlzfaXNp91HeW4MjiYOLgFhtiyMjIMYIK5bJOA3b6ORJpbW5SQtKX+0qBnPG/Cj8uK+f8A4neG9DTx/aT3ljCkb6SG2RxgOWWaQs2AQWOAq4GTg9gMgA1NK8M2GoaRp7PY72S4uFmjYBrhUYPnhTyB8h3DJyqnK4xXjPhRtVufG/iDS9Vv9QvZ5ZxYmea43Hy4mOAWYkN8vG09iT1xXqXhXwvJ/ZWlDTPEV9EIGklAWYSRKqgMoHnBvLwZVXDbcYOCTg1xd1p+s6d8XtXubOWK51W2uobqY3Stb/MVRgSwJwjA7d2AORkAGgD1Kw0PV7SQXFxf30kcyRfZxYwlDPlBlZpyuU2x/dwsYAXrkgV3Nr4SEEYN1Dps9/8ALF9svz5ssynBEcgIbIyXUANkBV5yTXO6F4i1KXT1k1nwxe3to6PIL/Spku0ADEHZvYPjkjG0tyemK7G38f8AhO1P2e5vRorZ5i1K1ksBkn/pqqg5PcE5oAvJaRwP5EJlij8vd5BffJGqDAKA5yMnAHI6nIPBvzu0rMAYXlDGFo3wolBUMyjIz09/XPtbt7u0vrQ3FpcR3MBBHmW77wfoV/pVS5nkjjjnt7OScTyIWhd1jZO24Bj1+7xx0JHPBAOK1HU/tUyG/wBUs9NmtpVWLzYZJrrewwGSNtoBbecbEcY4zxgc7fWy2l0l3Hq1pc3rPPEPOCrGssLMJA2wgvt+Yn5GYFlxxkD0C40warZ2kt3emDVrXai6jaKkRWQuu9VDBsZ2gFG6hscHkcTJqF5Yz3Olx3k66jbRy3CrDFCsfzBTH5iFcRDcM7mbHzP8+RgAHAeNNOv9U0OexYwzXF8Wt7aeMPIfO3qqYZlUqD8wyUAPZ9w59V+HngTR/C2u65DYSC4lktII76WUhnklO8szfUEMc9SxPevLLyykj8f+FTBdXNzGdct3LJcs8eCSQzksS7kDBOFUbFxkHn21EGnavqk7OyXMunvcXKl8gHzH8s/UAsv0UelAHGNp8cfi3wa7fvPPt7dnJOfm8oKDz7RsPfJrvNE1RLJDYOS0drGqjPJCLHDg+/3yTXKXPh8Q3ukW1s8hW2V4ICW3MjRNOUx9AQK6qy09rqAvIhEMiz2+1gVdBkg+/O0fpQBm30sqTXkksjy3X73bEejcOBx05+zIe3U1yF1dnwt8b01VpRHo+oWrWWpOxCpHL9ocwyNnjA3qmc8bxXoWo2iyyySgq00bbgh/66SqDj6Ow/OvNfie1he3l/a30gjh1Gyv7WOUAEJKqWk0bN6fMo59SPWgD2+GWOaJJYXWSJwGV0OQwPcHvT68Z8A6FFrmiy3ejX91pmsRnyro4aNZ8A7JlClWCyD5hu3AEkYOK2oPEnifwvd2tl4mt01GG4lEMMwdI5XY9AjfLHIeDhSInOOFagD0yvEPjU3iiDxbbXegPrGqWqWyRHRLVNRtkd2c5lF1bBU3AYyJHwAD3Ir1jQvEWl6200dhc5uYOJrWVGini/343AYfUjB7ZrXoA+dbyHx7ceOdUm1XUvEekNDfwy6bDYafdX0Etv2iLRyrb/75lXOed3asXSdT8Vap4h1lNEv/ABPd6xa+N5YExNcvZQWKsd6SZPkhR2U/MOMCvqSuV07X/BGm3l5babq3hu0up7iWW5it7mCN5Jl5lZwDkuMfMTyO9AHi+iX/AI7n+JGhXi6f4j0yym1G6gv7CRb+eGOHA2O8sztCQTu2mJVC468io/DVl410v4ORa1qX/Caav4ivZhaS6feXd2hs4xM5E4ji2ztxjIDZIPoMV7/Z+JtBvRYmz1vS7gXzOlp5V3G/2hkGXEeD85UdcZx3qG68Y+GbWzW7uvEejQ2jStAJpL6JUMi/eTcWxuHcdRQB80anofi/V9Cj/tm38UajaaT4vhmt2aC9SY2LBt8kaMzTEDC4JLOmSARls9NrEHjWfxhqzHV/FWl2MUts+iG10y9vFlgCj5HAlWMMeN/2hS2c8jmvddS8VeHtLMQ1PXtJs/Ni8+P7ReRx74843jJGV9+lEXirw9M10sOu6TI1rB9quAt5GTDDgHzH5+VMEHceOaAOT+L411rzwOugf2p5R8QWwv8A7AZAPs3O/wA0p/yz6ZzxXP8A7PGgzeHZfF9lqVnrNrfHWbmSP7V9pMEtuSgR1Z/3TsSDlgS5A5OMV6jofiLRdfWVtC1jTtTWEgSGyuUmCE9M7ScdKZqnibQdIvobLVdb0uxvJseVBc3ccUkmTgbVYgnJ44oA+eNd8O+J9L034xXvh618TwanPqNt/Zz2sl1vnQyoZGjAPz8AjcMkLkZAJFdH4p0XxJoWq6Taz6p421Twy9hczST2k08t2L9gSiubcBxGPl2jGwHrxXr9n4u8N32oS2Fl4h0e4votxkt4r2J5E2/eyobIx39KXSfFvhzWLpbbSPEGkX1yyGURWt7HK5QHBbCsTj3oA8CubT4k3kUK60/iZLuPwVPMfsE08aHUFmkMIJiIBn2eXlep6EEcV1Xwu/4TCD4g6OdZ/t+TTr7wtDcX5vvOaGO/8zDABvljfaOUGPXHevTE8c+E3jupE8UaE0doAbhhqEJEILBRvO75fmIHPcgVj/Er4j6d4N8NapqNqbTVr7TjB5+nx3ipIiyuoVmwGKghsjI5oA8/8W+G7mP4563qklhrkllfeG3htZ7UXUkTXWcCJzHlVXCk7HwmcHGSDXNeCdK8e6BYeDbfQLbXbeWbw/frcW92Jvs0V0PMMAdH+SJt2zHC575yc/RN14l0K01iLSbrWtMh1WXaI7KS6jWZ89MITuOe3Fa1AHh3wUtvEya1Y3Ou6v4lklksGjv9P1DTbtIY5lYfP588rIWJJA8kBSo5Va9xoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArN17W9O0Gy+1ardJBETtUHlnOM4VRyxwCcAdAT0FZvjHxZa+HYkhVTc6lNgQ2yZJ5OAzYBIBIIHBLEYUE8VwOqaRf3KR3viCS5u9XuZ4HGm2yq05thKpZSpyqRnHKZA4+d3OAADYW78WeOSx04v4b8PSAhbhx/pc65+8o/gGBwQe+Qx6Vc8KeFz4O1CcW2lwXcMspb+03mRZIoT/CVKjGOSdv3up5JrTl8RatLqf9mW2gT291KnmRTXMsbRIgOC0gjYlf9lf4iDyMEiHxLYwLZ2g8SeKltoBOkksc3kQwXKqcmMhhnaeONx/HnIAuoeJItM0u91Dw9od1qkHmPPPNC8UEbYHzSb5WUOMKBlcjA4OBXns15quqeEbnxdrf+h6lrFnJHbWaLuNjp7RuwQZ5MjlQ7Pj+FRgBa7LxDqul+MdQsfCmjaha3ttIRc6r9kkEipap0iZlOFMj7Fx3QPT9WsxqL6oXlkkBimaLncgARgo9h82aAIPhVZQaTBrsjMYrf+0DbRvK2B8m2FVBPJyVUe5OK7byC15vB4W58w/9+dv9a4/w6sN14SuCkiO76u87EfNkC/JU/Q7eD7V08Oo+ckEsUflSSSDzkfqqZZQfzWgCxpieWrguGzNMevTMhOOa8P8Ai6qxeOtLtr2Pzorm0vY3VlUgxeYsu7DAglMgjp7MvU+7QRqryADOJCQRxtyAT9ev618//HBlHxB8G3ImbymjniFwYg6sZIVK5BI/559jnnjJ4oA3PDEkMFx4guLSSVrizt43aZizPsK5IbJLgZjUEnzFwuK8p8YalLpXxM1zZt+w30qywfZ0DrJ5IaMgqrBQMqcsMDDEEDIx6V4X08umqMz7hPbwySSRHzI1Voic4wHTktyMHrwetcD4yhmDaNclSbua3miuZxyXPnb3ZmTJIG9iVboozmgD1bwv4zsrzSheT6lZx3bggpNPlo23qQWjHAOcuNq4zwGNdvb+If7X03bZbUu5JzGsc8DujLnOxiowMocEgsFPXOCK8r8IBNVtrG5tbc2Rt9sUV+IW8i4lj3srSt18skDD5J3cBmBNek6Vqc+rX0Nqy4uYoxO83kOYlBYH9zI3OdjsvIDcA4UYoAuwR6Tpkl01na2+mXDoHuoLaOOF3wcLISACy5+UN0+Y59ruoNL5zGJrdJ1kVv3/AO8QRjDMQoOVbCcds8881lpYlraFNTlBuYmee0v4FEM6xsQ2HGRhyThuCjbcsATir7ytZyWrm6t0aVl+0TLBs+1SFCqc4YZ+UEnJ2hR2PABgajqst1ps93pAnlnkKNL9otJlRNrBihHl8bRnBIzk88dOGk1eLSpVtfO1OaYvHd3NobdknSTc2Z5WRcFS5Pzbs5CDkArXoN9ZC9EkUM0AvZYw0U/necN0eNpKlgZQpLnJAAI5DVzQ8P6VNY5tFax1m4kEwnW48qYTvGrM8kxC+bjd/CDkRkckYUA84ZBd+JLA2GpXNzJZaodQhjkmVvMiiiaVSFHKr+7CgHLAEqfWvcLi3urzxRqZllX+z75BpYVVAaMpGZQ+e+TJKpHsvqa8j8N6fcQfEXShMlrKJ9PuU823kEqMFgZRzk4JbeSqkgbgD/CT7lFYTWvkO5Du96J3PpmPaf1oA5fV7gW3xC0uQuogikn81eS3zRBlwB16Sfp616Gjq6hkYFSAQR3BrzDU1hl8YPqDSKY44plRQwyTtugW/wDISjPqK6LT5Vae7mMu5I5ILaNjx8qXDgj8h+lAG5LDBdJvtJEdy6MSCCQBITn8935V4j8adOn3mKDzHd7TUplZThiyxQpkY9TGK9H3NLps1nKVZLmKGAfw7YxHGWJ+rSn864vW7651HxNq/wAzEJpJggf+9I7F+PTlkH0FADLLUdR0PQIdcsIXn1XQ4ANRsApDXVhwzDJ/5aoxd1P+8v8AFXVXvjHwn4++H18bC4F9BeQtFDbvAwkeb+FVRhywfbyMgEdcVnaFqR03V2ur+Z5IF82G7O0MXAcgFs9hkk+wJ9qytN1j/hUviKTw7baXf6p4Y1cSajoxsIxI0DkbpbfGRlB98EcgMevYAluPC0i2drpenx67d61p9tBJLK12jfYnZPuxyOyyYYq2dj4HvgLVyz+IOreGb+3svGFjemGcsI3lhUTKFAyQ6fu5l5HTZJ/sGu+1WzfUYItX8PXcSah5GbaUndBcofmVZMdUPUEcjJI6kGO08jxX4fNrrtlHDdrhbu037jbyjn5WwM+qtjBBz0oA1NF1ew1uxW80q6iurdiV3IeVYdVYHlWHdTgjuK8Xt/g/rsdxYSPdaURB40k8Rv8AvJMm2YphB8n+s+U8dP8AarVfRxo1/fXGkX7WGoWkrQs6fKs8YRWDFT8jBN4Uq2FB+60ecV2Phbxkl8YrTWVgtL2RgkM0b5t7psZxGx5V8cmJsMO24fNQB5D4q+HPiDw18NtSlsd914lg8TtrGj/2VFJOyLKUXaw2jaNu4twV4HJrfi+EGpaC3hy58Nyabdzafo0+l3NtqMrxRu825nnVlRzku7ZUryuBkV7fRQB4VZfBnV7CLSIIdSsrmKy8NXmjtJMzqzTzlyCBtP7sb8dc4HSotP8AhJ4u0xtCn0rWNMsb7TvDUmj/AGiN3YidpGYMoKcp8w5PIPIHFe9UUAeRfCv4d+IPDfjrUfEGvXNpL9s02G0fbqFxeSvMhXdIzyopwdpIA4XOAMDNa2m+E9f8P/EjxJ4g0qPStSs9e+zmQXl1JBPa+WpUhCsTh1IOcEr0H1r0eigD59uvhX43uvEGl6zrurWmpTabdXdw8xv7h2lidMJHHbmPy4iMchTznk8CqHwq+G3iDUvDPga51vT7bT7bQ7TUoxZ3DzQ3V21w0i+XMDGPKjweo3kg5xzgfSNFAHz5J8GvFdx4L8R+GhrUFrot1bRJp2mS3z3sdvKkySbvNMMbKvyldoU/ezzgCjxP8H/FniH/AITOeefQra612HTo4o0uZXSNrfZv3MYgcEJxgHrzivoOigDxC9+EN+3ivX7ySOw1ew1TUk1KI3mq3lsbSQHnMEXyS7eikspHTpXt9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcv4u8SNp8U9tppja8jVTNI3zLbBuEyP4pGJARMjJPJAqz4p1wabF9nt5I0u3QyNI/KW0Q4Mrj9FXqzcDuRi+GfD0axNqWrQywQx5mtUnc+cjEZkuJiP+Wz/+OKAoxkigDA1DQdQ8M6RPrn265k8S3t1Ctvb5WdDM7CMBsgFyFZssCoVQdoUDn0jR9Jt9LSYxFpbmdt9xcSHMkzerH0HQAcAcACuej8PJ4k1Wy8Q6xJdIbdll022imeNYBk4kcA4Z3U4IIwFO31J6LXNTi0jTZbuVGkZcLHCnLzSE4SNfdiQPx54oAwtXGp6drzf2O9jNcas6/JcowaFY0AZ8qfmReDtwPmfGfm4vx+HtKt7SeTVIbe9kf97c3V6iuXxzk5GFUY4AwFxxU9vcNpmiQXOv3EbXaR4lkCgZduSiAcnnAAHJwOprzz4ny6pe2unaBG7x33im8is7lY3P+h2HzNIB/tsqsCe+WxwowAN8GWVrpuhX2r6TYWmmT+I7j7V5VtAIlS0AKQDCjAJXDk9d0jVvxzzWGj3NrJl98IRHc7W2+VI3B7/c/U0uhK2r6zqiASQ6ZamCC1CoE8tFVX28jpnj6GrepJb6prsU80e2GzZrXOeJBIIcHI7ESkfjn1oA5r4ZSPPo97HuJWKW6RYyepzHOmP+/rfnXZalugv1CqHtZ4dzNtOM+ehwfwkb/wCtXH+DxDp3iWSBgYgVguVjJxtkDSWsoPuN0J98g9hXoRHmS2zwkIInkgKHnjBA57fdU/jQBV0q6uLjQS8qvFcQOQysu04Vs4wM9V4rzT466cI7XQ9QhEZWw1W2mKPIYwIwZImO4dAPMj5/PivWr9oApjlZF83AdScb1JCf+zD9K4j4j6a2qeCrpWjL3awlVbaG2OmyTkEHcC0WOAetAHA+BfKtZfLQNNJ5MaMysV8vy5WTdvXPADryV646Vz/xZ099Pj0+/uZ5YNNs9SW6a7tyA2ZUZM/I21jvXBIJ4bnHIrrtHvIZr25SOKFjdRrdxJaLwrFVBzEWJyCsZzE5IJORWp4+0+61bSNVsbeOKaW70+SOLLlg9xGwMa5ABJLNjEg64w3egDG0m7ubPSNOsN1tKqxvLIy5T7OpDFpI5xtKqEYntuKsuRnFdDFc20+lM8EN1eu94kiRRBllEq7lkdSSCxVYwwZBub5uCDivLvh3qCRaVb3losxhMLTtc28shghKsjyI6sAuAU5C4Y7QeRjPX6Zqc2rW9pDqMbJqENwY451ifZn5gSAcOu8HlAN4zuAwaAO38PavDNawBtft5L1Y9tzFK0TlWKb2UASfLjIBC9CF7CopLOfWALeyv9Uh0y3IhNxbXkiGZi/CwsQN6gNzIWb7u0c/MMq4ngvb64uVaW00qI/6RdRL5cd02cjO0lmUMwSQAgnIAAUNXWxafLqrLDqVne2iwOY4/Ll2CZIz8u505AJUMBnBBG4fwgA5Wbw9Nptta29ulxdWzKscUx1SYC3LKCq/KPu5BAJPzM3PUVkXf226sruOOC9ivET7NdfZ4Le+kZXAM46q6gNIrEsN3BGMmvQdZ1C00uNo76SBgJFWJFl+fBA4GRnJB27V3MwPHOa4608SavB4jtNK1JL7TtMCNexTXAd3uY4gD5bSKfkZFQMwJO8bgfmJAAOU8FI9r8U9JljtZPOdJxdNJaeQYJxA5KKANuzAQAggkgnoa9r8J6it3p0SbgUtbS33Mf7zRByf++WX9a8YvZZU8ceBdZnuI2LaobXJiMBmWYsNwi2gfK7KCfvAsFIyM16p4eAXQ9XlR4/LkHkpszhTFbqjD8GRh+FAHIedDc+JomeMsi2kSMuMEp5SMc/U3chz7VvwRTP4dlkihxcXF0E8tgCVYIc/X94W5/GsjURHF8Qja+aIEvo1th+86BR5ZwD0OfLxj0rtLy2a0W1Zo1EqPLICq5GXYvtUDqcqo/HigDK1S8jaOSSAKQJGyB97G4nOe2QkJH+8PWuUFtHJ4dvdcmSeWBtQYxRxAO8kUaKhCgdzIjAD3q542uPsPha4jtFcttW2t1kbbvlJSOPc2ecgxN36HPPFbmgaQmm+GtDSBgs1i8cTLK2Q4lmTLHjliB8uf7wzQA/TPCRureW6mZQL0ecY3TG0SLJuUjjBG9fyrI8a+Fb/AFbw3NoLzLFe26Je6FextiS3uoFG1FyO+0nOc4d/7tdhba/MfEEtjdQKtsflinQ/efey7CPouc9K09asP7QsiiMUuYmEtvIDgpIPun6diO4JHegDx/4ceN7qa0jltXtnkcGS906VvLEMh++yYBCruzlgNm4kOImyW67TNRv9Q1O28X2+mXC6RcWi27W8cwkmkXduWfYhKuF3MAuS2CSB2PnGtW62Hii7gutNjaw1KJNVSFguYxMD5qgjB+WQMxYHID9lyD1vhbV7fwKG04x3V3p877o2g5itZG3M0YXOBGSdwZVAIbOMAkAHWalr9lDqVvqWnzR3rECzltY/9c5ZspsB6sMMSpx8uTkbecHWNAstVh1CHQIf7OvrjDXWlX1uBHdqmfuq3HBbO6M4zjkH5hXi8XaR4l8c+HdTt55xpdjBLH9oST90l3PhVjlx8vCxuAwJBLqAfmGfVMDdnAyOM0AeW+FPGN5oksdh4qMgsGYwxXs2S0DgcpKx7YHVsMOCdykSH1JWDKGUgqRkEcgiuAl0G917W/Ewlv44bYXMcP2F7dZI32woyyluHDncMFWXGwdcVznhvxFqngXWRoHii1lWwYF7aRD5sZQDLNC2ASF5LREblHzKCuQoB7HRTIJY54Y5oJEkikUOjowKspGQQR1Bp9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWfrGtabo0SyaneRW4Y4RWOXkPoqD5mPsATQBoUVzK61rOqBv7F0V7eEj5brVSYATntCMyH6NsqrdaD9rmSLxNrN3qUsxJWwtiba3Iz3RDuZR3LuwoA0dR8VWFtdvZWST6pqS4zaWKeYyE9N7cJH/wNhVJ7zxNOPMuzo2gWrrhfOkNzMG9+UQHvwWH1qbTzcvpItNG0n+yYI3MO0gRbdrbSUXH3T1DYHHIB4zlX+iaozRXV8Vm8r+BnL4PXJJzhQTz+XIwwAMK78KQ3d5Le3njrxC88csV4HgS3SNZMYjG3yjuwASFOQM7uvNatla+Ibq2vEsfFdrrMUitELTVtPWInHUb4dhwQw/hPBHHNSfZBHB5ZDSNu4ZvmZ3bBJwf4m4/8dB4D1cuJf7BikhtPKfVZkUyyAFo7VCSEVV6sSSQq9XbcTjkgAz9U+I83hiFj428PXumn7sV1asLq0mfOAolGDGT28xUHvxWI/i2z1b+y9cl1m4t71iYrfSrSGKR4A5P7w7wediklzgbcgDJOdiHVb2V3eATXCtCiTre3KvDPkt8gQKBuILcrhcAk5UKW8s+L2i3Xw+0mLxL4PBbw8bmF5IfJDNbbZCwRWdSRCWOV4wG29Rt2gHqs/ivRtP1HUDb2uoateWaqReSEGJmYkFY5CdowVwQg6gjBINcV4e1m4v8A4jzX2pOJJrSyMg8skiKedxHGMdMCNZMZ5wSeMndzbap9u023voQIlmXzsLlhFuxuYs3Ltn+M8E4x/DhdEhmTw/qWs6EYLq8bXbO1ghkbAlkSAjYTzk7rg5/3T70Ae1W1zNZeCpJYtkF1cs4jYuGA3PsVsr3wVPPI6HmlsPPt7COKCIyLIgjjbcflPlyIAc9sxRj6mpPAVvbnQH08QwS2mnTtaRSD5vNKhd7+2ZC/HbAp8p0fTbR4G1ZUnidVVriYDEm5Nqn6si8D+8fWgDn/ABBsg8T22oyTNHCWFrMQo4guti5z2KzCAg+gaut0yWSe4K3G5HnQMwUjCzRNtf8AP5CPYVj6xpH22zWzuLSWS2Aks7jLhXWHDbJFbqcKWxjndjjijRri6kskeeZJdRgnEE2AQr3Ma8sOwEsRBHpuXvQB0+pFXiAUgS/cVj2LHaPr8239K52+ih1HSdRjg/cNcw+a0odgy55PXnq0nTpgjitdZAxIkZGW5fEfydQRnP5AE/7jVmQzAalArwhUnZg6SNkLvJ3D3xJvX/totAHkGjRtBb2Uq3lrdyRX0UF2PIVf3U7rLGNx+XJIUEPtYHIyK720a/bxfNau7yfZome3a5dkciVwQFfO7aux1yDIMFSR1riY5n0TWPEWn3zQxshZ4cSNExNswmQZUENlXBAkHIHXgiugsdGk+Iereda3LweDljEN8Y0VDqzhw2xSp2mMYw0iAbsso7mgDxb4e3ijTVi86VNPvPNa6t7V5W/0hJeLjEaZwqqgZQ2SrHBPIruJdattQvLePUrG2FuTHK14ZkQyoSr4QkKYWDjdtIBwwIG4KKm+OnhiDwx4pg1+xt4bfTdXC29w42rHb3SYKMQcDY6qAy5G4xjkEg1x+m3NnZveWl7aNBNcO0krxsxxjGYcMCqM2RmMkrtO3+EEAHr2kXFlfSWEepXdvb6bhbWxsYyBFIQpQTCEjPUJ5agDg7uvI2bXVb3Tp4P7OWXXFeUIzlkaSFvKO2OR9xwvzK24ZY7ujEsR51fazZ29jdW4uZmubkERx3MTxlCybkUjG77vzMTlQN3O5gKS48R3FpLAwg1SdoJlaRp7V4IzcL5sn73GNwWVU2giM8sDnBoA70a5faZokk99YyG2xG80sd0RmTapKogGEJBB2qQCW781y15r1tq8BfWNLvtHjMscwmijXbJgBlklQB1ZflbADkFc5I5NSf2stjqjLp0MmotIyPJHbTO4gBYZkyoJwQX3dQ4HRmBzU1a8ur67/wBEdojFCjpc2VxL5geQKfOhI+RmEblpOm5Wzj5aAOX8WeJBeaPptzplvLf31xqFm8NrZI8sjTxODLAXc+ZKoEauDj5GXGcEV7Np3ivTL3w39ot7iKK0M11AvO0iQn5EYYBWT94AVIyDkVi/A3whDEJ/Ft9tuLu7Bt9PkbkpZodqvn+9LjeT/dKjjkV0XjTwaZ5p9X0C2t31IkTy2crbIryRVIRyf4ZRwA3QgbW4wVAMHwLcDVPF+qXt7DHPHcSo0EbpzCQdyMuemcbj7qtddrN5eXtsbiwsPOjEcixOWxk7m59h+7Q5OPv8HivK/huLmTwfcxXUYt9YuL2S2ngkk2Txnd5MauP4W2ljjvjjINej2/iKK10y7a7UvYIq2dpb7ebgAhd2ec7hJHx9eKAOT15hftYHKo0U2+1MKF1KhWWPOTjK+YQPoD240Yb0Taza6dvlnkT/AE8gMCiCNMRk4HUho2A6Axn8djXbWI6rcXFxbOCYkt4IUGwiMBXfGOG6qmRkZYDtWT4IDPrV1qm4XB1Cby0ITJW3XcWx/stJvYf7PuRQA0SlrWzvF+0S3EaRhn5+YSE5Yn1B2kn/AGvevSdKuDeaZaXJUqZokkKk5wSAcV82+Nvhdqd802u64WlR2HlsHdfsyZxGqLkGNVUqAvHOS2Tiu0/Z31jVf7PutE1yaSR7KeWBJJSxeVlCPuJPP3Xx6EqxFADPjjbnSR4fvdPEmyG7lsZ4zkKy3AMi9eGCvGABzjdgc4rmLTVg0UaxRyy3Ez+VBboGeSWRhuChevYlieOMsSQMdP8AtO2lzdeAdXFrGDLBLp88IVBmSQztHjPc/MlUvCHhibw+I9GXUpJ9daJF1rVEP7wMVzHZwt/Av3Qzj5huj6F1KgG1pfg3VdRgKeINUi0yd90n9mac8ctwykZZWlk4JbkNhQCD8zN1Gna+CLiCxijig1jYiDar+K7xZEwAAoC/L0AHXFTCG1sIoBplra2drKhEe21UhVkBCuw6k/vATu/55SetX9P12TTLmFZ0/wCJRKY4y29ma2kkZhklif3fmZjx/BtXsflAMDTbPW9H1t5bG81SG8u4kh+za9CtzBJtLFcXUPIIBbG8kkHp0xp6t4lzpr2vjjw9eWNo4yNRsz9stVP8MgkjHmR44IZkXHrXoVY2oeG9OvLiS5VZ7S8kxuuLOd4HbH94qQG+jAigDzX4ZeNbeK3lhe/s7mC2lWDUktXDxWkrjK3MRB/49pev+wzHoM7fY6828R/C+01eWaSf7NcvOrxS3BQ2l40bLgobiDbuU85V0YHPNVNOi8V+DbK3sbe8+06XaqsUQ1a3M22Nf+nmDkDHGZIu3WgD1SiuEsfiCfKMuq6FfxWwyTe6cV1G3wOpJhzIo/3kFdFofinQddyNH1eyu3HBjjmBdT1wV6j8RQBs0UUUAFFFFABRRRQAUUUUAFFFFABRRSOu9GUkjIxkHB/OgBao6hrGmaapOo6jZ2oAyfPmVP5mnJptupbd50gZShEszuCCW4wxI/iP4YHYYq2PhvQ9PnE9jo2m204ORJDaojZ9cgZoAzH8c6TIm7S4tS1ftnT7KSVev9/AT/x6pF1PxJfrKLLQotPX+CXU7pST7+XFu/IsK6WigDlz4d1W/wD+Q34kvGjOCbfTUFmmfZwTLj/gdaWjeHNI0VmfTdPghmf782N0r/70jZY/ia1qKAK97aLdqivLPGqsG/cytGW9iVIOKW0tLezQpbRLGCctgcsfUnqT7mp6KACmyMFjYkEgDoOc+1OqpfuWCWsblJZ8gMB0UfeP1xwPrQBjXFw9ur6hJG0l1JJ5FpAcEPKeNw77evP91Wb+I1mx6aN5aVhcPuLSz4+eZiQrkDPG8jy1/uorYPNa0Ihudcurzdm00qI2scargLIQGkI9cLsUenzDualt7Fo4UllLRzy87RjCEjAH/AFGB26nvQBk3FnG0TBsSRFiA6jBkJYB8kdA7YT2RT2pV8rVtAmsdclt7vTrwPb3fmEA4l/1Z5OADnCrgn509Dm9cxRyAbCFXA24AZVjx2PqIw3ToZKzI4Jlupt/lyJz58QlCbmc7SCw6KAG98QJQB8o/ERNV8BaldeFNRuH2wbJrS7T711CThSoPRzyGPRShI5PPWfA6PX7jw7Btt41drqa60m22E5kkAie7Y9MKu5EJ6lpGPQV1HxS0SD4l674as5mlWTRTcxawkRPmtGWiEKLnnM2VKk9AzE/dNe06Zp+l+D9Cm1DUTaWogh3XFztCpDGq4Ea+iKoCge3qTQBDaRWvg/w9ZaRZfZxftGCiMpCTyZAYk9tzEKCTwWX6Vn6b4aivp7NprVZbCJAhF7FuLouPLPPO7bsBbqGh6c5rzrVvF/i/wCIuo/Z/CFsdK0gSGKO5KK106ngyMWDCJCQMADdxkkYxXpvhHwvP4Z0wDWPEWo6nITETNc3DjEm/nnPIY7RyPXscAAlDMZXlY+Q4kyA7fdDP3PfbMpyf7rn1rKu1i0zXobxj5NjcolndICFCIXxDJ/vRSkxk9NrqT90VaspioKzRSsBkmKQ5kZSCJEbnLEoM9OXhanXESzpNa3KpdwzDy2WQgJMGUjk/wB2WMYyTgSL6mgDaOk3TXGGlQI67ndc8PnJwp7buR7M69wal1bT4zHNc3V6tvDFiQSEBfK4xIS2cYIweehGeeMcX4b1q+sRFo119t1DUrF8WrEHzrq1cBozMrAbcKQrO2Bvj9SRWmks17qxbUVfVdRi5TTbQ5s7JhyPNkOA0g45bkdVQdSAZmpeCrXx54jt9X1S2aHRYQhELpsl1F0yEkkHVIwHcBeGYNzhcA2/GPxS8MeDo1sopFvb1CIEsrLbtjIHCu5ISMAepHHaovGGqPatNbatJNqF9NGTBpVo3lW/Rv8AWOPnYY6k4Xj7owTXimieG4fBuopBrlnZTWF64a3vTKQsHzYK9M7wODznjPqaAOi8X6/4x+JWiXumRWGnWugXSqGS1Rruc8goRK22LggMdvQDgk1zFt4W1nSLmNodXtvEtuweWK2geNb2GVU+UrbZZSVZVJIAb72epFd6zS6Bf213EbS50d5NjoyqhhOBsaKSVnAB7rgDPQjNdJNaW+tE6tYiaeWKQNNbmOd5GbAHO3YElC9G+nbBoA8o8G32narbST6hJb2cEBNvd27THESDJ2hWB2+YV3MrBmJGOGGQr6bbx6npseqWl8k6tFMlnbSyQ4zI0yJGHlYyHywE5CqoY85yK3/E/wAOJ7+9j1jQp5Y/EUhJUMsdsuqRAkskg/huV7lsglfmGM4x7XVILjw7c/6Hf6TcQSg3yrbx+ZHP5mzc3mFjIBIFOzp99cANwARSX5sdIeW5lWaKO4a5uJ3Zoog77/OCsQ8gdVUEFWHAxhiuD0Fv4O1fxXpqrcTXOi2+pwymz062CtcQwSOWbfKy/uYj8vy8sQSuP4Q/4UeEn1zUNK13xFbxSaJBDmxhLYineMZe8dehXex8pTwqtuGOK9NlvIpppxZTzXZvZtss8OVa5K52wQt0CKAdzg4HzHO5iQAeQyeF/FfgaCSTwnqY1S2t9kK28RYPI68CMSZXzW4I2rwMfdHNdD4G+Ndxf6nBpupWM9xNM3lLJDCzqZ+rQ70XBK/MPudsk8jO7rF0NU8qx06WOSNx5Mk1mcKFOR9nt+yqcAFwPmHJGMA9DpXhjQYEWwiiig1NUwssS/6rH8CH0HBYA85BbJNAGbq1nofjW4F7ol9HpniiJSiu6g+YB/BKgOJFGTgg7kPKkHOavhezWXxrFb+I0bTb6xLS2dgZC0VyxLEyxSnHmKu9yFwGUvgj5FNbGoWmlXV02k+JLdZpI41UaiuVl4GVLOvIIA3ZzxnkAYZqXiDw/rNhYTJdXEPiTw8h8/yr9xDd2YGT5kVwMcr2JwR2agBfincXaTrp9kxW51SMWySM4jEUfJkIOewyxPr5dTeGwthp4mheG2jiV0VmXag2qNzt0ARFHI9dqnla53S2e+ml1Kea91m2MSQCWaEpqWlwZDFXt8DeWOD5qjcRjKsBV3xdA2v+FxZ6NPaS2Wona08bboFhQjbb5yDljy/Q4354FAGJqv7QMMOoyS6T4W1HUfDkBJl1NZRGxQEAyJCRuZBnqSPwqpZ6pa6H8crCwtLhG07xDBFqVlIkpIbl1Xr6rJNx6bfSo7LwobOxWfaY5EcMsLoCJUOQe3RgGVRgZG5zhWwOG12ax8PJ4bkl3Rnwn4qksbdZT+8jtmWKcKW/iVSSgzjgg4BoA9v+PmqLpXgS/uZHZltTbXvkBOX8u8gOQ344x7+1ZvhmMzaALhlaa9neS/YKd2ZmYNNtY9BteMhezQnHStf9oLSRqXwo8SSRQGW6gsi64z9xZI5WGO4/dA/hVT4VW4vfDti9sFMcaowZGAURMMqvv8jsfqw+tAG1cbZ7XaY1WBz5pjZSSqSAy9v+26cHuKoasGutKmfyVuovLZmilB2ykqwdDjnkxTD6yg12Npp1rplqvnyqFGELsdoJ8wsgznszED61Fd6X9nillgd9iZlEajLAjYwAz15Q9f75oAh8CanJqXh+IXLBrq1b7NMwOd5ABV899yMjf8Croa4XwOr6drdxYEu0LwlFYn5f3LDYfqYJoB/2z9q7qgAooooAztQ0TTdRkSS7s4nmQ7kmA2yKfUOMMPwNc7rfgO21GNVeWG9RQQsOsWyXyD0+dsSj/vuuzooA8vbwNc6ba/8AEvtL+1cn5l0PXJoVz/eWGU+WD7ZpwbXtP3BfFerWyQDLDXNFjnjI/wBqWAID9d1enUUAcNpuueIpipS98H6mj/cMF1Lbk/hiStBtd8RwTlLjwhPNGBnzLLUIJB+UhjNbuoaVp+ort1GwtLtfSeFZP5iqY8M6Kv8Aq9Nto/8Armuz+VAFfR/Ey6jfLaS6PrdhM2cG7syI+Bn/AFilkH4nmugqtp9jBYQtFbCQRli2JJWkwT6FicD2HFWaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlq16mnaXfXzAP9mhaRlzjO1Scfj/AFq3JIkYBkYKCQoz6k4A/OuL1xI59Fs7YoQda1aPfg/eRXMhz7GKHFAGnpenyWejaRp90yG5lfzbsk7t8hzLJg+hk/Tittt7zOCD5aIBnruJ68fQDn/arNs7+4e3jkdY5XKRsDjB3SMfl/4CuK0N0UUE7QMp2uzPzn5uuD+goAyZ2QeaZRGMyfNnOWIILDjqN3lp+FZ2sSRQ6QhLDZIrTtn94fL27QeBkgrwcf3jWwyMtm8QXIDiIHld7MRub/vpmP8AwGuJ+KN0LnTJLG3RzJqFzBpMPluU5kcK/TGAFYt/wGgB3wt0ZpWfV71M3t7IupXLsg3MWj2W8ef9iHBI7GT2Nc74uOo/EvxodK0/e3hvSJ8SqBhLmdDkuzZ4AI2oMHLK57CvR764k8N+BtZ1QwrDcW9tPeeVksE2Idi/gqovHpXNfDiGDwT8L7jVtTjYMsL3czbQHlABIAAHOSTjrktn+KgCn468fad8N9Nt9B0O0TUfECW4ZYPmKRKf+WkrKCeTk7epx2GDVvwVqviXWtGXU/Exs1hu0+W2s0dCEKZbG45yVKyDHZD3NeT+E9Ck1k33i3xlPDFuuXuLlZZSEDDOzcoI3KvUA54hwBxivWdH1HVvElvB/wAI1pb2VnjC6nqSlUCKcxtHFkO5GSvJCkA5JBxQBqanNb6YjajqepiwgClfNUZaaXja0aYO/dlWAXPO9edxrn9YuNRv7ePzI38P6JNlIvNgEuqXmSG8qCAgiEZGRuDMvXCdRNHPpUGp7tDI1XVo2MM2uXaebDabf9YsQGFLL3jiwAMlj8pFaMem23mzXssklxeuiwzXV3LhnBIIRivEXOGR48LnHU/eAIbTRL+88OzSaeH0+yciVbdJjJd3mMAtcykkl8A/JnkjazEZA3dKmfSNLtdLs4ohdnBS2UbVgU/Nt5AOOHIyM4BzkrzbuNehTTYks5PtF8/7tIHcLI0gVmMZPRXIR8ZwCRU+jywfYZNQkkdptv78yxhXiYKNylRkqeASASO44NAGI3huezuP7QnuJbu6ZizStyYCQM7ByQhwCVB+UgEdOY9S0G2v7Zre8treZJdpY5wkwOPnG37snTBHBxx3WrcN3I486ObymjHmKpbf5IbkhsffhbGVcdB6YOLZgiuldQhh2qXe3AJZSf4kxw6HnjucEYYUAeC3ugal4GmuJH36n4byVLSBpJYtzH5DH0U4Jw33Tjsck9XpepSXFqNS0K/lkljMatDIZPmUDmOTPseD2znkHFegyQRCVHM0MnmpuEmQySITjbJnrz0bHPfDYNcHqngBzcPP4XdLG6g3H+z5mMW8kg4DY+ZfQHjnHGd1AHSQX2i6l9okzPHMhJkCRRQSIyj7+5m4I67lIztHXFeO6r4duPib4ou/svl6NrkiBtQguy3k3ccYCpcIABgg7QwBPoQO/R2OsXunXF+mqWk1jewJtWSZPm+Y4U7VJI3dNxA6kAkVl6dNFrWs2S3vhNtVUylYp7e9kibevHyCWXAO3OVIU4HPQUAep2Ph/T9PtILK7uDcadpUaWMa4PlgLjbEiZO+VuCzc44UdCRwnxD8UXutzf2V5strBfERotsjBorQvt5Zc5MrLgYIBAHbJbsfGF//AGdaxrcR2lqyrseFG3LZROCSoxzJNKw24GPl3cgZYw6BosT3CahrVtFNqzN5iK/lSfZ07c7WIccZIUY6DAzQA/wToQs7BLjfHAqxCJpwdsUKDjy42BA2jAB8v7xHLgALXa6RLbQXMcVpbk7htaZowJH56442p1OTgcjAOc1mQBb3VJGctLNHkn5ydo7FQC7r1P8Azz/lSrIwiuLZFcyYLNGv7vdgD5iqsZDk8HzHUetAG1rKWmo2d0nmwhrXmSRgP3YGGI3HhTwDnnHBxwK4SLVbvxG0FkF3aPG48soh/wBLYcqAG5ZFADfN944LYQfPNc6bPrUEQ1C4eHRhJlNPiCKhYHgyumVbB6RR7hkcknkaMkTWEn2Lb++kXyljQMWkXrl2wCBgZ8uMZJ+83JNADLqytr1kadXa5QGGO5hmKyRYOSkcowSckmSToMYxnpma1YSWri48+4mhul8xdVtLcFpASoVLmAAJc5HdRu2jgDqdtIS2EnCTZ/c+UwAjAXor7fv4zxFHx/eJPzVauFnurG7W4m3+XglZPvszAgg7c+WCDjYnz46nLUAc1p97m5tri+aEWtxIBHqUcpltnYkZLMeUbIGEfHzbRkiNRXC2/h2DxFoXjoyQLcJq9xcapGFPLIlzcQnBIOCFWNhjrgV6A9vFZy6je290LG78p5r19oaGYopJEsW7aeFYHHzABVDfKxrM8K3FpNa6PcaZFBoF7qNk/wBn0ieQNZ3CybXdYXXBRgeqrjaSfkPWgDpvh1q8PjD4WWUt7GZXNq1newI5LeYgMciHODk4PX1rmPhFO/ha3vvCMqqZdJuEWO4uMq9zaS58mQDHGN0aHqPlbpir3wes7nwvd67o2r289i1zdrd2ouJVZJi0arIsTD72CgPPzfNyOpqnrpNhr0U9mVzYXR0m6UfKfstyN0JbPACOxVcdm7dKAO3u559SgjDxmOSWLYF3bo1d0PDY7rJHjPv71JFqd3DI52LJbtvly7/MgKo6g+2PNA4/hFV7N5biFphIibcz+VEORuKyYyeD+8SVT357daim8gxeXdItwwJjbbwfLWXyyG9vKn/WgC5eS2cepaRe2QVlmuvs0jJ0UGJwOO3zCMflXSV5tI5tLGSW3U5s57dyhzjmcF8Z9V716M7lXjXYzBiRuGMLxnmgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUN3FJNDshuHt33Kd6KrHAIJGCCORkfjU1FAGPenX4Zi1ium3cIQfupmeBy3c7wHGD6baqReJLmGRY9W0DVbRsEtLDGLqL8DGS35oK6OigDJ0bxHo+syPHpuo2886HDwhtsqH/AGkOGH4itOWTywDsdgTg7RnHvj/Cs/W9A0rXYlj1fT7a72fcaRAXjPqrdVPA5BFY58OatpaE+G9fuAoPy2mqg3cIHoHyJR9S7Y9KAOma4jURb22+a21AwIJOCcYPsDUtcdJ4sfT4mi8Z6VcaSi4JvYXM1m2CMHzVwyc/31X6mr+mW7W/lX2mXbatYyodreeHbazlsq2drjJI7HHc4xQB0VFcbY32ryS6laXFw7KrKkdwsartLsgwBjII3N94c449a101Ce4jBykYMsQG3PTzmUjPfIUD8/WgCTV50k+zmKUHyJ2aQLzykbHB/HbWNrMezxDoNmZf3FlY3Nw/I4cLHCh/ESSfrV+e1zPEsp2Ru1wG2nBJeZAD+RP51UuYRJ431K4kk2Rw2FlHnOOtxKzfmFUUAaUCR+fE2F2+fJLkDhVjUxj+lQaLeRz2iwXy48yTegc5LFmLDPvuV+OmFq1E5NirPEVBtVJCjcN0nX68jn61lzolpFFcRK5SWDcGB53NtRcE9MGWQ/jQB07xBiD0wcgjg9CP6mvIPGTXc/xR8DWFhAZktlvNTeLdtLmKErGMn1eXbk+ntXVfb7wwSxmaWRbpvKCbCoijIGMHgg/v4xn/AGD3rg/Cc17q3xu1jVNMsnubTS9MWwgOfLg82VxIxLkH7qhVOATwOOtAHpfxIHn/AA08RR3IVGn02aMhm2hWaMgZPYAmuF8SWep+NPAGleGPCabY2aCS91KVGS02xvuZEJ+ZyXUcINuM/MOlehS+Hk1BRN4puF1BUw5tiNlohHfy8nfj1ct0yAK4vX/iza3Ek2n+AFttXubc7Li9JJtLT5XYAleZGIjbCrwfXrQBrxeGdD8O21lP4nvW1a9R/wDRhcIMNIBwIbdeC4UAA4ZwB97rVXWru78VoltLcSWemzpvWxt3KzXCHj55RxkEH90p5wQW7DlvBbPqFvdapqVxcXevuJI7u4fAZY1kYDygeIody4KgEZ2liVL12um6ViSO0jxHnkIyfKOxIXnjoCD/AHcEghXoAt6Z4ektdOihtbaKGNVDJHFmJGC/dBGAyOONrgZxgNnGS6e0fSYoWKyzyuCqiNQhQZBaP5SRuIJIUjYWXgKSK17q9aGdmLsbSHC3C8h4MciT/aQ45zn9CKfJpsN9cPLOmPMTy50HMc69VYejA9CORz7EAHPRaLF5zX5kWS6vMZiDiNbwABvMUcFJMAN7Mp6A5q7BPIJY3WfbeSfJFcyJsS5xnEMwH3ZByOmc9B1WtDVmtxbLYXa3UsgVWhkUgSOy85RuPnAGccE+h5ql5onh23JhmFwfLEpXbHc842uP4JRjHbnp6AAf9lgmR5raKWC6gyzWy7fMhZjlinYg8kjlWx61BBN9laFCi7WYrEsJK7fUxZHB45hPpxnGDdvLSa1aNmaeWGP/AFd0hzNDz0cf8tE9e/rk/MGTlbqOL7RJbpNNtCyL81vcn+HB6huOOcjsWxQBDJEJhviWOQzMSro2I5zgglTyEk6gg/K3Q57XdKt0uLZoZXZ0j27Y3DLLAQOOT8w6+p9iR0i+xXmn3G+2YyLJgNIFBJOQP3i8bv8AfGGx1BxmtaZo4IlurmMeYi4Zo0LkZ6gYGSPwoA4XWvDVlfLcWFwi6hbo27bdJuMLdcBgu6LPHIGCOdwNcBf/AAb0d7hJrFbeCHzlYOS8TpgjBE0TfNnsGbPTkV6XBP5k0cJYXUZYiJyTJhf9h8iQdB0MnXt0FslHkYBpIL4ZJkJLYOMBSV2yMMdNyn9BQBynh7wZqRuIb/X421G+EjyIv2tGtog38QDKzM2AAXbLcADGBXUfZrb7TJEXslfZseCPfdMpB9DhF691p2neWmpBoI7TzBmEtGEDhSwyDzGQf+AnnGM9KdJavBezokE9xhtyNJavKR9HeTBPuAKAFWR7q22RJNMi7R13k8YKlE2xjseW9eKnmsoIYIoZ5YIFPKrLtZiT6RLhN2T1w360y4lmTMl7JNGjx5Zby9S3Ef0EWc/iTUsCtbws8C4eQ4JsrXBIzxl34OAep4oAkkYRz+dDCxlBCm8viQF/3E4OT6AKD61k6uFutYntoUdJ2jCzbGQyzAHj5U+bac4+dlX1BrTs1QXrTQxLdSwrzmTzpjkADDEhIz1JAPIqgIjNdzxXEixREs/9nwKsjYz1ZUGMknnfuFABCIoITIpQpjyl2SbRjgbTMBx0+5EOD2NXbWWaHTL7CrAqR/u0ERQICW5WMfPzz1ILHstMjTq1vkOqmMyLtkmA9N/3IxjGQM1FfbYtCwIWnQu7sEy0Rx1MrMQZBn3G7GDgZIAOK8dn7P8ADvVxA8cclxai2tt/LZuGW3EuF4yBJwRwOQvAJbR0rSrW98WaRY3EEL2J0OW5e3xlMym2XGD05iYj3NUPFVq9/LpVpHOzXd3M1zcOWO1fKG1FOQAOZc9Bjy8djWv4RaKbx5qtyZEaPRtFstPLpk/MwaZxkdfl8o8f3qAKVlr1yfFut+GINPbWdN05Fk8i4mDzBPkwYnb/AFhDeYNsjBgU+8cgC7qegReKtP1BND1iWOR444ZrW9jJeBldZE3ZxIGBGRuLdTjgnNb4WzQ6p4u1/UYgzPHBDE8zYYszs8m3dwflTyxg/X+KsP443ev6Dq0Ou6NcgCJYrdJIVUNbmSRVKy9nRicgN3zigDttP1WTTL3b4g0+Wwj2F3n2eZbq2VbIkUYA3vL94KelWHJu0eVFRLWXC+eD/fDwthuh5WM57g0uleKJYkVNeiSNRGrtewDMKZ/hlGSY2Gec5XvuHStObQLN5vtemyS6fcMd5ls2CrJnn50IKPn1Iz6EUAclrsDxaTqUowWXS5bgjkhjjcPxGGFdlq12ltLYzyStFApkkl64KCJicgdccH8KzvFFvMngfWvtbQyXf2C4QvEhjVhsfbwScdR365p3ieMNY/Z5mAzY3A3k9GKqg/8AQ6AN63uIrkMYXDhSAcdsqGH6MD+NS1x0DX0Gr3H2eUJA0uxQwyOXijHHchYZMfU1pfbZYbgPJKBHcX0ik7uIooo2z16DdHz/AL9AG/WYmuae87QrP+8ABQbT+9ByMpx844P3c1hRT3L3WsXmtPJp+jhldpLmUInkhFIUc4UEli5OOy89RF/wkGq+IZIo/BllHFp5Hza1fxkRbT/zwi4aU+52p0ILdKAOku9Xt9Pspb3V5IdOsox/rbqVU/PsPzz7Vz58aTajtHhTQdQ1dXGVupR9ktcf9dJBuP8AwBGqzpvgvT4b+PUtXkn1vV0O5LvUCH8o9f3UYASPHqqg+pNdRQBxv9l+NNRYNf8AiGw0iL/njpVmJX/7+zZB/CMVdPg+2nXGo6prt6c5O/UZIQf+AwlB+ldLRQBz1v4M0CH/AJhyy5zk3ErzH83Y1t2lrBZwLDaQxwwr0SNQoH4CpqKACiiigAooooAKKKKACiiigAooooAK5a68G2sN2194cuJdDv2JZzagG3mP/TWA/I3+8Nrf7QrqaKAPPb7VCk6WfjizXS7x8RQaxaZNpNzkIWPMef7knGfusTg1uwl7a9a1uI4YBIYmjdGO2dvOLttznHL525yO2RzXQ3NvDdW8lvdRRzQSKUeORQyup6gg8EV59qmj3Pg6ylNhFLqfhFSHl0sBmn09QQfMtmHzMqkbvL6rj5DwFoA6iyE3lxifduE0uGbrj7T0+mAKq3AT/hJdVWQ4Uxae5yf+m8oH/oNRWF/5sVpJZzQ31lPC89tfK+VuCWDhRjIDfK2RwD1HcBdRZLfxvbyZEiajpckajGQWhcOv1yJWP4UAaC6tFcwI6wlYjMsb7xn5TK8akAdcso/Bqmv76zeyaMrK8Lof9WmNo2M4PPsv5kVkacUGmXEbkswl7jGP9JlIz9MVT05gbS3MjFkhs2QhX6t5Vuuc+vzHn3oA6iLT4G81JLUIgfKneTu+6xPHT5gBj/Z9Ko67rdj4as0hit2km8tmhtYF25CgsST0UAAkk+hwCeKxviF4vm8OeFr27tkV7sCZIizKArAuqHB4J3KBzx61Z07RrqXwro5up5ri6itQ063Y3vMzbWbdnBB+8uO24igDzea1vPin48m0rWdXYeHNMVDdabZs0UdzKUDspYAmQJviVgxGckgDFavgTwvpui6t4ri8N6fDZ2/9oKkduisQz28cTIFLH+LM4J9c+lO/Z5IOiSStlpLp57guyYdi07n5yPqMZz1OD95Rq+FdTnn1rX7Zl2rZ6xPGgOCrOSHQg5+TIZkPrvX1oAzdI0+az1vUbVPJhuWhGs2DAkq8R/dTREk9PliYg9DKwzg13mgS2j2D3SgIiYDRSKS0DDIIJ9MHAOPu9Tgccp4xMWg38Wu2o/0eyn824YBjstZAFuFA6Dbvjn6c7D6Cup8PXQs5Dp9y8bHP7mZcAOOgH6ED0wV4wMgDPmidDA4jEPyo5bd5BPPlyf3ozxg9uKv6TN8zxwr5UcZ2y2rYBt2xng90Pb9PQULmFba8fyFKRJ8u1k3AIfvAf3oj0I6oeelOO+V7eWyjELxDaDncYc/wuAfmiI6EdMA/QATV5LkXZE6Jc6fNgBAQA3ptbjZID0ycHAwVbrES0UbS5E9tL8jPONqydtky4+VxjG/Hsw6Ve2sUmMFsjFx+/sJCNsmerITxz78HvtOTTNOtklDvZXLKyjYUmBLqP+ecqnlgOxPPuQaALVldiKKTzJJXjQgFZFzJF/vY6r6Nz9T1pl1Yw7Hns54YknOXjfDwTFu5X1PqOuec1Ets9rE0zAW8MLFjC7box0OUYfMi+oIx/s0y6a3jEjBBDZTLkTRqJrdycZLrjjnvwCOpHYAvmWPS7dEdpHLcRw7wzcYyqk4LevOT6elZ2qXUl4u6zxcWpAEke0syHPUoMOh9xkjH3eKhEeF8naZbB2zk/wClW5A59d6HP1UYpDp3nYKv5kcTAIwc3BjAwflcFZF5Hq1AECww3Knf+8LjzGEo83d22kptfgHHzqcYoOmzpA0VvPLcQKM+Q7JdLIDySVbaVwfT/wCtV0I8zxK/+kR7wQJVWbYu054O11P/AH0adiMGHAZ1hHyp5oZ8j/ZlGV/A0AUHjlMsu3T/ADHJEimKeS2bHsr8DoBwau6jaXmp2sdwIAJQf9RJNGVUY6hvLfmpldraQbZpYwRuKyLJjk9MtuGeOgNXFmI0Yz3QFyNhkwqfeXqODjnGOOKAOWsVks7uQPDcQXbkKVSKaSPbwcho4Ez34zWkYIfmiuvPdpFO6V1AA+nns36D61QtJbImS4he22Pz89pN1+m/bn6VoC5htGSe1WBg4AZLS2SNyfXc7AY9uTQBN5phshHaSx7Q4hbfFJcK67eiqu0Dj0+UVTtliMfkeWAoIAhkUYzg5xBF2PJ+c1d110k0y3We4EZf59s28s/ttiYbvpyKqWrqIEjVnkjLbSkS/Z4+e4jQGT04bj1oAsHLqFlUhQFKQNhmHB4EKcenLE4xVHxVcytJbW7rIiIu9nkOAWzgdCAW74BOM5+TAataMnc6SMwj6rBbKE3Hqc4JI+pK/SsDUPsNp4lvdY1K3dYrKDcxc7vKjRSchQSFGRx/ePRTjdQByceqW1x4/wBY03TZLmyj0yOBbnVDErhEKs+2NSOHZptvTjYAFPNWfHvhr/hC/DOrav4Nk1IazK5upWe/kYO2zBkdWba3ITOQcDpjitT4d6NPceHpp9SneHWtTni1m4gEQxbFpfNSM8fMQBtOTnjjHFZia9beMtS0+1clI2ea4vkBOYIISm+KQejsIeeQwEmCaAN74P2Fzo/gOzuteRLfVdVl+23MYUqI3lIEcYHUbUEa47ba4r9oQyzeDPGE+5ytlFbkKuVDATxNtbjt97n1BU/fFeoarfhtU8OJJHsE8zSeW4IZT5TYORxxuAIP94elec/E/S1vbDxfo7bC13plybZljxtlXFwI89VztzjoSCw5LAAHV+Hb6PTdQRIo3lt5/PfeuM9IXGR/uufwHet/StNtYpkv9JnmtLaUnzLQEGFznGQp+42f7pAPcE1574DlkuNF0rUZH8wXlrby5CfczYupz6D92nP0rttJYpahCThbhFAI6D7VKAfyAoAn8W3Ty6JfW9shMjTQWvOCG810U/htek1+ITa5a+ZygRI8dgDIJGLe22DGfeqzW7SS6FAr4+03K30gXukcIH/ofl1BrV7tu7pvswIuJhatM/MaRD5Sz/3QM3GPU4HcUAXNGg+13aXMozKJVd052qQjv8ueuGn6+o9qwfFerwwNp9tbSXF3dCSQpa2iK0t87HcRGrcBFbkysdi4wSecVZ9b1LxDfJpWgWxiukDtc+af3NqjtkeeRySeMQqQzDliq9ey8LeGbTw/FJIrvd6lcYN1fzgebMR0HHCoOiouFUdBQBkaV4SutSe3vvGky3ckTeZBpauXtbZs5DNnmaQf32wAfuqvWu1oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPO/EWmr4Pu7rV7OBZPC122/V7BFJ+zMTzeQgdCOC6jHA3j5gd3Q6vp5utK0q78PyRyy2DrPaEy5SeMoUZN/P3kY4P94Ka6IgMCGAIPBB714D4jtNR8GfEc6b4Q1m60iHVZRcx2K2y3FmA6ENtiONh8yNiduM+YBxQB6LpmvRPc3trLDcwXeEme3aB/MVfM3sSAMZAlGcHtStPLHC0SWs91dRBlaFE5DqLdwpI4UlRkZPNeeQX3xLv9Zn0rUvEMthemIzWT6fpaeVKnKl38xWOVk2goCMKc5OciKxvPjFoYnh1fWdOurlnP2Z7rTAYZ/m2hA8Wxlc4ZtpU5AGD1oAs/FzUrd/Dl4ZEkWNLm1sgwi373kvm84Kp+9gRMPf8a9r02HyGu1Fs0C+d8rGXf5o2KNw5+XpjH+znvmvlH4v+JvHPjCLStG1TRLWxa2ulu1gtDK8s8iq4Up0yB8xwPmHXHHPq3gHx22v3d1pmr3lxZz3tmI1nEgwkoOwMpUkKzb174JXscigDB+Emp6xpnjvxB4XOlpB/Z11Jbw3U52gxuzOmQeZNyqHBDA4J+8FG3vtV8M6r4f1bVfEXh4NqZv5EuL/AEZ32CRljCF7duz4UHa3DEDlcVynj21u4tc0PxjarGqyKdE12OVykasHxHI4HG0Sbl3HBAkQgr1Ho+neMra8jKwWN9cXMIC3UdtH5gt3IztLHGTgg8Z6igDH8OS6frul2tzY7LrTrxHcROSRDKpYSwMpAIJSR12kcbMdhWT4dQWYu/DVyJWudHfyMvhhNBtDQS8YLEx/KwHJMLEHcgqjfSmz8f6zf+G7aa/0aaCG+1OOy+WaxvUYqJVjYfM7RjDx8MVXkEkApNqMc5svEkdws8LqsUtyGHFvO+BIMHnybjawPaOVqAO+1EGO2g1GFWiik+adFdThgMLKr+vH3uhU/MMZIpW0hhnDW5aORSRCi8cnBZVBIHuYTyPvIeBU2lI14r6dfN5RDHKj5GSVed0RHQ9CV6c5GVbFLDai21LyLtEkLEKxTASQHoCDwDwDsbHqjfw0Aadq8GpoirMsUiAhPJGDGw67SRwcHlGGfUY6zPBN5ivPbedcxJlLmFxH5hHOxhnIBPbkc54qG5nmiuRFLEY1GfK8nktjOCpPBO3qh544zVmWW8urEtYvbb9+Mljh06EA9Ub6g4Ixz2AKUupm7kaE213GVAbETBZ4T0yyH7yjPVd4PpVS0hZ98lhPHNKG3yNZsLeXnJAeJsqWPcttP0qVp3nYWmqQpIxyqifEMvPTYw+Vj7qVI44FGQzJA5EjMNvkX/7udQc8JIPvfhn/AHqAFjZWcM8Obz7rNGptpmOP7pOH6HuRViIrNMULpJcNg4fNvcAcdcfe/DApsrtCCJJzEhUt5GoKGTt0kHTr3LH2p1yg8svNFNCoBYFFFzD36LgkDvwFoAkEyq227lAWLBC3sYBBHAIcfL+WTzTpYZfJaOWOVIzlSoIuIyueCQ3zHjsOn61FGsjpNHaXUUmBsCo4kAPXlGORgY43VLlgyvLbiJAcZAaNlI4525BGOetAEDBR57QmNHBBcNLLbD/Z9R6dqsSQ/Y9NnY3JUSZeSSa6IEeQB8rEcD04/DmpLW5twyRR34maXIAMqMRxnjuar+IZpIUy90lrAw2h3aLaSexV8Z/BqAKlsdQe3jUyTTfKMMk8EufoSi5+taF1Fc/ZwYDch1wQC0SfUE7TjPfArEhu5ImISC2vAOA8MEHzZ9P34/lV5LyZkEbwx6e0vyxSTwx7Wc9FAEpyfagCTUnhubCEzRJc3KceXGjXKgkchgNoOcdWwKpWAljVbW7dIdqrtt1KoRnn/UxZIHblz0rVaxnntriF5SPM2qRLGrIQOpCqQRnOOSegrEvydGbzHiKoZCQ0hIU4HURxALj03sOvWgDWiS08v7PLKzHobWNQo5x/AnIB68nvzXnXxCiurzW9F8GadOBea1KbzU5gvliC2jBKKAp4LMmOpLbGGccjo7jWdtpNPJIsNpDC91cXEuFihjQbi4jU/OOn8TDp64rhPBfixZ7ka3rcElvq1xq0yW1pcBVma3W3KRbQBg4w24L0Z3GMnFAHdeJtP1TS9A1JU1fzPt5RZrmRQJyxARliAwqggcd1+Y8nmuB+FOm6y0GranesW07ULb+yNLm8tYSIxcyJ5hjHQncXxjooFb3j7V9Y1XR5p9Osd6RNHCGaULHHLJJ5e3JHzsCycAHkMMjcK1NZV4PHPgTwrp7mDTtPhe8lYrnf5cZjij655HmsTz9wfgAdD42m+xJp959oaP7NIZHy2A8YALZGMHoDjg9SOhBw/HqRnxHDAcOb23+zlWnOBu3fw9BwDx/FhiuCrbr/AMSDKv8AZbBoPszyPDMroXYbkIUgDtkAE9iVb+E58y+L/wARo9B1y4vLe3WS4tLdk2SzsqB8OFVgOCS3zADIO0ZKEHIBv/C+5874Z6NFCiiGDR445WRcld0TjcfXBX9a9A81LWwurq5kS0s4plbzZ2ADIJfM3A+hDYHvXhejePNL0PRNG0bSL7VtWbybaxCaDbovnTCPJDzy8Yzv4jGFGCW5q9a+O9QGv21lovw3u59WYLJ9o1fWfPW2XdgSkkvsHDcgqSFbGdpoA9b0WwudOtZtVuUkvLmCzMFpGgO50zvJC4ypdtgIPQRr05rxPx148mtNQi0fQLlLvXLyeKze4tl3WelMAS3zniaZcyPngKWJxkVp+M7b4heKrfS9P1LxBFZHULjypNP0OBkQxDcX3TMS2Nq4zwN24EcVbsvAljL4jsPD2mxxJo2l77VY1JO5sBrqXPchHSHJ/iuJP7tAHpfwk0mLSfA9mIrdoDeSS3rK5YufNcspYsSS20rkk5zXY0iqFUKoAUDAA4AFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXA/FjS5Ht9M1u1YxzabOBI4H3YnZTvPskiRO3+wr131R3EMVzbywXEayQyqUdGGQykYII9MUAclqusDVrOzXTbC9k1XY1zF5ZRDbujhHVmcgH5sowGcjPqCZZvP8WW8Ns8l3psPlOL6CMx+bDN8hVGLA8AFiGUc4BBxjOJ4Jkk8I65qHhnUZGezMwnsLh33FY5CQqsT0yVK57sOcF1z2mq6fNLKl5psqQahHxucEpMnP7twO3PB6qeRnkEA5rVINXtdOttP1ZLXVA8myDUyxgeB8nymfAbD/dG9cAsTwuRnE8W+CdK8R3VrLqNvDpfiiJBsuR8kF6x6r8py3Izz8y5HBGQezm1iyv7SSxvI7iK7kV45rZYWlkiIAyflB4+ZSG6HIx6VqxvZ6pZHBhu7dvlZWAYZ9GB6H2NAHgPhnx42heIrvwx47t2nS732M77clinyoWQH5iYzjcPvBFxyNtdH4C1ZPBHiW58M6reqNNuC19pt0x3R3MEjFgwf+8pOG7cg8A5rpte8AaDql+9rrdq93BeFWtJi5WWzljQ42SA7gdoyD/sc5wK8p+I+l+KfAkthd3M1pqPhiynEyXLIFlTPyuj5IClwcnGAzIpGxsZAPbTqMdn4p1B4ILq6idIkn+x25dYpACdznPLFWThQTgLnjFcTo2jXEOralaX2y78P6zPdTWaxcGOCU7JoTjvykoHUBHHG0V0/hXxRog8Gz65b3kc0by5uJS4/eTYVRnHfAUE4HQnAORXJS6xqFppkl5q8SRz2MyanGYydwAkkDZGOslusnA443c7iaAOg8NW94dFsrnUp0murZvs1wzSHAmicxvuI5CsV3K3VS3dWIrt7W2CyNdJHJDJLkyQuQ3P1BOO3Q49s151pwubfX9e06W4ikkmeHVIHSIK+5g9vLsBOCS8KttPB8wr3BHbaOYZtCnVgHgCkHfJ+7Axyoz8yAY6MMr05wKAJ5rmO8jl+XzIVYI6BSXjbuHT06HI57j1qm8bxXxaykkIZd6uOfMxn5d33X9MMQw7NVSCdJX89vOE6oFEseDcxJkHkDIlj4GGG7r0zk1dtzLsM+UkV85uLQbopODkyRZyD2+Uk+46UAXYrqKaIx3aIBt+dCMxjn+LIyv4/hms/VRbae8SyXnkW8j7fJu4jLATzjDH7n54HpUc13BPP5Ylja4WIsRC/mFVwOmPnXPoVZeKSO+OnCGCRoEtmiMiK7hSwPTK4yByOcKB3FAEkKPDCklslxFFJ82+0kF1Acj+6fmx/ugVJFcLNMixGwmfjHlStbycdfl5P4E1lWpmkke80qys5dwIK2k6YUj1dGXjrxtY+/aprm+lt7Oaa4s9SLLtVEaJZ1Q9yNwU/maAL88Mwki8y3nkXcdzTwxz4HoCpDA+/NLbxOkhC28kas+EMUsyjHqUK4Xk+496rWU1rECLOKON2GRHHbSwgsc5ztyM/hWjq159gtBFbz2ttKV3B7pzgc++N3PbcDzQBRmNpCl5aX9y0TM4mH2m5kCfg/y4GR0BNT6Y8hlSb7RE9owJfbfedHjHBG5M9vUdT1qpv1KOcmbTW8l8FTbzMvJ6kqpYYqtcYsHeW6juNrnhPKEij6HyM/maAFnmtobyaJZIrnLgoqyKSQ3IXBnBJ5x0GcjArT07RrDTLuXUp47WGZkwG2bPLXgkEliCc96k0K+t7xhEyM1zEuQ7RH7ucD59iqD/ALI5xVTUCqXQ+0TKkiyfJ500MRf0wQpb34waAC/1mZw3kyJFag4NxFyD9JHAQc4HAc+1Z/jB4bfRNJS4t5pWmk2bBvf5ihZtxJEnY4xg561PbQPdXXnRq7SvwZraE/Lg/wDPaXJYf7g9ayfGc0Uljo8TlfskWqBLpo1aVY9yufvHlzzgle7YNAGJqss+sX3hfwrDCsi6hKL/AFUKoVI7KFiVUjriV1Uckk8g9a6O3EUXw91eyupLV72Jr9QkmOZPOcqcHuS8Z+rD1FUfBFr/AGlqfiTWo5JJZrjVEhRBtVYobebywo9tse/3zVDxRqS3MuoT2FrBAxmkQw6rBIkdw8beVIY5Yt/31QKUZd3CsAMAkAdp9xYa14r0Pw5ozynSNOtLe/lRgfLaOLmDBPVi7IxPcAGujs2GsePPtXkwK+m+bCHCDzRGflAZs5IZxIRgcbP9rNee/CPyfDOpeIr/AFP9xdtBb21voyT+fcW6IHk2EADbnzFYjACAjJHIEupa5/ZLafomjbf7V1Z2n1S82O3B3OzqEG8jcSh+UE7QvHUAEnxV8QDWfF+kaB4XMt5qDrKbxbcEkxxuNiqxBVP3oIMhxtCuMnpWb4i+EUF3BYXWsTC88RowNvp9mgMJXzASX3/eO0kNI2BnGBnAPpPw00jwzoGiypodwJpo0UXt3cjZO20HBkDAFB94gYA6kdzUnh6TUdSjvJrSF7OS4mbzdRnQN5iAnYIEycoFPBbA5J2tk0AR+GfBFvbWs/8Aa1pbpcM8scIgmLiOFj8oBKKQ2OD1z6kYAxvh1daTD4dlupIpb3Wr68l+0WaxEypJgL5O1gAFSMKpJO3rz83O/wCIdGTyYYLS9vLe9jXzn1OS5YtbxqRvY5O0lgCAMbepxxiue0jxVpthLql59ssLCxhK3UrOyyzzQsBt24OSzHO4sSwJxgDDUAJ448Sz+GNd0eeXR3haazvYbcw4lijkYxMGkAxjlTwuSxbauScV0vw+8PS6VY/bNRA/tC4RV2f88I8lgnu5Zmdz3dj1AWsnwhp194n1oeLPEdsbe3wP7J0+TrDH1Esg/vnqB2znqF2+h0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGB4u0EaxaxywbV1C1DGAt92RTjfE/wDsPtAPcEKw5UVF4L1hr6wNveM4uoJGgHnsolfaBkOoPDruAbseGX5WFdJXHeOvDDajBLfaV5keoDY0iwv5bTbDlCrfwyLztPQglG+VsqAWtZgkt/GmkXtk0Innt5rWaJzjzkBV1OQDgrhsH/ax3yLtzpV4NSn1Cwvo4J5AqmIw5jkUdPM5yW6gMCMA8g4Fct8OtRS+1u/+3z3El6kKLbG4clTH0l8sMAwO8DerfMp2Bv4Sekh8UWi3FzHfhrSOKeSFZ3VvJOzGSz42ocnGGIzjjPOADF1/WGF3Zi4sLmy1G3kUTXSxGZLaFgwaVDjDDjbuK/LvyQOhv3dhqEunz28z23iTRLuLDwXIRZZEYchWUCNwR0BC9fvdMX9dlga50kwSKb9rhTb7DktGSPN/4BsyfTIXvinaVHZ2er3lpY3dsE2rK1ijgtC5J3MFz8qtkcYxnnucgHz7a6De+B73VobbT7258F3LiWHUrOBJZIAvWG4iILZQjaHIOMKeuca2i+ILe5m1DSTeLd2d0ZNQspZHjllni8lopYz5ZwpUAsi5GV3AZ2gH2i3uNO03U9Xlm1eAvLIryQtIirBhAMH0JAySfb0ry34p+AD4j8N3V14ctP7Iu54PMD27rJBKM7trKnKE9d8eR/ezQBJoU0l34jkN3GyJ/YlsNjp5hJlbzCdnVlJikOB8wG4jpkeg+Ir6W1W1sHVk3oJDJ5rckHkLIeQQcHJz0+YBSSPGfgv40tta1K8tPEDeV4nMzPc20mNkxgAWNYygIO0Rr8vDAksuQxWvVReTazqIkS2bLoFMasSuASykkdCAeHUj1BcfKoBpWVt5VuiRQeaAwKhVKopJznC5MbHP3kyh68ZqOW+hSe7ttOS8vNWKjzI7dlBgODjzJR8mR2DZbHQGvOvGfjmSW3uNE8D3ht5NjLc6opEgQgHcsGcL7GU4Udstkrx1sZYUEMd/rflIQ6xwX0sMahvRYyu5icncRluflc8kA9wur3xHKmBYNA4j/eS2oDtnd0AkC5wOn48HoMi2hnuEZLiyLLK+7KwPDj5ucK6lST6BOT3714pqOp/2ZOJLfxFf2cpYKFOpXBaQZ5ZR5mXGD14BIHstXNE8QeNr1M6Le+LnIYYY28twjnpx5kZwuOSWOeeMYwQD2qGwiukuLVLWWN8ltklsU+UHHJGQc9vlFWojJY3Cwm9QxQAo0cInlYED0jwM/h/hXm7XXxhO1rC0v50yCTctZwYXqQQRn2HoBzknjCutN+MutZGoavDBJs2hLTWI7Xocgnyh3zg/TrQB79pjK483ztRnEpyqNFLCFGPR8EfiaJIZCjJHaak4cEHzLlcD8GY/yrwUfCP4h6jDbNfa9ZXEkZ3+bc6xeSTKecgFRswcLzjoOxq7rHwt8Z2scEOmzPe20R3gHVZQxbknKsQp3E4PPIzmgD2KPQ5C/mPDucDCGXymKfTEYPX3pZE1u3jji+zpdkfxxOYQPqPM/l+VfPF54I8aadNLcXugXs6RRkZtpUJYEklvkcknluBg9PbGDqF4Jbq0kvJda0dlaWSAXFzNaIflGVGSqjOOFBA68mgD6kTV7nSZJG1vTLuG3Cg/bIJWuYsZxgpkup567SMckitGCS31WE3ulzZ6hXEQXecZBDMvIOR8wyPrXzdDrfji1vYrjRPEtzBbbdksV0/2iNQAT5n74MVHQE7gM8D1O9YfEzV/Cd3GviWz3aPO5M13pkTKbZzghjCSwGQSWUdfvBe5APW79J7eOOLVTGYpMKrStNdtI49YkVVx/Om6lZvqGjXGns0qNJEJrd3Cxv5sZDr5cWMqAVyc88jrVnw1rZ1u0g8250+5truJpre6sbkqZUDYB2cMpPfBODkHFUA39jaxLETEJ5H3ho1VDIPQrveaU9OAAOKAOa+GL3MPwqXUNNhF1d3Di9hhkkK+a7PgKxPIyR35plz4nGn6i9zqXiCz0Bbp9s9vBazPNPIABlI5Y8q+ABuAYcDIOM1P/wAJZpXhibVvDVy7wSicX2nxhdzSQSyb5BxnaY5fOUg4wAtczoN1ffETxxeHUbQx29nObO8SKQq8YVlDQA54UNG7Ow5PmBevQAt6BoB8VSQt4R8/RfDwnNxc3jKryX7sDly5yzswbDA/KDxyQRXp1jZ+HvBlqyRGO3kmzJI7kyXFwc8serPye3Az2q3c3Bt/L0jQoIlnjRVwqbYbSPoCQOOg4QdfYZNVxdaPoF00TyTT6jKN0zrE9xOw65fYpKr6dF7AUAULR7PxZr32u0ZpNLs4zBOGjKGacOGEbhgGxHjO0jrIPQg9hXG6RpkWtXN1q9rdX1rot+VnWGKYxi7O0fvj/EisoUBQRkDJ64rkfFXifTdH+26F8OLaG6168Igdbfc0ET987TgyYYk4ORgFyBjIB2PiPWB4alv9SuWtEhnVCk8sxyVVeUVAOSMs2chfm5IxmsHR/Dd1411yHxJ4ws1hsoOdN01lAODg+ZLxk5wMKfTkDpUngX4fXFvFY3vjK7Op39sii2tWx5FoByoCjhiOMdlwMZIDH0mgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjPG/hCPUg2oaamzUFZZWVDsaVl6MjfwSgcBujD5Xyp+WfwNrVpd6eunyRJa3iFw8JUoJWzudgrchstlkPzKTzkEMesrn/E3h1NUieezKQagNrLJ90Oy/dyRypGSA45XJ6glSAQP4cm07U5r3wy1hZC4Rjc272+RLJxtYOD8nfIwQeDjrmTwNNEdI+ytaLZ6jZsYbyDILeZ/z0JH3g4w4bvn1BqjoHi9RPJpviMrY6hABmSbEayDOAT2BJ6EHa38J6qtue21W51+K+t7b7FJbQvFIXlV4rxSwKrx8wxhiGIBUscAgnIA/RmFhq2ow3M7ww3cwlt7aeBU2u2S4WUEiTcecfeHPbpc/sOOCeebTbq5s5JSWKI++Hd6iNsqOmTtxk5PU1PFLZ6zZzQTRBh92e3mXDIfQj8OCPTIPeq1pfDTZnsNUuQNvzW00zAGaP0J7sp4PqMHuaAPLfiZ8MLbxPf/AG+wjj0jxpCwmhuoGMUGogdQ2MkNjP8AtD1Zea8l8UeOvHltqz+CdX0qS2kdfLu5o5Sj3MZ6YlJCqjE/MwwW6HnIr60u0tdb06aK3uY3wcCWJgxjcdOnf27g471yGt+DNL1rw8dOvbCKUtArXOktPvVc9TESSYmznDKQDjB9QAebeH/hrqd9ZB7nW7HS9OZFK2WhxG9kUdszY27uOCEwCOPWuwg+HPhqxkV7+w1K+jcFt2q6iI4QW6gxKwHOB1Q9q5ixnvfh7qlrpd/dvqfhW9O6wvr2WQkHn9yyggeYvvjd6Ag49S0ubTmgS5sXguLPBKfYNMYjdnkhvmHXNADtFtNG0xIl0PTvD9quMKbd1HPplU54z3roJr1Aj7JY1K8klSwx2zjFUvNuDGQiaoQeRtSFP54x+NVrZbyZmM2n6qpx1mvUXJ9hG+KAI77SZrjT5Jftsssbx7tiGZ94I7L5ozn0rBt7GWFsH7eiA5wmmy4P4GRuPbFdoLm8hiQNp8jscjEcyuV9MlivH51z0ulXNxP5tzoljJIzFmdrSIsST1z5vXj3oAcmkPOih7pShOdr6QV559eaelg9pEEjvJIIl4Hl28sYHP5CrENpNbr+5sWgY9fKjCjn2WaopSTMQ8V5xy3zXUP/AI8u4H86AIdJtb20nkzrct2xid9jN53lkdMLkMfy56UrR2VzP5U8No807gf6PL5LvgdWhfAOAeh3fSrdqESeOI3Myhsdb92I7dHAJ/8Ar1TaG+Waa1aaK9kEpdoxIk+xTzzHJhlBzjAc4HTigDE1LwT4avFRo7ePTXEqugUPYOG6cFcK2B0+U/WuY1n4ZXkEEv8AZ8j3AbefJuX2LIo6LvAZRknqQg/2Sc13vnfZGPnRy2kK/u+JGijxjJ/dzDysDH8LHrViN2tI1lSQQhQxYEG13HOeA26JifUY+vNAHgDyal4Ntp/stsiQyFnm068Ci3ucZz5TYKb8D74Izj7rYJHXW3xOsdX8PnZbXkeq7DCiQHbJCQPu3EakYXH3c5BGSOhrt/Gmr/2doV2dV0db0zpshTygDLO3+rideVcE8EqT0PA4ryvwv8LNL+JWpR+IPtt5b6GjvDItuTHHdKpAEUW75hHnfuOSMnav3SaAMHS/CV/8VfFk0dvC1lYadciBtXgmUyIiKo2qY8JlgD8q56gnHGfdI9Ji+HunNZeF7m0L3RQRWl/IzSyzH5QysDk5O3jAAOTkZNJqEGpaB4o0fQPBzWdtpt+HkngWzDCxjjRR5gIYABiAoBB+Y+gOOvGgWItmjCyea0izNclszGRejFj3Hp0xxjHFAFbwl4cTRLZpbqZr3V7gmS7vHHzSOeSF/ur0AA7AelWZtT0rS574SvDapCn2q7nYBI0zwC79NxA+uB9M8zq+vLardeTr097GrbCI1iiWA5x+9n27VBPQAbjn5Q1c7Z+ALnxdNb3HiC4vbbRInMiWAzEbhz1kcHLjP952MjdcR9CAUbuybxf4huovDNlbxaUSQThljVzy80q52q542oFMh5LeWGzXpXg/whpnha222UYa5ddslwVAJGc7VA4Vc87R9Tk5NbdhZ22n2cVrYwRwW0S7UjjXaqj2FT0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBl69oVjrkCpexkSR5MU8fEkRPXafQ9wcg9CCK5Hz9W8D5FzGbzQl2gPHnEYA54P+rPtny+ODHwp9CoIyMHpQByFtpyeJ2n1aPVrmPLFLKewn2BIsKcMMcncDlXzg9AKtromrxXUFyuuG4a3RwkU9su12IAyzD5h07H8DTdR8MvDun8OXP2CcP5wgyfs7Pzk7R93OTnHB6kE4IrQeJtSSU295pyC8RstChYPs4G4Jg7hn+JC/uF5wAa8Vtb6xbx3ojezvxlDJGQJYnBwyk9GAI6HIOOlULHT4IL6Wz1a0ikuLmVpor1Fx5x643D5kcAdM9BweCBW0HVYbnxWwsre4ggvrVrmYuUaJ5lKJlGVj8wUYYD0U+tdPqVnHf2clvKWUNgq6HDIwOVYH1BAI+lAGD4p0U3+hXGn3kcmo6fIOQD/pEJHKuh/jKkAgHn3bofGtP1PXfBOuxJcrc3OiTAmGaO4fyZ26MVUMoSTgny2weo7ZPuwvp7fxC9pemNbWeNPsbAYLuN3mKx6bsbSB6Z9Dih4n0y0KTTXdtHc6bd7YdRtpBlGQ/KJcdivGT/AHfdRQBz8Nzp2sWcWppcWLCYYhjluI8lv7p+WRgfUA/hW7pptrNlkNoxeXnEFnK4X5ccNtAX64Ga8f8AEzaz8IPFEN1a373fhHU3WL5nRGhlzwsjbTwR0kxns3qfRNA16LVtHS60l1nR85Et/czsrDqGCrgY9uO/egDrls7aW1aWKzuNyj5Y5JGQt37njr3qGG0YMSNLaNiOSbs/zBqpZGCyRZEtnWbqGjsbiTGevJ5NboiF5abbtQ6NztKFDx7E5FAGXNp08yqDDNEFOf3OpSr+eBzVqKC8IEJlngQD/WrKkjfT5kNYupNHp8jRSXturNyFN1PBgf7wZh+GKZpNxBJOoS/iln3cRJrEkgx7grQBsXN99gm8u41SAs3AR4csD1GdpGBj1FUo7u11eRo5k0S+Aby2ZZ/nHrwVP86sXt5cpqk/ly3BhjADQrFFMG4HIVW8zvzkVjXT3LzzMU0i/kTBiWQNZz8/wgnt6GgCYXKWtzJFHcSKGOyNBOy7lx2Sf5eM/wALcjmodQv7PRYWnmlhtCysSgBtGlI+U7VfMcnUc9ORzTb7WY9JspW1Zb61tI9qqs0XmxsTwu2VCM5/2ienavMLSDV/FeuXNppkdlJd3YP2qWQbrfT4BygOFXzJGDAFSDyoJIoAt2ttP4r8XxtqbXFlpWmr513FExjLNICIodq/I0jg5LIORxxmvV2TVdO0PdpkWkabb28Y8mznUhEQY4Z1IC8Z6AgHuetc34K0C107xPqVzcuIJbAiGWVp/wDkIS+Wp+0yAnjakmwdhlscBQNHVfEGknW5RqV1DPNbECx0sOu+V9oYzEE4xg8MflVcsTzwAL4Y1jTrbTZdUnvl1PU75Fu55IFB2RHJjQ87Y0VePmIGdxzkmoJta1/X5xHYWEdrpzxeYkcshWe8AYAgNjEUXzLl/mZhnYD1qDTtNv8AxS8VwzLZ6WgDQtEv7tT626EANxn984941AO6u50nTLTSrZoLKIoruZJGZi7yOcZd2OSzHA5JzxQBi+HvCFnpxgmuoraW4g5gihiEdvak9TEn9493OWPqBxXT0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVbUbG11G1a3voVmhJB2t2I6EHqCOxHIqzRQBwPiLwvewl7mymnmZNrpcRf8fcZUcbhkCcDnrh8ZALZwTRvHMsKxQa5aySsWMa3lmhZJCOoZOGR8ZJQjdweOld9WNrnh2x1ZXd0EN0wA89FUlgOgcEEOv8AssCPTB5oAvTw2er6dslWK6s51DAg5Vh1DAj8CCOnUVzUGm3d9HdaFrOsTyRqrBkREV7m3bKjc5GcY+U7cNnvyM875eveBrlpINk2kv8ANJbuxFsGLctHIxLQE/3XyhJ4YE1snxLb60sbW1lqNrrtkRKlvJAdxBIDIWGV2OO5OOjdgaANbxJ4L0LxBoM+k3lhDHbyQtArQIEeNSMfKQOPp045Br57ni8SfCHUo9M1Ga/u9Ak2JFewTMEKhtoL5f8AdnBAJIKg4HKkY+koNY/fpDf2Vzp7SNsiafYUc9huRmAJ7AkE9s1D4kbS5jBZanZNfyTJIyW6w+YSgXa59hhwPqwxzQByegXGkatZwXwnmvEOCZGzKUOBkHEW0Hkd/wAa7lpray0xp7dDJCoz/oyBi3bIA6//AFq+dJYB4A8XRQ28rzaRccWYuolV4z8p+zS+YhO7buKE43DODuBDe+eHdRsL/ToYIJrGaOSMny4rgTcHllIwOBnHT2xQBhosGolmY6vJv5LS6VFz9T5f9a2rCwe2VEtjNGAeC8WAPqFYD9KyL7SrKC6aARfZlQ5EohscPkDnDDcMfSug8Px+TDJGsxmQEYbZEoHsPL4/MUAZHiW6t4NRCpcxrPwxhbyVL+2ZE5yP9sVVQxW0TyMkcNquXaSIPDGp7kmNpIz75xWtd3d2bu4PmXNuiEqpSNipAPXmFh+TV5hfX154o164XR7eK/WxUxgRKqefL83zllYAAMMZcAZTjk0AZuqXsnivxFHp+ioyWMQ/eTWzruldm2LgphcnD43oRjex4TFekaR/ZnhqPTrC11Owia5lSBgkqbIY0V2WNFJzzgjc2SSSSckVifDvwtMxik1WyVLdt8rNFPvSeQARhT0/dqownXd87H72DP4z8Wada6/o2gaJpo1bUIrhZFsbTC8qCOW+6qpksxOACFHJJwAL4o1jQbbxBFd21nZ3k8RMxl8ve88zDy1AfBJVRxgA5bYqgkEDS8P+GL3Vbw614uO6ebayWO3CxqMbVcZOQDyEyQDydzYK6HhjwnHY6nc61qnlzaxcuXwrForYdAse7ngcbjz1A2r8tdXQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACEBgQwBB4IPeuY1PwpFhH0jZbmM5S2YlYl9fLK/NCx9U49VauoooA4231a4tjLYazE94hXLW8kYNwqdyFHyzoOPmQbh3UmphatKtnreg6o99aQqxWLcsnmxN9+NZDz1Cn5snKgZHNdDqWnWupQCK9hEiq25GyQ0bdmVhyrc9QQa4zXdGvrN0muWl1CyhV8SBMttYjKzIuC3/XSP5xjlWGcgGt4y8NaX418OeVdWqXIkRZrd9/lsDwykNg4/EEeorzDwJrWseFNfu9G1a1vilqPnVwzZjGAJYl3BGV/YsUKkcjp63o2v6dcRWcCNHbGWIGBNwMcigciJx8rgDsOQByBWL8UPDdlr2jRXQvINO1m1YNpt/JJsCykgiMnI3I5ABXvwRyAQANlkvdTuZMpdxF3JRvst3DtA6ZIcDOMdMd63GEmnaDi4+1XDs2H8vz3bk/w7SzgfjXkvgX4h2MkX9m6o8dlqFs7W8kLyOvluhKsrBpRjBHBxyD9TW1rHjyK0W9ghktZVhiZrmSQuIo4xjcd3mHPLKo4+8aAItZ1Cxd72OxtNRuNQuEkRIYvPlkZwQpISSIYwScsTgY5OeK7TwfZQ+F/COl2q2Mkeo3EavLbDaZHnKgvkg7QAT1zgDHtnkPBGlaxYzNe4A8QX1uhhsZ5W8mwtgTh58HLyOzOxXpuJAxtLVJBqGpL4tOhjUV17xHLCY7u9trcW8WlW5JOcbj85YrwTk7RQBoeN7nVX1Sz0PSJJZNYu4DIyRnZDBCCBkuOVXIIPGW468LXReB/B9h4TsNkAWe/lA+03jLh5T6DrtQdlzx7nJO9ZW5gijMzLNdeWkcs+wK0pUdTj3JOO2TVigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOT8SeFvOSe50dEWaWQTT2jOUiuGHO8EcxSggESL3HzA9uah23Fxa3ktp9qudJm8zE0RBgcp92aAZET4HE0YKnk8A8+o1ja7oUepSJd20zWWrwIVgvYh8y99rjo6Z6qfqMHBABwHiPwDofi/Uby+Ol3yPdWxuPtFpOIWMyEYUNyjb8ghuR8pzwazLrwRo624XXJ9YuLC0jFwbLULqNZJtr/ACKVhCqq72By5POOmM12NrZ2euWN2Rpiwa7ZzgXdiLlokEuMbxwVKupLK23nIzgg4yNRmHhZb2aJrW2luLdd0ETNdJApbHnSbsGRy3yRxgDcxxyMlQChHqcVldS6b4SSXUfEeo4jutWmZ8SPtzhHbPyopBJHCrtxuZlB9A8FeFrPwrpZt7bM13O3m3d2+d9xL3YkknHoMnHuck0vAPhuTSYJNQ1MZ1a7HzqX3/Z4yxYRhv4mySzv/E5J6BQOtoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMLXfDq6jf2+pWV7cabq0CGJbqDDb4zz5ciMCrrk5GeQeQRk5zdK8FRwapDfaldRXLQSGeO3t7RLaDziMecyLkvIBnBZiBkkDPNdfRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39333=[""].join("\n");
var outline_f38_26_39333=null;
var title_f38_26_39334="Treatment and prevention of Shigella infection in adults";
var content_f38_26_39334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Shigella infection in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Rabia Agha, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Marcia B Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39334/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/26/39334/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella infections are a major cause of morbidity and mortality in developing countries. Worldwide, about 165 million cases occur annually with 1 million associated deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, the incidence of Shigella infections is 4 to 8 per 100,000, with nearly 14,000 reported cases in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/2\">",
"     2",
"    </a>",
"    ]. The mortality in developed countries is less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shigella gastroenteritis is typically characterized by high fever, abdominal cramps, and diarrhea. The stools are characteristically small in volume, bloody, and mucoid. Individuals with underlying immune deficiency (including HIV infection) or malnutrition are at increased risk for complications of shigellosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of Shigella infection should be considered in a toxic-appearing patient with the sudden onset of bloody diarrhea, cramping, and tenesmus, and with polymorphonuclear leukocytes on a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    stain of the stool. Shigella is isolated by culture of a stool specimen or rectal swab using techniques that are routine in most microbiology laboratories. Isolation of the organism from blood is uncommon.",
"   </p>",
"   <p>",
"    The treatment and prevention Shigella infection in adults will be reviewed here. The clinical manifestations and diagnosis of Shigella and the management of Shigella infection in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38535?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=see_link\">",
"     \"Treatment and prevention of Shigella infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with Shigella is generally self-limited; the average duration of untreated Shigella gastroenteritis is seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/8\">",
"     8",
"    </a>",
"    ]. Antibiotic therapy is not essential, since infection clears spontaneously in most individuals; however, because of the severity of the disease and for public health reasons, most favor antibiotic therapy for patients with positive stool culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/9\">",
"     9",
"    </a>",
"    ]. Antibiotics have been shown to decrease the duration of fever and diarrhea by about two days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Shortening the duration of shedding with the administration of antibiotics can also reduce the risk of person-to-person spread.",
"   </p>",
"   <p>",
"    In the absence of specific antibiotic treatment, patients with Shigella gastroenteritis may shed the organism for up to six weeks in the absence of symptoms; risk factors for asymptomatic shedding are not known. It is uncertain whether antibiotics reduce the incidence of reactive arthritis (formerly Reiter syndrome), a rare complication of shigellosis.",
"   </p>",
"   <p>",
"    The Shiga toxin produced by Shigella dysenteriae type 1 is structurally identical to one of the Shiga toxins produced by enterohemorrhagic Escherichia coli (EHEC) and is associated with hemolytic uremic syndrome (HUS), although the mechanism that controls Shiga toxin production in S. dysenteriae is distinct from that in EHEC. Therefore, although antibiotic treatment of EHEC infection has been associated with an increased relative risk of developing HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/12\">",
"     12",
"    </a>",
"    ], antibiotic treatment of S. dysenteriae infection has not been observed to increase the incidence of HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=see_link\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing antimicrobial resistance of Shigella species is a major problem in the treatment of shigellosis. The major route for dissemination of multiple resistance is horizontal transfer of plasmids carrying antibiotic resistance genes (R-plasmids). A commonly isolated plasmid carries resistance against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , sulfonamides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/14\">",
"     14",
"    </a>",
"    ]. Ampicillin resistance is mediated by beta-lactamases, most frequently OXA-1 and TEM-1.",
"   </p>",
"   <p>",
"    High rates of antimicrobial resistance were first reported in Asia, Africa, and South America, and antimicrobial resistance has spread rapidly to developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In India and Bangladesh, 20 percent or more of isolates are resistant to nalidixic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Resistance to nalidixic acid has also been reported in England [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/21\">",
"     21",
"    </a>",
"    ]. Increasing levels of resistance to ceftriaxone and azithromycin have been reported in Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to other antibiotics is common among isolates from Africa. In a study of Shigella-infected HIV-positive patients from Africa, a high prevalence of resistance among the isolates to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , TMP-SMX,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/15\">",
"     15",
"    </a>",
"    ]. No quinolone-resistant strains and only a few gentamicin-resistant strains were seen.",
"   </p>",
"   <p>",
"    Antimicrobial resistance is an increasing problem in the United States, with some reports of strains resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and nalidixic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/17,25-27\">",
"     17,25-27",
"    </a>",
"    ]. Some of these cases have been associated with international travel or adoption. Since 1999, the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria has tested every 10",
"    <sup>",
"     th",
"    </sup>",
"    (through 2002) or 20",
"    <sup>",
"     th",
"    </sup>",
"    (since 2003) Shigella isolate submitted from public health laboratories across the United States for antimicrobial susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/28\">",
"     28",
"    </a>",
"    ]. Among the 407 isolates tested during 2010, the following results were reported (",
"    <a class=\"graphic graphic_figure graphicRef73405 \" href=\"mobipreview.htm?29/5/29790\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most isolates were susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (only one resistant isolate) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (seven resistant isolates).",
"     </li>",
"     <li>",
"      Forty-eight percent of isolates were resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX).",
"     </li>",
"     <li>",
"      Forty-one percent of isolates were resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , which was a decrease over time from 80 percent in 2001.",
"     </li>",
"     <li>",
"      Forty percent of isolates were resistant to &ge;3 antimicrobial classes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on 1118 Shigella isolates reported to the Foodborne Diseases Active Surveillance Network (FoodNet) of the Centers for Disease Control and Prevention, and tested through NARMS between 2000 and 2010, were subsequently evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/29\">",
"     29",
"    </a>",
"    ]. In this analysis, strains isolated from individuals with a history of international travel within the preceding week were more likely to be resistant to TMP-SMX (75 versus 39 percent of isolates from those without such travel) or resistant to at least five antibiotic classes (13 versus 4 percent). For these reasons, antibiotic susceptibility testing is essential for management of all patients with suspected Shigella infection.",
"   </p>",
"   <p>",
"    In May 2012, an outbreak of S. sonnei infection with decreased susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    occurred for the first time in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/30\">",
"     30",
"    </a>",
"    ], although sporadic cases of shigellosis with increased azithromycin MICs have occurred. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the low inoculum required for transmission of disease and the efficacy of antibiotic therapy in reducing the duration of diarrhea, antibiotic therapy is warranted for individuals with positive stool culture for Shigella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8687025\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydration is important to compensate for fluid loss from the gastrointestinal tract; oral rehydration is sufficient in most cases. Intestinal antimotility drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/32/20997?source=see_link\">",
"     paregoric",
"    </a>",
"    , diphenoxylate (Lomotil) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (Imodium) should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antibiotic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For public health reasons, most favor antibiotic therapy for patients with positive stool culture, although antibiotic therapy is not essential since infection clears spontaneously in most individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/9\">",
"     9",
"    </a>",
"    ]. Antibiotics have been shown to decrease the duration of fever and diarrhea by about two days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Shortening the duration of shedding with the administration of antibiotics can reduce the risk of person-to-person spread.",
"   </p>",
"   <p>",
"    While culture data are pending, the choice to initiate empiric antibiotic therapy in the setting of diarrheal illness should be based on the degree of clinical suspicion for Shigella, the severity of illness, and the presence of host factors that predispose to severe infection. Empiric antibiotic therapy is warranted in severely ill patients with diarrhea, particularly when hospitalization is required. Other groups for whom consideration of empiric therapy is warranted include elderly patients, malnourished individuals, patients with HIV infection, food handlers, health care workers, and individuals in day care centers (including children and their caretakers).",
"   </p>",
"   <p>",
"    In the absence of susceptibility data, the antibiotic of choice for adults with Shigella infection is a fluoroquinolone (",
"    <a class=\"graphic graphic_table graphicRef68382 \" href=\"mobipreview.htm?22/38/23147\">",
"     table 1",
"    </a>",
"    ). Oral quinolones achieve high concentrations in serum and stool and have activity against Shigella as well as other bacterial causes of diarrhea including Salmonella and Campylobacter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The duration of therapy is three days; five to seven days of therapy should be administered to patients with infection due to S. dysenteriae type 1 or with HIV coinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of shigellosis that may have been acquired in the Asian sub-continent, empiric antibiotic therapy may require a third-generation cephalosporin, given widespread resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    in that region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasonable agents for treatment of infection due to isolates with known susceptibility include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (three days) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (five days) (",
"    <a class=\"graphic graphic_table graphicRef68382 \" href=\"mobipreview.htm?22/38/23147\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/33,37\">",
"     33,37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     Ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    are not appropriate agents due to high resistance rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Antimicrobial resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Food handlers should not be involved in food preparation as long as their stool cultures are positive; conversion to negative stool cultures generally requires at least 48 hours of antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control measures to prevent spread of infection are an important component of management. Hygiene measures include frequent handwashing with soap and water, particularly after using the restroom and prior to food preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/39\">",
"     39",
"    </a>",
"    ]. Food handlers should not be involved in food preparation as long as their stool cultures are positive; conversion to negative stool cultures generally requires at least 48 hours of antibiotic therapy. Access to safe drinking water is an important component of prevention in developing settings.",
"   </p>",
"   <p>",
"    There is no effective vaccine against Shigella; potential vaccines are in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/40\">",
"     40",
"    </a>",
"    ]. Use of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    in travelers to areas in which shigellosis is endemic has been proposed as a measure for prevention of shigellosis; further is study is needed before routine use is warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39334/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8687084\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection with Shigella is generally self-limited; the average duration of untreated Shigella gastroenteritis is seven days. Hydration is important to compensate for fluid loss from the gastrointestinal tract; oral rehydration is sufficient in most cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8687025\">",
"       'Supportive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increasing antimicrobial resistance of Shigella species is a major problem in the treatment of shigellosis. Antibiotic susceptibility testing is essential for management of all patients with suspected Shigella infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antimicrobial resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the availability of culture results, we suggest empiric antibiotic therapy for severely ill patients, elderly patients, malnourished individuals, patients with HIV infection, food handlers, health care workers and individuals in day care centers (including children and their caretakers) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antibiotic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antibiotic therapy for treatment of adults with diarrheal illness that is known to be due to shigellosis (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Antibiotics have been shown to decrease the duration of fever and diarrhea by about two days. Shortening the duration of shedding with the administration of antibiotics can also reduce the risk of person-to-person spread. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antibiotic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the availability of susceptibility data, we suggest treatment of shigellosis in adults with a fluoroquinolone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In the setting of shigellosis that may have been acquired in the Asian sub-continent, we suggest treatment of shigellosis with a third-generation cephalosporin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Subsequent therapy should be guided by susceptibility data; other antibiotic agents that may be effective include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef68382 \" href=\"mobipreview.htm?22/38/23147\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antibiotic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frequent handwashing with soap and water is important for prevention, particularly after using the restroom and prior to food preparation. Food handlers should not be involved in food preparation as long as their stool cultures are positive; conversion to negative stool cultures generally requires at least 48 hours of antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/1\">",
"      Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651.",
"     </a>",
"    </li>",
"    <li>",
"     Notice to readers: Final 2004 reports of notifiable diseases. MMWR Morbidity and Mortality Weekly Report 2005; 54:770. www.cdc.gov/MMWR/preview/mmwrhtml/mm5431a4.htm (Accessed on May 22, 2008).",
"    </li>",
"    <li>",
"     Ashkenazi S, Cleary TG. Shigella species. In: Principles and practice of pediatric infectious diseases, 3rd, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, Philadelphia 2008. p.817.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/4\">",
"      Baer JT, Vugia DJ, Reingold AL, et al. HIV infection as a risk factor for shigellosis. Emerg Infect Dis 1999; 5:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/5\">",
"      Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/6\">",
"      Struelens MJ, Patte D, Kabir I, et al. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis 1985; 152:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/7\">",
"      Greenberg D, Marcu S, Melamed R, Lifshitz M. Shigella bacteremia: a retrospective study. Clin Pediatr (Phila) 2003; 42:411.",
"     </a>",
"    </li>",
"    <li>",
"     Dupont HL. Shigella species (bacillary dysentery). In: Principles and Practice of Infectious Diseases, 6th Ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2655.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/9\">",
"      Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/10\">",
"      Haltalin KC, Nelson JD, Ring R 3rd, et al. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967; 70:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/11\">",
"      David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/12\">",
"      Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/13\">",
"      Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/14\">",
"      Rowe B, Threlfall EJ. Drug resistance in gram-negative aerobic bacilli. Br Med Bull 1984; 40:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/15\">",
"      Kruse H, Kariuki S, S&oslash;li N, Olsvik O. Multiresistant Shigella species from African AIDS patients: antibacterial resistance patterns and application of the E-test for determination of minimum inhibitory concentration. Scand J Infect Dis 1992; 24:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/16\">",
"      Ashkenazi S, Levy I, Kazaronovski V, Samra Z. Growing antimicrobial resistance of Shigella isolates. J Antimicrob Chemother 2003; 51:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/17\">",
"      Sivapalasingam S, Nelson JM, Joyce K, et al. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother 2006; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/18\">",
"      Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992; 14:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/19\">",
"      Munshi MH, Sack DA, Haider K, et al. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987; 2:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/20\">",
"      Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/21\">",
"      Cheasty T, Day M, Threlfall EJ. Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy. Clin Microbiol Infect 2004; 10:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/22\">",
"      Rahman M, Shoma S, Rashid H, et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. J Health Popul Nutr 2007; 25:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/23\">",
"      Kuo CY, Su LH, Perera J, et al. Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004. J Microbiol Immunol Infect 2008; 41:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/24\">",
"      Boumghar-Bourtchai L, Mariani-Kurkdjian P, Bingen E, et al. Macrolide-resistant Shigella sonnei. Emerg Infect Dis 2008; 14:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: emergence of Shigella flexneri 2a resistant to ceftriaxone and ciprofloxacin --- South Carolina, October 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1619.",
"     </a>",
"    </li>",
"    <li>",
"     National Antimicrobial Resistance Monitoring System: Enteric Bacteria 2008. file://www.cdc.gov/narms/annual/2008/NARMS_2008_Annual_Report.pdf (Accessed on January 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/27\">",
"      Wong MR, Reddy V, Hanson H, et al. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb Drug Resist 2010; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     National Antimicrobial Resistance Monitoring System: Enteric Bacteria 2010. www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf (Accessed on June 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/29\">",
"      Shiferaw B, Solghan S, Palmer A, et al. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010. Clin Infect Dis 2012; 54 Suppl 5:S458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the Field: Outbreak of Infections Caused by Shigella sonnei with Decreased Susceptibility to Azithromycin - Los Angeles, California, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/31\">",
"      DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/32\">",
"      Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/33\">",
"      Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/34\">",
"      Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992; 117:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/35\">",
"      Bassily S, Hyams KC, el-Masry NA, et al. Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am J Trop Med Hyg 1994; 51:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/36\">",
"      Gendrel D, Moreno JL, Nduwimana M, et al. One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin Infect Dis 1997; 24:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/37\">",
"      Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003; 22:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/38\">",
"      Replogle ML, Fleming DW, Cieslak PR. Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis 2000; 30:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/39\">",
"      Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/40\">",
"      Jennison AV, Verma NK. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 2004; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39334/abstract/41\">",
"      Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006; 42:1283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2701 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39334=[""].join("\n");
var outline_f38_26_39334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8687084\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIMICROBIAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8687025\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antibiotic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8687084\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2701\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2701|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/5/29790\" title=\"figure 1\">",
"      Antimicrobial resistance pattern for Shigella US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2701|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/38/23147\" title=\"table 1\">",
"      Treatment of shigellosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/16/8457?source=related_link\">",
"      Treatment and prevention of Shigella infections in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39335="Management of vasogenic edema in patients with primary and metastatic brain tumors";
var content_f38_26_39335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of vasogenic edema in patients with primary and metastatic brain tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     Jan Drappatz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39335/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/26/39335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasogenic edema that surrounds many brain tumors contributes significantly to morbidity. This edema results from disruption of the blood brain barrier, allowing protein-rich fluid to accumulate in the extracellular space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of peritumoral vasogenic edema and the use of glucocorticoids are reviewed here. The acute treatment of elevated intracranial pressure (ICP) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'General management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H29#H29\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Specific therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor-related disruption in the blood brain barrier is caused by two major mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The local production of factors that increase the permeability of tumor vessels such as vascular endothelial growth factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/2\">",
"       2",
"      </a>",
"      ], glutamate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/3\">",
"       3",
"      </a>",
"      ], and leukotrienes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of tight endothelial cell junctions in tumor blood vessels. These vessels develop in response to angiogenic factors such as vascular endothelial growth factor (VEGF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/2\">",
"       2",
"      </a>",
"      ] and basic fibroblast growth factor (bFGF, FGF - 2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In large part, VEGF is responsible for the loss of integrity of the blood brain barrier in brain tumors. Gliomas, meningiomas, and metastatic tumors all have upregulation of VEGF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. VEGF is secreted by tumor cells as well as host stromal cells and binds to its receptors VEGFR1 and VEGFR2, which are located primarily on the surface of endothelial cells. VEGF stimulates the formation of gaps in the endothelium, a process that leads to fluid leakage into the brain parenchyma, thereby resulting in vasogenic edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vasogenic edema tends to spread more readily in the extracellular space of white matter rather than gray matter, possibly because of lower resistance to flow within the white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/12\">",
"     12",
"    </a>",
"    ]. Tumor-related edema may disrupt synaptic transmission, alter neuronal excitability, and contribute to headaches, seizures, focal neurologic deficits, and encephalopathy. Furthermore, unchecked cerebral edema may result in fatal herniation because the brain is encased in the rigid cranium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with brain tumors and peritumoral edema can be adequately managed with glucocorticoids. Reduction of intracranial pressure and improvement in neurologic symptoms usually begins within hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/13\">",
"     13",
"    </a>",
"    ]. A decrease in capillary permeability (ie, improvement in blood-brain barrier function) can be identified within six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/14\">",
"     14",
"    </a>",
"    ], and changes of diffusion-weighted MRI indicating decreased edema are identifiable within 48 to 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/15\">",
"     15",
"    </a>",
"    ]. However, adequate reduction in elevated ICP resulting from peritumoral edema may take several days with glucocorticoid therapy alone, and additional treatment may be required in the initial management of these patients (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute treatment of elevated ICP'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Systemic glucocorticoids are indicated in all patients who have symptomatic peritumoral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is the standard agent, because its relative lack of mineralocorticoid activity reduces the potential for fluid retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, dexamethasone may be associated with a lower risk of infection and cognitive impairment compared to other glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of action of glucocorticoids for control of vasogenic edema is not fully understood.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    has recently been shown to upregulate Ang-1, a strong BBB-stabilizing factor, whereas it downregulates VEGF, a strong permeabilizing factor, in astrocytes and pericytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/19\">",
"     19",
"    </a>",
"    ]. Glucocorticoids may also increase the clearance of peritumoral edema by facilitating the transport of fluid into the ventricular system, from which it is cleared by cerebrospinal fluid (CSF) bulk flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe symptoms, the usual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    regimen consists of a 10 mg loading dose, followed by 4 mg four times per day or 8 mg twice daily. There is some evidence that lower doses (1 to 2 mg four times per day) may be as effective and less toxic in patients without impending herniation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/21\">",
"     21",
"    </a>",
"    ]. Although dexamethasone is typically administered in four divided daily doses, its biological half-life is sufficiently long to allow twice daily dosing and this approach is often used for maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/22\">",
"     22",
"    </a>",
"    ]. To minimize complications, subsequent dosing should be modified to use the lowest possible dose necessary to control peritumoral edema.",
"   </p>",
"   <p>",
"    Absorption of oral glucocorticoids is excellent and is complete within 30 minutes of administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/23\">",
"     23",
"    </a>",
"    ]. Intravenous dosing may be necessary if oral absorption cannot be assured, or if mentation is altered.",
"   </p>",
"   <p>",
"    Most patients begin to improve symptomatically within hours and achieve a maximum benefit from a given dose of glucocorticoids within 24 to 72 hours, although standard neuroimaging studies may not reveal decreased edema for at least a week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/22\">",
"     22",
"    </a>",
"    ]. In general, headaches tend to respond better than focal deficits. If a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    dose of 16",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of dexamethasone per day is insufficient, the dose may be increased up to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once patients have responded, glucocorticoids should be gradually withdrawn if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/25\">",
"     25",
"    </a>",
"    ]. Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , the most commonly used corticosteroid for brain edema, has a long duration of action, the drug should be tapered about every four days. For patients in good clinical condition, this may entail a reduction in dose of up to 50 percent every four days. However, for those not tolerating glucocorticoid withdrawal, a more protracted course and chronic treatment may be required.",
"   </p>",
"   <p>",
"    These recommendations are consistent with a systematic review and evidence-based clinical guidelines for the use of steroids in brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/26\">",
"     26",
"    </a>",
"    ]. Those guidelines recommended a dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    of 16 mg per day or more for patients with severe symptoms due to increased intracranial pressure and edema due to brain metastases. For patients with milder symptoms, a starting dose of 4 to 8 mg of dexamethasone daily was recommended; steroids are not recommended for asymptomatic patients. Based upon this review the drug should be tapered slowly over two week time period or longer in symptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the beneficial effect of glucocorticoids, they are associated with a large number of well known side effects (",
"    <a class=\"graphic graphic_table graphicRef71400 \" href=\"mobipreview.htm?24/28/25036\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) The frequency of these complications can be reduced by using the lowest possible dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/22\">",
"     22",
"    </a>",
"    ]. Common complications include insomnia, essential tremor, and hiccups; patients should be warned in advance that they may occur. Three complications are of particular concern to patients with brain tumors: gastrointestinal complications, steroid myopathy, and opportunistic infections such as Pneumocystis carinii pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Gastrointestinal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids increase the risk of gastrointestinal complications such as gastritis or peptic ulcer disease, especially when used in conjunction with other drugs such as nonsteroidal antiinflammatory agents (NSAIDs). Concurrent anticoagulation therapy and a prior history of peptic ulcer disease are other factors that can increase the likelihood of gastrointestinal bleeding in patients receiving glucocorticoids.",
"   </p>",
"   <p>",
"    The effectiveness of prophylactic therapy to prevent peptic ulceration in patients with brain tumors (especially those with gliomas and lymphomas, who often require prolonged therapy with high doses of glucocorticoids) is unknown. In NSAID-treated patients, proton pump inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ) can protect against both gastric and duodenal ulcerations. However, there are no studies evaluating the efficacy of these drugs in patients with brain tumors treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Standard doses of H2 blockers are",
"    <strong>",
"     not",
"    </strong>",
"    effective for the prevention of NSAID-induced gastric ulcers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We usually restrict prophylactic therapy with a proton pump inhibitor to the perioperative period and to patients receiving very high doses of glucocorticoids. For other patients, prophylactic therapy is probably unnecessary unless they are at high risk for developing peptic ulceration (eg, previous peptic ulcer disease, concurrent anticoagulation, NSAID therapy). When NSAIDs are necessary, use of a selective COX-2 inhibitor or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    appears to reduce the risk of gastrointestinal complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A less well recognized complication of glucocorticoid therapy is perforation of the gastrointestinal tract. This is frequently difficult to diagnose because clinical features of peritonitis can be masked by the glucocorticoids. The prevention of severe constipation may decrease the risk of intestinal perforation. A high index of suspicion is important since early diagnosis improves the outcome of this serious complication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H11#H11\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Gastrointestinal tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Steroid myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid-induced myopathy contributes significantly to morbidity in patients with brain tumors. Myopathy is a common complication, with an estimated incidence between 2 and 20 percent. The risk of developing steroid myopathy appears to be significantly lower in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , possibly due to induction of hepatic metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    by phenytoin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients develop proximal weakness between the ninth and twelfth weeks of glucocorticoid treatment, although there is marked variation in individual susceptibility. Some patients become weak after a low dose of glucocorticoids for a few weeks, while others never develop myopathy despite receiving large doses of glucocorticoids for months or years. The onset is usually subacute, occurring over several weeks. Muscle pain is not a feature and tendon reflexes are preserved.",
"   </p>",
"   <p>",
"    Treatment of steroid myopathy is difficult. Ideally, glucocorticoids should be discontinued but the lowest possible dose should be used if this is not feasible. Recovery after discontinuation of glucocorticoid therapy can be expected within two to three months but may be much slower if treatment is continued, even at a reduced dose.",
"   </p>",
"   <p>",
"    Another treatment approach is to change the glucocorticoid preparation. Steroid myopathy has been particularly associated with the use of fluorinated glucocorticoids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Although the evidence supporting this relationship is not strong, anecdotal reports suggest that weakness that develops during treatment with a fluorinated glucocorticoid may improve when equivalent doses of a nonfluorinated preparation are substituted. Some reports indicate that growth hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/27\">",
"     27",
"    </a>",
"    ], insulin-like growth factor-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/27\">",
"     27",
"    </a>",
"    ] and amino acid supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/28\">",
"     28",
"    </a>",
"    ] may ameliorate the weakness of steroid myopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pneumocystis carinii pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis carinii pneumonia (PCP) is a life-threatening opportunistic infection that occurs in immunocompromised hosts, including patients with brain tumors treated with glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of symptomatic PCP infection is increased while glucocorticoids are being tapered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Concurrent chemotherapy may be an additional risk factor for the development of PCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/29\">",
"     29",
"    </a>",
"    ]. In a retrospective review of 587 patients with primary brain tumors seen at a single institution over an eight year period, there were 11 histologically documented cases of PCP in 10 patients (1.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients had been on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for a median duration of three months when symptoms first developed. In 8 of 11 episodes, PCP occurred during the steroid tapering.",
"   </p>",
"   <p>",
"    The mechanism by which glucocorticoids predispose to the development of PCP is poorly understood, but suppression of cellular immunity leading to reactivation of latent infection probably plays a role. Why PCP more commonly develops during steroid tapering is also unknown. Possible factors include increased immune-mediated lung damage from PCP infection, which had been suppressed by higher doses of glucocorticoids, and a positive effect of glucocorticoids on surfactant phospholipids that are decreased in PCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians caring for patients with brain tumors who are receiving glucocorticoids should maintain a high index of suspicion for PCP. Although the hallmark of PCP is fever and dyspnea with or without a prominent dry cough, the presentation can be subtle and nonspecific. Thus, the diagnosis should be considered in any patient developing respiratory symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of PCP pneumonia in patients with brain tumors is the same as in other non-HIV infected patients and is discussed elsewhere. Because of the risk of PCP and its associated morbidity and mortality, we suggest PCP prophylaxis in patients who are receiving prolonged (more than six weeks) courses of glucocorticoids, especially as steroid therapy is withdrawn. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ACUTE TREATMENT OF ELEVATED ICP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant increase in ICP can be a medical emergency, and treatment should be undertaken as expeditiously as possible. Although glucocorticoids are an important component of therapy, additional interventions during the first 24 to 72 hours may be required. These approaches are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'General management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H29#H29\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Specific therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269793298\">",
"    <span class=\"h1\">",
"     STEROID WITHDRAWAL SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms not caused by recurrence of brain edema may develop during the course of the steroid taper (steroid withdrawal syndrome). These include headache and lethargy that may mimic recurrence of brain edema as well as myalgias and arthralgias (steroid pseudorheumatism). All of the symptoms respond to raising the dose slightly and tapering more slowly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC PLATEAU WAVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plateau waves are sustained pressure waves that normally occur within the brain and are caused by activities that transiently raise the ICP (eg, standing, sneezing, coughing). In the presence of a brain tumor, significant further increases in ICP can temporarily cut off cerebral perfusion, leading to loss of consciousness. Although the treatment of choice for such cases is glucocorticoids and acute neurosurgical intervention, patients with steroid-refractory symptomatic plateau waves may benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of brain tumors\", section on 'Syncope'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H2314865#H2314865\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Waveform analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NOVEL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the complications of glucocorticoid therapy, there is interest in alternate treatments for peritumoral edema. Corticotrophin-releasing factor reduces peritumoral edema by a direct effect on blood vessels independent of the release of adrenal glucocorticoids and has been effective in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a placebo-controlled phase III trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/19/38195?source=see_link\">",
"     corticorelin",
"    </a>",
"    acetate, a synthetic peptide of corticotropin-releasing factor, the primary endpoint of 50 percent reduction in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and improvement in performance scores was not reached. The study, however, demonstrated a strong trend in favor of corticorelin acetate leading to statistically significant reductions in steroid-related adverse events of myopathy and Cushingoid syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary study suggested that cyclooxygenase-2 (COX-2) inhibitors may be effective in treating cerebral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since VEGF plays an important role in the pathogenesis of peritumoral edema, anti-VEGF monoclonal antibodies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or inhibitors of VEGF receptors such as cediranib may be helpful in reducing the edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39335/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link&amp;anchor=H5#H5\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Vascular endothelial growth factor pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasogenic edema that surrounds many brain tumors contributes significantly to morbidity and requires treatment in conjunction with specific measures directed against the tumor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment of peritumoral vasogenic edema with glucocorticoids&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with severe edema, the usual starting schedule includes a loading dose of 10 mg, and then 4 mg four times a day or 8 mg twice a day. Lesser doses may be used in patients with mild to moderate symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To minimize complications, subsequent dosing should be modified to use the lowest possible dose necessary to control peritumoral edema. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate attention should be paid to prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treat potential complications of glucocorticoid treatment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      may be helpful in reducing peritumoral edema in patients who are refractory to steroids or have significant steroid-related complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link&amp;anchor=H5#H5\">",
"       \"Experimental treatment approaches for malignant gliomas\", section on 'Vascular endothelial growth factor pathway'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who have significantly elevated ICP, additional measures may be required while waiting for glucocorticoid treatment to become effective. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H19#H19\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'General management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H29#H29\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Specific therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Peritumoral edema. In: The Gliomas, WB Saunders, Philadelphia 1999. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/2\">",
"      Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/3\">",
"      Baethmann A, Maier-Hauff K, Sch&uuml;rer L, et al. Release of glutamate and of free fatty acids in vasogenic brain edema. J Neurosurg 1989; 70:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/4\">",
"      Black KL, Hoff JT, McGillicuddy JE, Gebarski SS. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol 1986; 19:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/5\">",
"      Takahashi JA, Fukumoto M, Igarashi K, et al. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992; 76:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/6\">",
"      Carlson MR, Pope WB, Horvath S, et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007; 13:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/7\">",
"      Provias J, Claffey K, delAguila L, et al. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997; 40:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/8\">",
"      Strugar JG, Criscuolo GR, Rothbart D, Harrington WN. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995; 83:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/9\">",
"      Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60:4959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/10\">",
"      Dobrogowska DH, Lossinsky AS, Tarnawski M, Vorbrodt AW. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol 1998; 27:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/11\">",
"      Machein MR, Kullmer J, Fiebich BL, et al. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 1999; 44:732.",
"     </a>",
"    </li>",
"    <li>",
"     Intensive and postoperative care of intracranial tumors. In: Neurological and Neurosurgical Intensive Care, 3rd, Raven Press, New York 1993. p.309.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/13\">",
"      Alberti E, Hartmann A, Sch&uuml;tz HJ, Schreckenberger F. The effect of large doses of dexamethasone on the cerebrospinal fluid pressure in patients with supratentorial tumors. J Neurol 1978; 217:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/14\">",
"      Jarden JO, Dhawan V, Moeller JR, et al. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann Neurol 1989; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/15\">",
"      Sinha S, Bastin ME, Wardlaw JM, et al. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry 2004; 75:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/16\">",
"      Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/17\">",
"      GALICICH JH, FRENCH LA, MELBY JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet 1961; 81:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/18\">",
"      Batchelor T, DeAngelis LM. Medical management of cerebral metastases. Neurosurg Clin N Am 1996; 7:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/19\">",
"      Kim H, Lee JM, Park JS, et al. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun 2008; 372:243.",
"     </a>",
"    </li>",
"    <li>",
"     Neurological effects of steroid treatment. In: Neurological Complications of Cancer Treatment, Butterworth-Heinemann, Boston  p.173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/21\">",
"      Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44:675.",
"     </a>",
"    </li>",
"    <li>",
"     Use of glucocorticoids in neuro-oncology. In: Neurological complications of cancer, Marcel Dekker, New York 1995. p.199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/23\">",
"      Kehlet H, Binder C, Blichert-Toft M. Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf) 1976; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/24\">",
"      Vick NA, Wilson CB. Total care of the patient with a brain tumor with consideration of some ethical issues. Neurol Clin 1985; 3:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/25\">",
"      Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol 2004; 16:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/26\">",
"      Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/27\">",
"      Kanda F, Okuda S, Matsushita T, et al. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001; 56 Suppl 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/28\">",
"      Paddon-Jones D, Wolfe RR, Ferrando AA. Amino acid supplementation for reversing bed rest and steroid myopathies. J Nutr 2005; 135:1809S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/29\">",
"      Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996; 27:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/30\">",
"      Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991; 48:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/31\">",
"      Rice WR, Singleton FM, Linke MJ, Walzer PD. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest 1993; 92:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/32\">",
"      Watling CJ, Cairncross JG. Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. J Neurosurg 2002; 97:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/33\">",
"      Tjuvajev J, Uehara H, Desai R, et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 1996; 56:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/34\">",
"      Villalona-Calero MA, Eckardt J, Burris H, et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 1998; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/35\">",
"      Hariharan, S, Shapiro, W, Chang, S, et al. Phase II randomized dose-ranging trial of human corticotrophin releasing factor in symptomatic brain tumor patients. Neurology 2000; 54:A12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/36\">",
"      Recht L, Mechtler LL, Wong ET, et al. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy. J Clin Oncol 2013; 31:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/37\">",
"      Portnow J, Suleman S, Grossman SA, et al. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro Oncol 2002; 4:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/38\">",
"      Gerstner ER, Duda DG, di Tomaso E, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009; 6:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39335/abstract/39\">",
"      Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5182 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39335=[""].join("\n");
var outline_f38_26_39335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Gastrointestinal complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Steroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pneumocystis carinii pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACUTE TREATMENT OF ELEVATED ICP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H269793298\">",
"      STEROID WITHDRAWAL SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SYMPTOMATIC PLATEAU WAVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NOVEL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5182|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/28/25036\" title=\"table 1\">",
"      Complications corticosteroid Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39336="Microbiology, pathogenesis, and epidemiology of relapsing fever";
var content_f38_26_39336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, pathogenesis, and epidemiology of relapsing fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39336/contributors\">",
"     Alan G Barbour, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39336/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39336/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/26/39336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever, caused by spirochetes of the Borrelia genus, is an arthropod-borne infection that occurs in two major forms: tick-borne (TBRF) and louse-borne (LBRF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"     1",
"    </a>",
"    ]. As the name implies, relapsing fever is characterized by recurrent episodes of fever that accompanies spirochetemia.",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, and epidemiology of relapsing fever will be reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=see_link\">",
"     \"Clinical features, diagnosis, and management of relapsing fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick-borne relapsing fever is caused by eight or more Borrelia species, whereas louse-borne relapsing fever is caused only by B. recurrentis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The agents of relapsing fever are spirochetes, a morphologically unique group of bacteria species, which cause syphilis, leptospirosis, and Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/3\">",
"     3",
"    </a>",
"    ]. As their own phylum of bacteria, spirochetes differ substantially from both gram-negative and gram-positive organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The agents of relapsing fever and Lyme disease are in the genus Borrelia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"     1",
"    </a>",
"    ]. Every known species of Borrelia is host-associated; free-living forms have not been found. Borrelias are usually extracellular in location within the host, but they pass through endothelial cell layers to enter and leave the blood. Borrelia spp are susceptible to drying, hypotonic or hypertonic conditions, dilute detergents, and temperatures above 40&ordm;C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Structure of the organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirochetes are wavy or helical filaments in shape, with both inner and outer cell membranes separated by a periplasmic space. One or more flagella are inserted at each end and run the length of the organism through the periplasmic space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/3\">",
"     3",
"    </a>",
"    ]. Most members of the genus Borrelia are approximately 0.2 microns in width and 10 to 30 microns in length. The spirochetes are too thin to be seen in wet mounts by light microscopy but can be visualized by phase microscopy or dark field microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"     1",
"    </a>",
"    ]. For fixed blood smears, the spirochetes are detected by Wright or Giemsa stain. Borrelias have fewer and larger amplitude waves than the tightly-coiled treponemes and leptospires.",
"   </p>",
"   <p>",
"    Borrelias lack classical endotoxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/5\">",
"     5",
"    </a>",
"    ], but they do have outer membrane lipoproteins that are potent B cell mitogens and stimulators of the release of pro-inflammatory cytokines, such as tumor necrosis factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The lipoproteins are anchored at their amino-terminal ends by fatty acids embedded in the fluid membrane of the spirochetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cultivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelias are microaerophilic microorganisms with complex nutritional requirements for growth in cell-free medium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The medium contains serum, glucose, albumin, peptides, amino acids, vitamins, a thickening agent such as gelatin, and, critically, N-acetylglucosamine, the building block for an arthropod's chitin exoskeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A commonly used medium is Barbour-Stoenner-Kelly, or \"BSK\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/14\">",
"     14",
"    </a>",
"    ]. B. recurrentis was only successfully cultivated in the laboratory for the first time in 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/15\">",
"     15",
"    </a>",
"    ], and some Borrelia species have yet to be cultivated in serial passage outside of a natural or experimental host animal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genome and taxonomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unique feature of the genus Borrelia is a largely linear genome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Each genome consists of a linear chromosome of about 1000 kilobases and one copy each of different types of linear and circular plasmids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. All Borrelia species studied to date have GC contents of approximately 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The species of Borrelia causing relapsing fever and Lyme disease form two related but distinct groups by DNA sequences of their ribosomal RNA genes and their genomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. A phylogeny of relapsing fever agents based upon DNA sequences has generally confirmed a taxonomy based upon biological considerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/21\">",
"     21",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56833 \" href=\"mobipreview.htm?33/56/34699\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the past, the different species of tick-borne relapsing fever agents were categorized according to the species of tick that carried them in nature and their host range among ticks and experimental animals in the laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/21\">",
"     21",
"    </a>",
"    ]. The several tick-borne species are generally divided between Old World (or Paleartic and Afrotropical) species, such as B. duttonii and B. crocidurae, and New World (or Neartic and neotropical) species, such as B. hermsii and B. turicatae. It is likely that additional species exist: in a study of patients with relapsing fever in Tanzania, 11 of 17 isolates were B. duttonii, but six were a new species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/22\">",
"     22",
"    </a>",
"    ]. The louse-borne B. recurrentis is closely related to B. duttonii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spirochetes can be detected in tissue sections with silver stains, such as Warthin-Starry or modified Dieterle, or by immunofluorescence with conjugated antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Borrelias move through or between endothelial cells as they leave the blood to enter the tissues, but they do not appear to proliferate in endothelial or phagocytic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/26\">",
"     26",
"    </a>",
"    ]. Spirochetes have been found in the spleen, liver, brain, eye, and kidney in autopsy cases and experimentally infected animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The severity of relapsing fever generally correlates directly with the numbers of spirochetes in the blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In fatal cases of relapsing fever, the usual gross findings were widespread petechial hemorrhages, enlarged spleen and liver, and an edematous, congested brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The most common general findings on histologic examination of autopsy cases are swelling of endothelial cells, microvascular leakage, perivascular mononuclear cell infiltrates, microabscesses, and hemorrhages. Fatal cases of louse-borne relapsing fever frequently have myocarditis with histiocytic infiltrates and microhemorrhages. The spleen and liver, but not the kidneys or adrenals, often have focal areas of necrosis. Although bleeding is a common complication of louse-borne relapsing fever, evidence of intravascular coagulation is not prominent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borrelia infection most commonly begins with contact with a tick or louse bearing the spirochetes. Transplacental transmission from mother to fetus also occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/29\">",
"     29",
"    </a>",
"    ]. Rarely, the disease is acquired through accidental inoculation of infected blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/30\">",
"     30",
"    </a>",
"    ] or contact of blood with abraded or lacerated skin, mucous membranes, or the conjunctiva.",
"   </p>",
"   <p>",
"    Transmission to humans by aerosol, fomites, human saliva, urine, feces, or sexual contact does not occur. The incubation period between the exposure and the first fever is between 3 to 12 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initiation of infection and mechanism of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single spirochete is sufficient to initiate an infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"     1",
"    </a>",
"    ]. Once in the blood, the borrelias divide every 6 to 12 hours until they number 10",
"    <sup>",
"     5",
"    </sup>",
"    to 10",
"    <sup>",
"     8",
"    </sup>",
"    per mL of blood. The spirochetes leave the blood to invade the brain, eye, inner ear, liver, heart, and other organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, the blood is the main site of replication during the acute illness.",
"   </p>",
"   <p>",
"    Antigenic variation accounts for the reappearance of spirochetes in the blood, which also correlates with relapses of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/33\">",
"     33",
"    </a>",
"    ]. By changing a major antigen on its surface, the Borrelia population is able to evade the host immune response. Other pathogens that use the strategy of multiphasic antigenic variation as a strategy to evade specific immunity are African trypanosomes and Neisseria gonorrhoeae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During or just before a recurrence of fever, spirochetes can be easily seen by microscopic examination of the blood. They may be as frequent as erythrocytes. The borrelias do not completely disappear from the blood between febrile periods, but the numbers diminish to the point where they are undetectable by microscopic examination of blood smears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Significance of serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single strain of a relapsing fever Borrelia spp is able to produce several antigenically distinct variants that are called serotypes. As an example, a mouse or human infected with one strain of relapsing fever Borrelia spp may initially have serotype A in the blood, then have serotype B during the first relapse, and finally serotype C during a second relapse. However, the order of serotype appearance is not rigidly fixed. In passive transfer experiments, antiserum raised to a specific serotype (eg, A) protects mice against challenge with the homologous serotype but not against other serotypes (eg, B or C).",
"   </p>",
"   <p>",
"    The antigens that determine serotype identity of relapsing fever Borrelia spp are abundant outer membrane lipoproteins called variable membrane proteins (VMPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In Borrelia hermsii, for example, there are approximately 30 to 40 different VMPs. There can be as little as 30 percent identity in amino acid sequences between two different VMPs of the same strain of a relapsing fever Borrelia spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The lack of cross-reactivity between antisera raised against different serotypes, as noted above, is explained by the considerable divergence in the primary sequences of VMPs.",
"   </p>",
"   <p>",
"    Studies in experimental mice suggest that differences in disease expression with B. turicatae infection are determined by variability in VMPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/32\">",
"     32",
"    </a>",
"    ]. With mixed infection, one serotype may predominate in the blood while another invades the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Variable membrane proteins",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a complete or near-complete gene for each VMP protein. Only one VMP gene is expressed at a time in a cell. Expression of this gene occurs at a site near the end of a linear plasmid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The other 30 or 40 VMP genes in the genome are also located on linear plasmids, often tandemly arrayed, but they are silent (eg, not expressed in this storage or archival form) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/43\">",
"     43",
"    </a>",
"    ]. The expression site, unlike the silent sites, has a promoter adjacent to the 5' end of the VMP gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During infection, a different VMP gene replaces the one at the expression site at a frequency of approximately 10",
"    <sup>",
"     -3",
"    </sup>",
"    to 10",
"    <sup>",
"     -4",
"    </sup>",
"    per cell generation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/34\">",
"     34",
"    </a>",
"    ]. In other words, by the time the population size in an infection reaches 1000 to 10,000 organisms, a new serotype has probably appeared. The new serotype is still infrequent at the time the host responds to the infecting serotype with an outpouring of IgM antibodies. But the new serotype continues to proliferate while the original infecting serotype is cleared from the blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/45\">",
"     45",
"    </a>",
"    ]. Once the second serotype reaches a population size of 1000 or more organisms in the animal, another one or two serotypes have spontaneously appeared. The antibodies do not cause the change in serotype; they merely select against the majority of cells in the population, allowing new serotypes to predominate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mechanisms of gene replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two ways in which a VMP gene at the expression site is replaced by another VMP gene, thereby switching the serotype of the organism. The first and most common mechanism is recombination between two linear plasmids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. A simplified representation of such a switch in VMP genes is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef66891 \" href=\"mobipreview.htm?9/8/9357\">",
"     figure 1",
"    </a>",
"    ). The boundaries for this recombination are regions of sequence identity between silent and expression sites around and flanking the 5' and 3' ends of the expressed and silent VMP genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/38,42,44\">",
"     38,42,44",
"    </a>",
"    ]. The stimulus for the recombination is probably a single strand or double strand break at the expression site.",
"   </p>",
"   <p>",
"    The second mechanism by which a new VMP gene is expressed is an intramolecular recombination between two tandemly arrayed VMP genes on the same plasmid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/46\">",
"     46",
"    </a>",
"    ]. A deletion between short direct repeats at the 5' ends of each of the two genes effectively excises the sitting vmp gene. The one behind moves up with deletion to take its place next to the promoter. After this deletion, the newly expressed VMP gene is susceptible to further small gene conversions that provide further diversity of the VMP gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/43\">",
"     43",
"    </a>",
"    ]. Ironically, this is similar to what happens with immunoglobulin genes: first there is a deletion to bring about joining of separated gene segments, and thereafter there are somatic mutations at the rearranged locus. The relapsing fever agent's evasion strategy matches the offense the immune system uses against it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Role in tissue localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the attention they draw from the immune system, VMPs also have a role in tissue localization during infection. Within a given species, certain serotypes can invade the brain, while other serotypes, which differ only in their VMPs, cannot [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/24,32\">",
"     24,32",
"    </a>",
"    ]. Some species of Borrelia, such as B. duttonii in Africa and B. turicatae in North America, are particularly noted for their neurotropism, that is, the ability to invade the central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever is primarily an extracellular infection of the blood. Involvement of other organs, such as the CNS, the eye, and liver, is the consequence of the large numbers of intravascular organisms migrating into tissues. IgM antibodies alone are sufficient to limit infection in infected animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental animals with deficient or nonexistent T cell function, such as nude mice, are as effective in clearing spirochetes from the blood as their immunocompetent counterparts. Whether T cells play a more important role in long-term protection from infection or in control of the infection in the CNS remains to be determined.",
"   </p>",
"   <p>",
"    Because specific antibodies to outer membrane proteins, even Fab monomers, can kill borrelias in the absence of complement or phagocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], deficiencies in the latter immune effectors may not hinder clearance of borrelias from the blood. Immune deficiencies known to increase the seriousness of the disease and prolong the infection are absence of the spleen and impaired B-cell function.",
"   </p>",
"   <p>",
"    Animals and humans have antibodies to a number of different components of spirochetes during infection, but only those directed against the VMPs appear to be effective in controlling the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example, patients convalescing from relapsing fever are found to have antibodies to heat-shock proteins and flagella, among other components of the Borrelia spp, but in passive transfer experiments, these antibodies are not protective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/49\">",
"     49",
"    </a>",
"    ]. No other, less variable, antigens to which the infected animal or person makes neutralizing antibody or responds with cytotoxic T cells have been identified. The reduced numbers of fully virulent spirochetes in the blood during relapses in comparison to the first fever indicates that there are specific or non-specific factors that limit the infection after the initial attack.",
"   </p>",
"   <p>",
"    The immune response often is not successful in clearing borrelias from the brain, cerebrospinal fluid, or eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/31,45\">",
"     31,45",
"    </a>",
"    ]. In these locations relapsing fever spirochetes, much like Treponema pallidum, may persist for years.",
"   </p>",
"   <p>",
"    With increasing concentrations of neutralizing antibodies in the serum, spirochetes are cleared from the blood. Lysis in the blood or spleen may be more rapid after opsonization and complement fixation. This event is often accompanied by a \"crisis\" or worsening condition of the patient. This crisis phenomenon with fever and hypotension during relapsing fever is very similar to the Jarisch-Herxheimer reaction, which occurs soon after the start of antibiotic therapy especially in the treatment of syphilis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=see_link\">",
"     \"Clinical features, diagnosis, and management of relapsing fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of Borrelia recurrentis, relapsing fever Borrelia spp are transmitted from one vertebrate to another by ticks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tick-borne",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major types of ticks are ixodid or hard-bodied ticks and argasid or soft-bodied ticks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/51\">",
"     51",
"    </a>",
"    ]. The vectors of TBRF are argasid ticks, usually of the genus Ornithodoros. Ixodid ticks are the vectors of Lyme disease, Rocky Mountain spotted fever (RMSF), anaplasmosis, and Colorado tick fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    .) The following figure shows an Ornithodoros turicata tick (",
"    <a class=\"graphic graphic_figure graphicRef64167 \" href=\"mobipreview.htm?2/44/2767\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ornithodoros ticks usually remain close or near to the habitations of animals and humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/52\">",
"     52",
"    </a>",
"    ]. Unlike the ixodid vectors of Lyme disease and RMSF, they are not found on vegetation in the forest or brush. Instead, Ornithodoros ticks usually attach to humans residing in or visiting an infested house, other dwelling, or a cave. In Africa, the Middle East, and parts of Asia, the ticks live in the thatched roofs of the houses or in the cracks of mud walls or floors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/52\">",
"     52",
"    </a>",
"    ]. In western and southwestern United States, relapsing fever has been acquired in caves, crawling under a building, or sleeping in or near rustic cabins, particularly those built of logs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Humans share the habitation with rodents or other mammals, such as pigs in these locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Blood meal and risk of acquiring infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ornithodoros ticks usually feed on just one type of animal, such as squirrels, during their lifetimes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/51\">",
"     51",
"    </a>",
"    ]. By contrast, the ixodid tick vectors usually feed on at least two different types of animals as they mature through larva, nymph, and adult stages. Ornithodoros ticks may live for up to 15 to 20 years and can survive without a blood meal for several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blood feeding itself takes less than an hour and usually occurs at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/51\">",
"     51",
"    </a>",
"    ]. Consequently, most people are not aware of the bite or exposure. By contrast, most ixodid ticks feed for days at a time and attach to people during the day as they move through forested areas or bushy vegetation. The only sign of an Ornithodoros tick bite may be a small red or violaceous papule with a central eschar that appears within a few days of the exposure. The risk of relapsing fever after a bite of an infected tick is approximately 50 percent. TBRF is acquired directly through the tick bite, usually from saliva secreted by the tick into the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vertebrate reservoirs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing fever is maintained in the environment by vertebrate reservoirs, which harbor the spirochetes. These are usually rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"     1",
"    </a>",
"    ], but other animal reservoirs include wild and domestic pigs, insectivores, and bats. In some areas of Africa in which the ticks live in houses, the natural reservoir for tick-borne B. duttonii is other humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Geographic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;TBRF occurs on every continent except Antarctica, Australia, and the southwest Pacific (",
"    <a class=\"graphic graphic_table graphicRef56833 \" href=\"mobipreview.htm?33/56/34699\">",
"     table 1",
"    </a>",
"    ). In the last decade it has been reported from the United States and Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/54,56\">",
"     54,56",
"    </a>",
"    ], Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/57-59\">",
"     57-59",
"    </a>",
"    ], and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/60\">",
"     60",
"    </a>",
"    ]. In the United States TBRF usually occurs west of the Mississippi River, particularly in the mountainous West and the high deserts and plains of the Southwest. In the mountains of California, Utah, Arizona, New Mexico, Colorado, Oregon, and Washington, infections are usually caused by B. hermsii and are often acquired from exposure to cabins in pine forests at altitudes of 1000 to 2700 meters. In the nonmountainous regions of the Southwest the usual agent of relapsing fever is B. turicatae. Common exposures in this region are entering caves and crawling under houses. A Borrelia species related to the agents of relapsing fever has been found in dogs in Florida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/61\">",
"     61",
"    </a>",
"    ]. It is possible that the risk to humans of relapsing fever agents extends now into the southeastern United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Africa, TBRF is caused by B. crocidurae, which is transmitted by Ornithodoros erraticus, or by B. duttonii, which is transmitted by O. moubata. The incidence of TBRF in west Africa (Senegal, Mali, and Mauritania) was evaluated during the time period 1990 to 2003 through clinical surveillance and blood testing of individuals with fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/63\">",
"     63",
"    </a>",
"    ]. The average incidence was 11 per 100 person-years, with a range of 4 in 1990 to 25 in 1997. Twenty-six of the 30 studied villages (87 percent) were colonized with the tick vector; the B. crocidurae infection rate of the vector was 31 percent. This incidence of TBRF is the highest described in Africa for any bacterial disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Louse-borne",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vector of B. recurrentis is the body louse, Pediculus humanus corporis, which only feeds on humans and lives on clothing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27\">",
"     27",
"    </a>",
"    ]. Non-human primates can be infected with B. recurrentis, but they are not critical for maintaining the infection in nature. Humans are probably the only reservoir of B. recurrentis.",
"   </p>",
"   <p>",
"    B. recurrentis is currently endemic in Ethiopia and Sudan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. The highlands region of Ethiopia may have hundreds to thousands of cases of LBRF annually. The highest incidence in this region is during the rainy season when the poor gather together in shelters. Lice move from one person to another, thus spreading the infection to new hosts. When LBRF spreads outside the Horn of Africa, true epidemics can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homeless people are also highly exposed to body lice in crowded shelters. A prospective study of 930 homeless people in Marseilles, France detected body lice in 22 percent and IgG antibodies to B. recurrentis in 15 (1.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Famine, war, and the movements and congregations of refugees are common predisposing factors for epidemics of LBRF and epidemic typhus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27\">",
"     27",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/29/38358?source=see_link\">",
"     \"Epidemic typhus\"",
"    </a>",
"    ). Under these conditions there is crowding, poor hygiene, few changes of clothing, and lack of access to washing. The large epidemics of LBRF during this century occurred around the two world wars. Millions of people were infected in these epidemics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/69\">",
"     69",
"    </a>",
"    ], and at least one million deaths occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The louse has a life span measured in weeks, instead of years for the tick, and must feed on blood frequently. B. recurrentis grows in the body cavity of the louse but does not appear in the saliva or feces. When people crush a louse with their fingers, the organism is introduced at the bite site, into the skin of the crushing fingers, or into the conjunctivae when they rub their eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsing fever, caused by spirochetes of the Borrelia genus, is an arthropod-borne infection, which occurs in two major forms: tick-borne (TBRF) and louse-borne (LBRF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39336/abstract/1\">",
"       1",
"      </a>",
"      ]. As the name implies, relapsing fever is characterized by recurrent episodes of fever that accompanies spirochetemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tick-borne relapsing fever is caused by eight or more Borrelia species, whereas louse-borne relapsing fever is caused only by B. recurrentis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spirochetes are wavy or helical filaments in shape, with both inner and outer cell membranes separated by a periplasmic space. Most members of the genus Borrelia are approximately 0.2 microns in width and 10 to 30 microns in length. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Structure of the organisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The spirochetes are too thin to be seen in wet mounts by light microscopy but can be visualized by phase microscopy or dark field microscopy. For fixed blood smears, the spirochetes are detected by Wright or Giemsa stain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Structure of the organisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The spirochetes are detected in tissue sections with silver stains, such as Warthin-Starry or modified Dieterle, or by immunofluorescence with conjugated antibodies. Spirochetes have been found in the spleen, liver, brain, eye, and kidney in autopsy cases and experimentally infected animals. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A borrelia infection begins with contact with a tick or louse bearing the spirochetes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antigenic variation accounts for the reappearance of spirochetes in the blood, which also correlates with relapses of illness. By changing a major antigen on its surface, the Borrelia population is able to evade the host immune response. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initiation of infection and mechanism of relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With increasing concentrations of neutralizing antibodies in the serum, spirochetes are cleared from the blood. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vectors of tick-borne relapsing fever (TBRF) are argasid, or soft bodied, ticks, usually of the genus Ornithodoros. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tick-borne'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blood feeding itself takes less than an hour and usually occurs at night. Consequently, most people are not aware of the bite or exposure. TBRF is acquired directly through the tick bite, usually from saliva secreted by the tick into the skin. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Blood meal and risk of acquiring infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TBRF occurs on every continent except Antarctica, Australia, and the southwest Pacific (",
"      <a class=\"graphic graphic_table graphicRef56833 \" href=\"mobipreview.htm?33/56/34699\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Geographic distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vector of B. recurrentis is the body louse, Pediculus humanus corporis, which only feeds on humans. Homeless people are also highly exposed to body lice in crowded shelters. &nbsp;Famine, war, and the movements and congregations of refugees are common predisposing factors for epidemics of LBRF. B. recurrentis is currently endemic in Ethiopia and Sudan. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Louse-borne'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Barbour AG. Relapsing fever. In: Tick-Borne Diseases of Humans, Goodman JL, Dennis DT, Sonenshine DE (Eds), Washington, DC 2005. p.268.",
"    </li>",
"    <li>",
"     Rhee KY, Johnson WD, Jr. Borrelia species (relapsing fever). In: Principles and Practice of Infectious Diseases, 7, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. p.3067.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/3\">",
"      Barbour AG, Hayes SF. Biology of Borrelia species. Microbiol Rev 1986; 50:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/4\">",
"      Paster BJ, Dewhirst FE, Weisburg WG, et al. Phylogenetic analysis of the spirochetes. J Bacteriol 1991; 173:6101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/5\">",
"      Takayama K, Rothenberg RJ, Barbour AG. Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1987; 55:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/6\">",
"      Radolf JD, Norgard MV, Brandt ME, et al. Lipoproteins of Borrelia burgdorferi and Treponema pallidum activate cachectin/tumor necrosis factor synthesis. Analysis using a CAT reporter construct. J Immunol 1991; 147:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/7\">",
"      Brandt ME, Riley BS, Radolf JD, Norgard MV. Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect Immun 1990; 58:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/8\">",
"      Bergstr&ouml;m S, Bundoc VG, Barbour AG. Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol 1989; 3:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/9\">",
"      Barbour AG, Burgdorfer W, Grunwaldt E, Steere AC. Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest 1983; 72:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/10\">",
"      Kelly R. Cultivation of Borrelia hermsi. Science 1971; 173:443.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson R. Comparative spirochete physiology and cellular composition. In: The Biology of Parasitic Spirochetes, Johnson RC (Ed), Academic Press, New York 1976. p.39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/12\">",
"      Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 1984; 57:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/13\">",
"      Barbour AG. Cultivation of Borrelia: a historical overview. Zentralbl Bakteriol Mikrobiol Hyg A 1986; 263:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/14\">",
"      Barbour AG, Burgdorfer W, Hayes SF, et al. Isolation of a cultivable spirochete from Ixodes ricinus ticks of Switzerland. Curr Microbiol 1983; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/15\">",
"      Lescot M, Audic S, Robert C, et al. The genome of Borrelia recurrentis, the agent of deadly louse-borne relapsing fever, is a degraded subset of tick-borne Borrelia duttonii. PLoS Genet 2008; 4:e1000185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/16\">",
"      Ferdows MS, Barbour AG. Megabase-sized linear DNA in the bacterium Borrelia burgdorferi, the Lyme disease agent. Proc Natl Acad Sci U S A 1989; 86:5969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/17\">",
"      Casjens S. Evolution of the linear DNA replicons of the Borrelia spirochetes. Curr Opin Microbiol 1999; 2:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/18\">",
"      Hinnebusch J, Barbour AG. Linear- and circular-plasmid copy numbers in Borrelia burgdorferi. J Bacteriol 1992; 174:5251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/19\">",
"      Kitten T, Barbour AG. The relapsing fever agent Borrelia hermsii has multiple copies of its chromosome and linear plasmids. Genetics 1992; 132:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/20\">",
"      Hyde FW, Johnson RC. Genetic relationship of lyme disease spirochetes to Borrelia, Treponema, and Leptospira spp. J Clin Microbiol 1984; 20:151.",
"     </a>",
"    </li>",
"    <li>",
"     Barbour AG. Microbe-Vector Interactions in Vector-Borne Diseases, Society for General Microbiology Symposium 63.. In: Microbe-Vector Interactions in Vector-Borne Diseases, Society for General Microbiology Symposium 63, Gillespie SH, Smith GL, OSbourn A (Eds), Cambridge University Press, Cambridge 2004. p.75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/22\">",
"      Kisinza WN, McCall PJ, Mitani H, et al. A newly identified tick-borne Borrelia species and relapsing fever in Tanzania. Lancet 2003; 362:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/23\">",
"      Duray PH. The surgical pathology of human Lyme disease. An enlarging picture. Am J Surg Pathol 1987; 11 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/24\">",
"      Pennington PM, Allred CD, West CS, et al. Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease. Infect Immun 1997; 65:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/25\">",
"      Park HK, Jones BE, Barbour AG. Erythema chronicum migrans of Lyme disease: diagnosis by monoclonal antibodies. J Am Acad Dermatol 1986; 15:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/26\">",
"      Comstock LE, Thomas DD. Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect Immun 1989; 57:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/27\">",
"      Bryceson AD, Parry EH, Perine PL, et al. Louse-borne relapsing fever. Q J Med 1970; 39:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/28\">",
"      Southern, P, Sanford, J. Relapsing fever. A clinical and microbiological review. Medicine 1969; 48:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/29\">",
"      Jongen VH, van Roosmalen J, Tiems J, et al. Tick-borne relapsing fever and pregnancy outcome in rural Tanzania. Acta Obstet Gynecol Scand 1997; 76:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/30\">",
"      L&oacute;pez-Cort&eacute;s L, Lozano de Le&oacute;n F, G&oacute;mez-Mateos JM, et al. Tick-borne relapsing fever in intravenous drug abusers. J Infect Dis 1989; 159:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/31\">",
"      Cadavid D, Bundoc V, Barbour AG. Experimental infection of the mouse brain by a relapsing fever Borrelia species: a molecular analysis. J Infect Dis 1993; 168:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/32\">",
"      Cadavid D, Thomas DD, Crawley R, Barbour AG. Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis. J Exp Med 1994; 179:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/33\">",
"      Barbour AG. Antigenic variation of a relapsing fever Borrelia species. Annu Rev Microbiol 1990; 44:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/34\">",
"      Stoenner HG, Dodd T, Larsen C. Antigenic variation of Borrelia hermsii. J Exp Med 1982; 156:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/35\">",
"      Barbour AG, Tessier SL, Stoenner HG. Variable major proteins of Borrellia hermsii. J Exp Med 1982; 156:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/36\">",
"      Barstad PA, Coligan JE, Raum MG, Barbour AG. Variable major proteins of Borrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides. J Exp Med 1985; 161:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/37\">",
"      Burman N, Bergstr&ouml;m S, Restrepo BI, Barbour AG. The variable antigens Vmp7 and Vmp21 of the relapsing fever bacterium Borrelia hermsii are structurally analogous to the VSG proteins of the African trypanosome. Mol Microbiol 1990; 4:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/38\">",
"      Restrepo BI, Kitten T, Carter CJ, et al. Subtelomeric expression regions of Borrelia hermsii linear plasmids are highly polymorphic. Mol Microbiol 1992; 6:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/39\">",
"      Carter CJ, Bergstr&ouml;m S, Norris SJ, Barbour AG. A family of surface-exposed proteins of 20 kilodaltons in the genus Borrelia. Infect Immun 1994; 62:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/40\">",
"      Cadavid D, Garcia E, Gelderblom H. Coinfection with Borrelia turicatae serotype 2 prevents the severe vestibular dysfunction and earlier mortality caused by serotype 1. J Infect Dis 2007; 195:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/41\">",
"      Plasterk RH, Simon MI, Barbour AG. Transposition of structural genes to an expression sequence on a linear plasmid causes antigenic variation in the bacterium Borrelia hermsii. Nature 1985; 318:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/42\">",
"      Kitten T, Barbour AG. Juxtaposition of expressed variable antigen genes with a conserved telomere in the bacterium Borrelia hermsii. Proc Natl Acad Sci U S A 1990; 87:6077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/43\">",
"      Restrepo BI, Barbour AG. Antigen diversity in the bacterium B. hermsii through \"somatic\" mutations in rearranged vmp genes. Cell 1994; 78:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/44\">",
"      Barbour AG, Burman N, Carter CJ, et al. Variable antigen genes of the relapsing fever agent Borrelia hermsii are activated by promoter addition. Mol Microbiol 1991; 5:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/45\">",
"      Barbour AG. Immunobiology of relapsing fever. Contrib Microbiol Immunol 1987; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/46\">",
"      Restrepo BI, Carter CJ, Barbour AG. Activation of a vmp pseudogene in Borrelia hermsii: an alternate mechanism of antigenic variation during relapsing fever. Mol Microbiol 1994; 13:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/47\">",
"      Sadziene A, Jonsson M, Bergstr&ouml;m S, et al. A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein. Infect Immun 1994; 62:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/48\">",
"      Sadziene A, Thompson PA, Barbour AG. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis 1993; 167:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/49\">",
"      Fikrig E, Barthold SW, Marcantonio N, et al. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun 1992; 60:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/50\">",
"      Hoogstraal H. Ticks and spirochetes. Acta Trop 1979; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     Sonenshine D. Biology of Ticks. Oxford University Press, New York, 1991.",
"    </li>",
"    <li>",
"     Felsenfeld O. Borrelia. In: Strains, Vectors, Human and Animal Borreliosis, Warren H Greene, Inc, St Louis 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/53\">",
"      Horton JM, Blaser MJ. The spectrum of relapsing fever in the Rocky Mountains. Arch Intern Med 1985; 145:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/54\">",
"      Centers for Disease Control (CDC). Outbreak of relapsing fever--Grand Canyon National Park, Arizona, 1990. MMWR Morb Mortal Wkly Rep 1991; 40:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/55\">",
"      Fihn S, Larson EB. Tick-borne relapsing fever in the Pacific Northwest: an underdiagnosed illness? West J Med 1980; 133:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/56\">",
"      Dworkin MS, Anderson DE Jr, Schwan TG, et al. Tick-borne relapsing fever in the northwestern United States and southwestern Canada. Clin Infect Dis 1998; 26:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/57\">",
"      Colebunders R, De Serrano P, Van Gompel A, et al. Imported relapsing fever in European tourists. Scand J Infect Dis 1993; 25:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/58\">",
"      Trape JF, Duplantier JM, Bouganali H, et al. Tick-borne borreliosis in west Africa. Lancet 1991; 337:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/59\">",
"      Barclay AJ, Coulter JB. Tick-borne relapsing fever in central Tanzania. Trans R Soc Trop Med Hyg 1990; 84:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/60\">",
"      Anda P, S&aacute;nchez-Yebra W, del Mar Vitutia M, et al. A new Borrelia species isolated from patients with relapsing fever in Spain. Lancet 1996; 348:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/61\">",
"      Breitschwerdt EB, Nicholson WL, Kiehl AR, et al. Natural infections with Borrelia spirochetes in two dogs from Florida. J Clin Microbiol 1994; 32:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/62\">",
"      Barbour AG, Maupin GO, Teltow GJ, et al. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J Infect Dis 1996; 173:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/63\">",
"      Vial L, Diatta G, Tall A, et al. Incidence of tick-borne relapsing fever in west Africa: longitudinal study. Lancet 2006; 368:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/64\">",
"      Borgnolo G, Hailu B, Ciancarelli A, et al. Louse-borne relapsing fever. A clinical and an epidemiological study of 389 patients in Asella Hospital, Ethiopia. Trop Geogr Med 1993; 45:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/65\">",
"      Sundnes KO, Haimanot AT. Epidemic of louse-borne relapsing fever in Ethiopia. Lancet 1993; 342:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/66\">",
"      Ahmed MA, Abdel Wahab SM, Abdel Malik MO, et al. Louse-borne relapsing fever in the Sudan. A historical review and a clinico-pathological study. Trop Geogr Med 1980; 32:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/67\">",
"      BODMAN RI, STEWART IS. Louse-borne relapsing fever in Persia. Br Med J 1948; 1:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/68\">",
"      Brouqui P, Stein A, Dupont HT, et al. Ectoparasitism and vector-borne diseases in 930 homeless people from Marseilles. Medicine (Baltimore) 2005; 84:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39336/abstract/69\">",
"      FELSENFELD O. BORRELIAE, HUMAN RELAPSING FEVER, AND PARASITE-VECTOR-HOST RELATIONSHIPS. Bacteriol Rev 1965; 29:46.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7898 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39336=[""].join("\n");
var outline_f38_26_39336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Structure of the organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cultivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genome and taxonomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initiation of infection and mechanism of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Significance of serotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Variable membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mechanisms of gene replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Role in tissue localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tick-borne",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Blood meal and risk of acquiring infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vertebrate reservoirs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Geographic distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Louse-borne",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7898|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/8/9357\" title=\"figure 1\">",
"      Gene switching in Borrelia spp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/44/2767\" title=\"figure 2\">",
"      Ornithodoros turicata tick",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/56/34699\" title=\"table 1\">",
"      Relapsing fever Borrelia spp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15033?source=related_link\">",
"      Clinical features, diagnosis, and management of relapsing fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/29/38358?source=related_link\">",
"      Epidemic typhus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39337="Devices for difficult endotracheal intubation in children";
var content_f38_26_39337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Devices for difficult endotracheal intubation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39337/contributors\">",
"     Brent R King, MD, MMM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39337/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39337/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/26/39337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18429462\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of devices have been developed to aid in the management of the difficult airway or to facilitate endotracheal intubation in adults. Many of these devices are available in sizes suitable for use in children and incorporate a variety of fiberoptic, video, optical, and mechanical technologies.",
"   </p>",
"   <p>",
"    This topic will review the techniques for use of such devices for endotracheal intubation in children. The following pediatric topics on the difficult airway are presented elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of the difficult airway (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link\">",
"       \"The difficult pediatric airway\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Specific techniques for use of rescue devices (eg, laryngeal mask airway) when endotracheal intubation has failed (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Needle cricothyroidotomy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16441?source=see_link\">",
"       \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wire-guided cricothyroidotomy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4905?source=see_link&amp;anchor=H20#H20\">",
"       \"Emergent surgical cricothyrotomy (cricothyroidotomy)\", section on 'Seldinger technique'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general principles of pediatric airway management and rapid sequence intubation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429469\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of airway device for difficult endotracheal intubation in children is dependent upon whether the patient has a difficult or failed airway:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Difficult airway",
"      </strong>",
"      &ndash; A difficult airway is present when a clinician experiences problems with face mask ventilation, laryngoscopy, or intubation. In an emergency setting, this also includes difficulty performing an emergency surgical airway, such as needle cricothyroidotomy. Pediatric causes include congenital anomalies (",
"      <a class=\"graphic graphic_table graphicRef79504 \" href=\"mobipreview.htm?43/15/44283\">",
"       table 1",
"      </a>",
"      ), epiglottitis, anaphylaxis, airway trauma, and airway foreign bodies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link&amp;anchor=H3#H3\">",
"       \"The difficult pediatric airway\", section on 'Causes of the difficult pediatric airway'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Whenever possible, a difficult pediatric airway should be identified prior to endotracheal intubation attempts. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link&amp;anchor=H12#H12\">",
"       \"The difficult pediatric airway\", section on 'Identification of the difficult pediatric airway'",
"      </a>",
"      .) In any child in whom laryngoscopy and endotracheal intubation is anticipated to be difficult, an alternative plan that involves the use of devices that enhance the clinician&rsquo;s ability to visualize and intubate the trachea should be employed, and the clinician with the greatest experience and skills should perform the intubation (",
"      <a class=\"graphic graphic_algorithm graphicRef58510 graphicRef63518 graphicRef73509 \" href=\"mobipreview.htm?8/26/8611\">",
"       algorithm 1A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Failed airway",
"      </strong>",
"      &ndash; There is no accepted single definition of a \"failed\" airway. Many authorities suggest that if an operator cannot place a definitive airway in three attempts after changing blade type and length once each, then he or she should consider the attempt failed and change to a different technique or allow a different operator to try. Others have stated that an alternative technique is indicated any time the patient's oxygen saturation falls below 90 percent during an intubation attempt.",
"      <br/>",
"      <br/>",
"      A contingency plan in the event of a failed endotracheal intubation should be developed for all patients, ideally before rapid sequence intubation is necessary (",
"      <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"mobipreview.htm?12/9/12446\">",
"       algorithm 2",
"      </a>",
"      ). Clinicians should have rescue devices available whenever performing emergent pediatric intubation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8355373\">",
"    <span class=\"h1\">",
"     CHOICE OF DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of device depends upon the specific obstacles to conventional endotracheal intubation that are encountered or anticipated during direct laryngoscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Able to see epiglottis but not vocal cords",
"      </strong>",
"      &ndash; Intubating introducer (gum elastic bougie)",
"     </li>",
"     <li>",
"      <strong>",
"       Unable to visualize airway",
"      </strong>",
"      &ndash; Lighted stylet, fiberoptic stylet, flexible fiberoptic bronchoscope, indirect fiberscope, or video laryngoscope",
"     </li>",
"     <li>",
"      <strong>",
"       Limited mouth opening or neck mobility",
"      </strong>",
"      &ndash; Lighted stylet, fiberoptic stylet, flexible fiberoptic bronchoscope, or indirect rigid laryngoscope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, a combination of devices is employed to secure the airway as discussed in the techniques section below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8355596\">",
"    <span class=\"h2\">",
"     Training",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of device depends upon the training and experience of the practitioner. Many of the devices for difficult endotracheal intubation require some assembly prior to use, and all require orientation and training. Inexperienced operators should",
"    <strong>",
"     not",
"    </strong>",
"    use these devices without prior practice. Just as providers must learn to use a standard laryngoscope, they must be trained to use advanced airway devices. Ideally, this training should be conducted first in a manikin or cadaver model and then, when possible, in an operating room setting.",
"   </p>",
"   <p>",
"    The degree of training depends upon the expected frequency with which the clinician will encounter a difficult pediatric airway:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All providers should have training and experience in the use of rescue airway devices. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Providers who are only occasionally exposed to difficult pediatric airways should gain capability with a limited number of relatively easy to use devices (eg, intubating introducers, fiberoptic stylet, or video laryngoscope). It is unlikely that an individual provider will have access to all possible devices so it is most important that providers learn to use the devices available to them.",
"     </li>",
"     <li>",
"      Providers whose exposure to difficult pediatric airways is extensive (eg, pediatric anesthesiologists, emergency physicians in busy departments with high acuity, and critical care subspecialists) should develop facility with a wide variety of devices, including those that require repeated use to be most effective (eg, lighted stylet, flexible fiberoptic bronchoscope).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8355493\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major devices for difficult endotracheal intubation in children include specialized stylets, indirect rigid laryngoscopes, and video laryngoscopes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15750903\">",
"    <span class=\"h2\">",
"     Specialized stylets",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429511\">",
"    <span class=\"h3\">",
"     Intubating introducers (gum elastic bougie)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, multiple randomized trials and observational studies have shown that intubating introducers facilitate intubation, especially in patients with Cormack-Lehane system grade 3 glottic views (",
"    <a class=\"graphic graphic_figure graphicRef55034 \" href=\"mobipreview.htm?34/2/34863\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=see_link&amp;anchor=H3#H3\">",
"     \"Devices for difficult emergency airway management in adults\", section on 'Endotracheal tube introducers (gum elastic bougie)'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The same benefit is probably achieved in children although reports of pediatric use are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"     1",
"    </a>",
"    ]. In one operating room series, the use of a bougie with paraglossal laryngoscopy allowed intubation in five of six infants with Pierre Robin syndrome who could not be intubated with conventional laryngoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional case reports have demonstrated that the gum elastic bougie can be an effective adjunct to pediatric nasotracheal intubation, the insertion of the Pro Seal&reg; laryngeal mask airway, and prehospital tracheal intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. One case report describes the use of Boussignac bougie (bougie that permits oxygen delivery during placement) passed through a size one Laryngeal Mask Airway to successfully intubate an infant with Goldenhar syndrome after several attempts at direct laryngoscopy failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; Intubating introducers are helpful when the epiglottis is visible but the vocal cords cannot be seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/7\">",
"       7",
"      </a>",
"      ]. These devices are semi-rigid solid or hollow rods with the distal tip bent at a 30 degree angle (",
"      <a class=\"graphic graphic_figure graphicRef55895 \" href=\"mobipreview.htm?20/30/20974\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63503 \" href=\"mobipreview.htm?20/24/20864\">",
"       figure 3",
"      </a>",
"      ). The bend allows the intubator to direct the tip anteriorly under the epiglottis and through the vocal cords. Once the introducer is placed in the trachea, an endotracheal tube (ETT) is threaded over it using a Seldinger-like technique. This approach generally requires an assistant to place the ETT on the proximal end of the introducer. The intubator then advances the ETT over the introducer into the trachea and the introducer is withdrawn. Depending upon the manufacturer, intubating introducers are available in sizes as small as 8 Fr. These can be used with endotracheal tubes that have an internal diameter of at least 3.0 mm.",
"      <br/>",
"      <br/>",
"      Intubating introducers can be used in conjunction with fiberoptic intubation techniques (see",
"      <a class=\"local\" href=\"#H15751198\">",
"       'Fiberoptic stylets'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H13595755\">",
"       'Flexible fiberoptic bronchoscope'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18429730\">",
"       'Indirect rigid laryngoscopy'",
"      </a>",
"      below) or video laryngoscopy (see",
"      <a class=\"local\" href=\"#H18429782\">",
"       'Video laryngoscope'",
"      </a>",
"      below). They can also be used to secure a definitive airway using some supraglottic devices (eg, laryngeal mask airway) as conduits. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link&amp;anchor=H8354652#H8354652\">",
"       \"Emergency rescue devices for difficult pediatric airway management\", section on 'Laryngeal mask airway (LMA)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &ndash; Intubating introducers are unlikely to be beneficial when the airway anatomy is not visible. In addition, airway guides should be used with caution when there is possible laryngeal or tracheal injury.",
"     </li>",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lubricate the guide so that the endotracheal tube will pass over it easily.",
"     </li>",
"     <li>",
"      Using directed laryngoscopy, identify the epiglottis.",
"     </li>",
"     <li>",
"      Pass the airway guide (with its curved tip up) beneath the epiglottis. Entry into the trachea is associated with the tactile sensation of running the tip of the airway guide along the rigid rings of the trachea. This is sometimes described as a feeling similar to running your finger along an irregular surface. If the airway guide is in the trachea, it will also wedge into the small airways and not pass any further. In contrast, if the guide has entered the esophagus, no such sensation will be felt and no clear stopping point will be reached. Thus, the guide should be advanced into the trachea and moved back and forth (gently) a few times to insure that it is in the correct location.",
"     </li>",
"     <li>",
"      Once certain that the airway guide rests within the trachea, insert the proximal end of the guide into the distal end of an appropriately-sized endotracheal tube (ETT) and advance the tube along the guide (",
"      <a class=\"graphic graphic_figure graphicRef63503 \" href=\"mobipreview.htm?20/24/20864\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Using direct laryngoscopy (DL), advance the ETT until it rests within the trachea. Alternatively, if DL is not used, advance the ETT over the bougie into the trachea, carefully noting the depth of insertion indicated by the ETT marking at the gum line or incisor.",
"     </li>",
"     <li>",
"      Remove the guide and confirm the position of the ETT using an end-tidal CO2 detector. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H24#H24\">",
"       \"Emergent endotracheal intubation in children\", section on 'Confirming tube position'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pitfalls",
"      </strong>",
"      &ndash; Excessive force while advancing the airway guide or the ETT can damage the trachea or larynx. In addition, the ETT, especially a cuffed tube, might become impeded by the epiglottis during placement. This problem can be overcome by using direct laryngoscopy during the procedure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by rotating the endotracheal tube 90 degrees as it approaches the larynx. If the procedure takes a considerable period of time to perform, the patient can become hypoxemic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15751030\">",
"    <span class=\"h3\">",
"     Lighted stylet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lighted stylet allows an endotracheal tube to be placed \"blindly\" without direct visualization of the vocal cords. In a case series of 30 children age 5 to 20 years with known difficult airways, endotracheal intubation using a lighted stylet was successful in 97 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/8\">",
"     8",
"    </a>",
"    ]. An additional case report describes successful use of a lightwand for intubation of an 18 day old infant with microsomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/9\">",
"     9",
"    </a>",
"    ]. The major disadvantages of the lightwand technique include longer times to intubation and lower success rate for inexperienced users (fewer than 20 intubations using the device) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, for clinicians with limited opportunity to manage difficult pediatric airways, most experts would recommend use of a device which is easier to learn and use (eg, fiberoptic stylet). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link&amp;anchor=H4073370#H4073370\">",
"     \"The difficult pediatric airway\", section on 'Lighted stylet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The technique below describes the use of one of the most commonly available lighted stylets, the Trachlight&trade; (Laerdal Medical Corp., Stavanger, Norway) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"     1",
"    </a>",
"    ]. This device contains a reusable battery",
"    <span class=\"nowrap\">",
"     pack/handle",
"    </span>",
"    and a flexible wand with a retractable metal stylet (",
"    <a class=\"graphic graphic_picture graphicRef63169 \" href=\"mobipreview.htm?22/21/22872\">",
"     picture 1",
"    </a>",
"    ). Wands are available in three sizes (adult, child, and infant) which means that this tool can be used with endotracheal tubes sized 2.5 to 10.0 (",
"    <a class=\"graphic graphic_picture graphicRef57820 \" href=\"mobipreview.htm?15/14/15593\">",
"     picture 2",
"    </a>",
"    ). Specific descriptions for the use of other types of lighted stylets may be obtained from their manufacturers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; The lighted stylet will be most useful when the patient has limited mouth opening or neck mobility or when blood or secretions make visualization of the airway difficult. It can be used in conjunction with the intubating laryngeal mask airway as an intubation guide or with direct laryngoscopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link&amp;anchor=H8354689#H8354689\">",
"       \"Emergency rescue devices for difficult pediatric airway management\", section on 'Intubating laryngeal mask airway (ILMA)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H20#H20\">",
"       \"Emergent endotracheal intubation in children\", section on 'Laryngoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &ndash; Because tracheal intubation using the lighted stylet is a \"blind\" technique, its success is somewhat dependent upon the patient having relatively normal airway anatomy. In patients who are likely to have significantly distorted airways (eg, neck trauma with an expanding hematoma), this technique may fail and is not recommended.",
"     </li>",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1,12\">",
"       1,12",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Select an appropriately sized and type of endotracheal (ETT). If using a cuffed tube, inspect and test its balloon.",
"     </li>",
"     <li>",
"      Identify the correct wand, and lubricate both its external surface and the retractable metal stylet.",
"     </li>",
"     <li>",
"      Mount the stylet on the handle and test the light to ensure that it is functioning. It may be necessary to replace the batteries in the handle.",
"     </li>",
"     <li>",
"      Pass the ET tube over the stylet and then move the stylet along its track until it rests in a position roughly even with the Murphy eye of the endotracheal tube.",
"     </li>",
"     <li>",
"      Lock the adapter of the endotracheal tube into position using the special clamp located on the handle.",
"     </li>",
"     <li>",
"      Insure that the rigid metal stylet is seated in the notch at the top of the wand.",
"     </li>",
"     <li>",
"      Inspect the patient's thyromental distance; the distance between the top of the thyroid cartilage and chin. Bend the wand so that the portion distal to the bend is about as long as the patient's thyromental distance. Note that although the tube has an indicator noting the suggested location of the bend, the thyromental distance is a more accurate guide.",
"     </li>",
"     <li>",
"      If the intubation will be attempted with the patient's head in a neutral position, the wand should be bent at a 90 degree angle. An extended neck requires more than 90 degrees of bend, and a flexed neck requires less.",
"     </li>",
"     <li>",
"      If desired, have an assistant dim the room lights to make the light from the wand easier to see.",
"     </li>",
"     <li>",
"      Standing above the patient&rsquo;s head, grasp the lightwand in your dominant hand, and gently lift the patient's mandible with your nondominant hand.",
"     </li>",
"     <li>",
"      Insert the lightwand between the patient's incisors keeping it aligned as closely as possible with the midline.",
"     </li>",
"     <li>",
"      Switch on the light and advance the tip of the lightwand beneath the tongue. At this point the handle and the portion of the wand proximal to the bend should be parallel to the patient's body.",
"     </li>",
"     <li>",
"      Gently pull the handle back toward your body while cocking your wrist rostrally so that the handle is now perpendicular to the patient's body.",
"     </li>",
"     <li>",
"      Look for an intense glow that seems to emanate exclusively from the patient's thyroid cartilage (",
"      <a class=\"graphic graphic_picture graphicRef74936 \" href=\"mobipreview.htm?7/51/7987\">",
"       picture 3",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      feel the ETT pass through the vocal cords. A glow that is dim, diffuse, or seen lateral to the midline suggests that the endotracheal tube is not in the trachea. In this situation, remove the wand and endotracheal tube and ventilate the patient before trying again.",
"     </li>",
"     <li>",
"      If the intense glow is seen within the thyroid cartilage, advance the ETT and wand while simultaneously withdrawing the rigid metal stylet.",
"     </li>",
"     <li>",
"      When the light is visible in the patient's suprasternal notch, then the ETT rests below the vocal cords. Remove the light wand and secure the ETT in the usual fashion.",
"     </li>",
"     <li>",
"      If the attempted intubation consumes more than 30 seconds, the light will begin to flash on and off. This serves both as a reminder to ventilate the patient and as a protection against heat damage to the ET tube or airway from the intense light source.",
"     </li>",
"     <li>",
"      Confirm the position of the ET tube using an end-tidal CO2 detector. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H24#H24\">",
"       \"Emergent endotracheal intubation in children\", section on 'Confirming tube position'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pitfalls",
"      </strong>",
"      &ndash; The lighted stylet is a blind technique, and trauma to the epiglottis, arytenoids, and vocal cords has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/13\">",
"       13",
"      </a>",
"      ]. If used inappropriately, the heat from the light source can also injure local tissues or damage the endotracheal tube. In addition, parts of the stylet can become dislodged creating real or potential tracheal foreign bodies. However, this complication is exceedingly rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15751198\">",
"    <span class=\"h3\">",
"     Fiberoptic stylets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiberoptic stylets combine features of the lighted stylet with features of a fiberoptic bronchoscope. These devices can be used for blind intubation similar to a lighted stylet or to perform visually guided intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"     1",
"    </a>",
"    ]. The Shikani optical stylet (SOS) comes in two sizes: an adult size, which can accommodate endotracheal (ET) tubes as small as 5.5 mm ID, and a pediatric size intended for use with ET tubes from 3.5 mm ID to 5.0 mm ID (",
"    <a class=\"graphic graphic_picture graphicRef55948 \" href=\"mobipreview.htm?31/57/32670\">",
"     picture 4",
"    </a>",
"    ). This device can be used in several ways, but it is primarily intended as an easy-to-use alternative to the flexible fiberoptic bronchoscope when the vocal cords cannot be visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other devices are similar to the SOS in design and function as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Bonfils Retromolar Intubation Fiberscope (Bonfils) is designed to allow insertion of the device laterally, along the gum line. It has an adjustable eyepiece and is available in adult and pediatric sizes.",
"     </li>",
"     <li>",
"      The Clarus Video System is a fiberoptic stylet that includes an attached video screen, allowing for indirect laryngoscopy and intubation. While a pediatric stylet is in development, the currently available stylet cannot accommodate endotracheal tubes smaller than 5.5 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Levitan fiberscope is another, similar device, currently available only in adult sizes. Finally, the Foley fiberscope is a fully flexible device that can be used as an adjunct to the intubating laryngeal mask airway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for use of fiberoptic stylets in children is limited. However, in one case series, four infants and children with congenital anomalies and known prior difficult intubations were intubated on the first or second try using the SOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/17\">",
"     17",
"    </a>",
"    ]. Several devices allow the simultaneous administration of oxygen through the fiberoptic stylet which prevents secretions from obscuring the optic view and can help maintain oxygen saturation during intubation attempts. The fiberoptic stylet can be used with or without direct laryngoscopy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; The SOS is especially useful when standard laryngoscopy is difficult or impossible because the patient has limited mouth opening or neck mobility. It is also useful when the patient has certain anatomic abnormalities that make endotracheal intubation difficult (eg, small mandible, large tongue, very anterior airway).",
"      <br/>",
"      <br/>",
"      This device may be used in conjunction with the laryngeal mask airway (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link&amp;anchor=H8354652#H8354652\">",
"       \"Emergency rescue devices for difficult pediatric airway management\", section on 'Laryngeal mask airway (LMA)'",
"      </a>",
"      ) or with direct laryngoscopy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H20#H20\">",
"       \"Emergent endotracheal intubation in children\", section on 'Laryngoscopy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &ndash; Like all fiberoptic devices, the SOS may be difficult to use when the patient has blood, debris, or excessive secretions in the oral cavity, though in these circumstances the SOS can be used blindly as a lighted stylet. Additionally, the fiberoptic lens can fog when introduced into the oral cavity. This problem can be avoided by applying anti-fog solution to the lens prior to use and administering medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      ) that will reduce secretions.",
"     </li>",
"     <li>",
"      <strong>",
"       Technique (preparation)",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prepare and inspect a properly sized endotracheal tube (ETT), if a cuffed tube is used check that the balloon inflates properly.",
"     </li>",
"     <li>",
"      Apply anti-fog solution to the lens of the SOS and lubricate its shaft so that the ETT slides off easily.",
"     </li>",
"     <li>",
"      Make certain that the light is working properly. The SOS can be used with either a battery pack or a fiberoptic light source powered by a wall socket.",
"     </li>",
"     <li>",
"      Suction the patient's oral cavity well and, if time permits, administer",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      (IV dose 0.02",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      minimum dose: 0.1 mg, maximum dose: 1 mg) or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      (IV dose 10",
"      <span class=\"nowrap\">",
"       micrograms/kg,",
"      </span>",
"      maximum dose: 0.2 mg) to decrease secretions.",
"     </li>",
"     <li>",
"      Slide the endotracheal tube over the stylet so that the lens of the SOS lies just barely within the ETT.",
"     </li>",
"     <li>",
"      Clamp the tube in place using the tube clamp. This device also allows air or oxygen to be blown down the ETT which can serve as a source of oxygen in the sedated, spontaneously breathing patient and can be used to blow secretions aside to improve the view.",
"     </li>",
"     <li>",
"      Gently bend the distal portion of the",
"      <span class=\"nowrap\">",
"       ETT/stylet",
"      </span>",
"      assembly into the desired angle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique (intubation)",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef67775 \" href=\"mobipreview.htm?36/0/36870\">",
"       figure 4",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Insert the stylet in the midline and direct it below the tongue.",
"     </li>",
"     <li>",
"      Using the eyepiece, identify the vocal cords and direct the ETT and stylet through them, stopping just above the carina.",
"     </li>",
"     <li>",
"      Release the tube from its clamp and slide the stylet out while holding the ETT in position.",
"     </li>",
"     <li>",
"      Confirm the tube's position using an end-tidal CO2 detector",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pitfalls",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Visualization may be obscured by secretions or bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13595755\">",
"    <span class=\"h3\">",
"     Flexible fiberoptic bronchoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flexible fiberoptic bronchoscope (FFB) is essentially a 60 cm long flexible and directable stylet that can be used for airway management in patients for whom difficult intubation is predicted and neuromuscular paralysis is best avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"     1",
"    </a>",
"    ]. FFBs are available in sizes down to 2.2 mm, thus allowing use for placement of endotracheal tubes as small as 2.5 mm internal diameter in infants and neonates. However, FFBs 2.5mm and smaller do not have a suction channel.",
"   </p>",
"   <p>",
"    Use of a FFB for intubation requires extensive training and experience and should not be attempted in emergent settings by inexperienced personnel. Because of the time required and the patient preparation necessary, intubation using a FFB is generally not performed in children who require immediate establishment of an airway. If time allows for adequate patient preparation, the FFB is an invaluable intubating device. The effective use of FFBs in children has been described in several case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In adults, studies have shown that emergency clinicians performing FFB intubations have a success rate between 56 and 99 percent, depending upon the operator's level of experience. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=see_link&amp;anchor=H6#H6\">",
"     \"Devices for difficult emergency airway management in adults\", section on 'Flexible endoscope'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; FFB-assisted endotracheal intubation is appropriate in patients with abnormal airway anatomy or lesions (eg, angioedema), impaired neck movement, or limited mouth opening who",
"      <strong>",
"       can",
"      </strong>",
"      be ventilated. Topical analgesia (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      4 percent, 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      nebulized over 10 to 15 minutes, maximum dose: 160 mg [4 mL]) and sedation (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/6/37989?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      ) are typically necessary for children to be able to tolerate the procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H2253122#H2253122\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Moderately or severely painful'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      This device can be used in conjunction with a laryngeal mask airway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link&amp;anchor=H8354652#H8354652\">",
"       \"Emergency rescue devices for difficult pediatric airway management\", section on 'Laryngeal mask airway (LMA)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &ndash; Because of increased procedural time, FFB-assisted endotracheal intubation should not be attempted in patients with a failed airway (unable to intubate and unable to ventilate). Bleeding and oral secretions must be controlled or of a limited extent to allow for airway visualization.",
"     </li>",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Apply antifog solution to the lens of the flexible fiberoptic bronchoscope (FFB).",
"     </li>",
"     <li>",
"      If present, connect the suction port to wall suction, or if preferred, attach the port to an air or oxygen outlet to blow away secretions rather than suction them.",
"     </li>",
"     <li>",
"      Apply water-soluble lubricant to the fiberoptic bundle and thread the endotracheal tube onto the FFB, assuring easy movement of the tube along its length.",
"     </li>",
"     <li>",
"      Administer medication to control secretions (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      [IV dose 0.02",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      minimum dose: 0.1 mg, maximum dose: 1 mg] or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      [IV dose 10",
"      <span class=\"nowrap\">",
"       micrograms/kg,",
"      </span>",
"      maximum dose: 0.2 mg]) and, if using the nasal approach, a topic vasoconstrictor spray (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/46/41696?source=see_link\">",
"       phenylephrine",
"      </a>",
"      1 percent, one spray into each nostril).",
"     </li>",
"     <li>",
"      Administer topical anesthetic (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      4 percent, 4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      nebulized over 10 to 15 minutes, maximum dose 160 mg [4 mL]) to the airway and sedate the patient while maintaining adequate ventilation.",
"     </li>",
"     <li>",
"      For nasopharyngeal passage, after application of a topical vasoconstrictor spray (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/46/41696?source=see_link\">",
"       phenylephrine",
"      </a>",
"      1 percent, one spray into each nostril) to the nasal mucosa, gently pass the lubricated endotracheal tube into the nasopharynx and then insert the FFB through the endotracheal tube until the glottic opening is identified (",
"      <a class=\"graphic graphic_figure graphicRef56432 \" href=\"mobipreview.htm?37/54/38753\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For oropharyngeal passage, place a bite block. Thread the ETT over the lubricated FFB. While maintaining midline position, advance the FFB with threaded ETT over the tongue into the posterior pharynx.",
"     </li>",
"     <li>",
"      For both nasopharyngeal and oropharyngeal passage, once the glottis is identified, advance the FFB towards and through the vocal cords and down to the level of the carina (",
"      <a class=\"graphic graphic_figure graphicRef70299 \" href=\"mobipreview.htm?30/50/31527\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Position the ET tube by advancing it along the FFB (sometimes referred to as &ldquo;railroading&rdquo;) (",
"      <a class=\"graphic graphic_figure graphicRef70299 \" href=\"mobipreview.htm?30/50/31527\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Once the ET tube is properly placed, remove the FFB (",
"      <a class=\"graphic graphic_figure graphicRef70299 \" href=\"mobipreview.htm?30/50/31527\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Confirm the position of the tracheal tube using an end-tidal CO2 detector. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H24#H24\">",
"       \"Emergent endotracheal intubation in children\", section on 'Confirming tube position'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pitfalls",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The FFB requires extensive training and experience for proper use.",
"     </li>",
"     <li>",
"      Bleeding or secretions may make visualization difficult or impossible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429730\">",
"    <span class=\"h2\">",
"     Indirect rigid laryngoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several different devices that combine some of the features of a fiberoptic stylet with those of a standard laryngoscope. These include: the Bullard rigid fiberoptic laryngoscope (CIRCON ACMI, Stamford, CT); the Upsher Laryngoscope (Mercury Medical, Clearwater, FL); and the Wu Laryngoscope (Pentax, Orangeburg, NY). These devices can be especially useful for intubation of patients in whom standard laryngoscopy might prove difficult (eg, limited neck mobility,",
"    <span class=\"nowrap\">",
"     Mallampati/Cormack-Lehane",
"    </span>",
"    Class III and IV airways (",
"    <a class=\"graphic graphic_figure graphicRef55034 \" href=\"mobipreview.htm?34/2/34863\">",
"     figure 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"     1",
"    </a>",
"    ]. However, like all fiberoptic devices, blood, vomitus, and excessive secretions can limit visibility through the fiberscope. Alternative devices are often preferred in patients with significant oral or laryngeal trauma. Furthermore, these laryngoscopes are not sized for intubating children less than two years of age. This section discusses in detail only the use of the Bullard laryngoscope. The other indirect fiberscopes are used in a fashion similar to this device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429737\">",
"    <span class=\"h3\">",
"     Bullard rigid fiberoptic laryngoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bullard laryngoscope is available in three sizes, adult, pediatric, and infant (",
"    <a class=\"graphic graphic_picture graphicRef76535 \" href=\"mobipreview.htm?40/26/41390\">",
"     picture 5",
"    </a>",
"    ). Except for size, all are identical. The lower portion of the Bullard is a long metal blade with a curve near its distal end. Running behind the blade and ending just proximal to its tip are several ports. These include a fiberoptic light port which directs light into the airway, an optical port which allows visualization of the airway through the eyepiece, and a hollow port which can be used for suction, insufflation, or as a conduit through which a guidewire may be passed. This latter feature allows facilitated retrograde intubation with the Bullard. There are two optional attachments for the Bullard. The first is a stylet which attaches to the right side of the device and allows the endotracheal tube to be mounted beneath the right side of the blade. This stylet is available in two types: a standard semi-rigid, malleable type that simply serves to hold the endotracheal tube in position prior to deployment, and a hollow type that can accommodate an airway guide, bronchoscope, or guidewire sized 4 mm in diameter or smaller. The other optional attachment is a tip extender for the blade. This device might be needed if the Bullard is used to intubate a large adolescent. The Bullard's light may be powered by a standard fiberoptic light source or by the batteries in a laryngoscope handle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; The Bullard laryngoscope is most useful when intubating patients with limited mouth opening or neck mobility and in those with predicted difficult airways due to poor visualization",
"      <span class=\"nowrap\">",
"       (Mallampati/Cormack-Lehane",
"      </span>",
"      Class III and IV).",
"      <br/>",
"      <br/>",
"      This technique can be used in conjunction with wire or intubating introducer-assisted intubation. A guidewire can be passed through the hollow port beneath the blade or through the hollow stylet. An intubating introducer (eg, gum elastic bougie) can only be passed through the hollow stylet. (See",
"      <a class=\"local\" href=\"#H18429511\">",
"       'Intubating introducers (gum elastic bougie)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &ndash; Bleeding and oral secretions must be controlled or of a limited extent to allow for airway visualization.",
"     </li>",
"     <li>",
"      <strong>",
"       Technique (preparation)",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Confirm that the light source is functioning.",
"     </li>",
"     <li>",
"      Apply anti-fog liquid to the lens and adjust the eyepiece to your focal preference by looking through the lens and focusing on your thumbnail or another object.",
"     </li>",
"     <li>",
"      If you choose to use the stylet, lubricate it well and insert it into an appropriately sized endotracheal tube so that the tip of the stylet extends just beyond the end of the endotracheal tube. Then, mount the stylet and tube in position so that the stylet and endotracheal tube run just beneath the right side of the blade.",
"     </li>",
"     <li>",
"      If the tip extender is required, place it on the end of the blade with the open notch facing downward. You should hear and feel a distinct \"snap\" as the extender locks into place. Failure to attach the extender securely can result in it becoming dislodged during the intubation attempt; thus, once the extender is in place, gently tug on it a few times to ensure that it is securely attached [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suction the patient's oropharynx well and, if time permits, administer medication to reduce oral secretions (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      [IV dose 0.02",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      minimum dose: 0.1 mg, maximum dose: 1 mg] or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      [IV dose 10",
"      <span class=\"nowrap\">",
"       micrograms/kg,",
"      </span>",
"      maximum dose: 0.2 mg]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Technique (intubation)",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef80376 \" href=\"mobipreview.htm?5/4/5187\">",
"       figure 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Begin by standing at the patient's head as you would for a standard intubation.",
"     </li>",
"     <li>",
"      Hold the Bullard laryngoscope in your nondominant hand with its body and eyepiece parallel to the patient's body. The tip of the Bullard's blade should lie between the patient's incisors. (Note: the Bullard can be used to intubate patients with an inter-incisor distance as small as one centimeter. In some cases, the limitation is not the Bullard's blade but the size of the endotracheal tube.)",
"     </li>",
"     <li>",
"      Advance the Bullard laryngoscope slowly along the middle of the tongue by gently rotating the handle back toward your body until it becomes perpendicular to the patient's body. In many cases, this rotating and advancing motion will cause the blade to come to rest just below the esophagus.",
"     </li>",
"     <li>",
"      While looking through the eyepiece, gently lift the handle of the Bullard directly upward until the vocal cords come into view.",
"     </li>",
"     <li>",
"      If you are using the stylet, you may consider positioning the Bullard such that the vocal cords are visible in the right portion of your visual field. This should align the endotracheal tube with the vocal cords. However, use of the stylet is not mandatory.",
"     </li>",
"     <li>",
"      If your view is obscured by secretions, consider applying suction through the Bullard's suction port or using an external suction device.",
"     </li>",
"     <li>",
"      If the cords are not visualized, reposition the Bullard by lowering it to the posterior pharynx, repositioning it, and gently lifting it again.",
"     </li>",
"     <li>",
"      Once the cords are seen, pass the endotracheal tube under direct vision.",
"     </li>",
"     <li>",
"      Confirm the position of the tracheal tube using an end-tidal CO2 detector. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H24#H24\">",
"       \"Emergent endotracheal intubation in children\", section on 'Confirming tube position'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pitfalls",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Like a standard laryngoscope, the Bullard or its stylet can cause local trauma.",
"     </li>",
"     <li>",
"      If the stylet is not firmly attached to the tip of the blade, it can become dislodged during the intubation attempt creating an airway or esophageal foreign body.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429782\">",
"    <span class=\"h2\">",
"     Video laryngoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video laryngoscopes provide indirect laryngoscopy and display the glottic view on a video monitor during endotracheal intubation. Four devices that can be used as video laryngoscopes are available in sizes appropriate for infants and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       GlideScope video laryngoscope",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef59169 \" href=\"mobipreview.htm?12/18/12576\">",
"       picture 6",
"      </a>",
"      ) &ndash; The GlideScope is essentially a camera mounted on a specially shaped laryngoscope handle. The operator guides the intubation attempt using a video monitor rather than under direct vision. The GlideScope Cobalt comes in an infant size with a smaller (10 mm) laryngoscope blade which allows for its use in neonates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Storz DCI video laryngoscope",
"      </strong>",
"      &ndash; The Storz DCI can be fitted with laryngoscope blades that are similar to Miller 0 or 1 blades (",
"      <a class=\"graphic graphic_picture graphicRef51631 \" href=\"mobipreview.htm?15/29/15839\">",
"       picture 7",
"      </a>",
"      ). Case series have documented successful use in premature infants as small as 500 grams as well as infants with difficult airways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Truview PCD infant",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef62179 \" href=\"mobipreview.htm?5/63/6131\">",
"       picture 8",
"      </a>",
"      ) &ndash; The Truview PCD can be used as a direct optical laryngoscope or can be converted into a video laryngoscope by attaching a camera with a magnetic adapter. The blade height of 8 mm permits successful use in neonates, including those with difficult airways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/24\">",
"       24",
"      </a>",
"      ]. It also permits insufflation of oxygen during intubation attempts.",
"     </li>",
"     <li>",
"      <strong>",
"       AIRTRAQ disposable optical laryngoscope",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef72818 \" href=\"mobipreview.htm?14/32/14863\">",
"       picture 9",
"      </a>",
"      ) &ndash; The AIRTRAQ can be used as a direct optical laryngoscope blade or can be converted to a video laryngoscope with a wireless monitor. It comes in two pediatric sizes and is capable of passing an endotracheal tube as small as 2.5 mm internal diameter (",
"      <a class=\"graphic graphic_picture graphicRef59113 \" href=\"mobipreview.htm?15/4/15426\">",
"       picture 10",
"      </a>",
"      ). Unlike the other laryngoscopes, the AIRTRAQ provides a channel for directing the endotracheal tube through the vocal cords (",
"      <a class=\"graphic graphic_movie graphicRef79844 \" href=\"mobipreview.htm?2/2/2085\">",
"       movie 1",
"      </a>",
"      ). Use is discouraged for infants with limited mouth opening (eg, Pierre Robin or Treacher Collins syndrome) because the relatively large blade height (12 to 13 mm) may be associated with intubation failures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple studies have compared these devices to direct laryngoscopy (DL) in simulated difficult pediatric airway models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/24,30-32\">",
"     24,30-32",
"    </a>",
"    ] and in the care of actual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In the hands of practitioners with training in airway management, all of the devices function as intended though, as described above, some of the devices have limitations under certain circumstances that might be encountered in the management of children with difficult airways (eg, the size limitation of the AIRTRAQ in patients with limited mouth opening). However, the impact of the use of video laryngoscopes has varied and has not always been associated with improved outcomes when compared to DL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two trials that reported use of video laryngoscopes in infants and children with normal airways undergoing elective surgery, visualization of the glottis was marginally improved while time to intubation was the same or slightly slower (up to six seconds longer) than by DL when performed by experienced anesthesiology residents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study that evaluated intubation performance by anesthesiologists in a simulated difficult infant intubation with restricted neck movement using DL with a Macintosh blade, Storz DCI, AIRTRAQ, or Bullard devices, the Bullard device provided the best glottic view (100 percent) and the shortest intubation time (median time 21 seconds) with the least potential for dental trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of endotracheal intubation by inexperienced pediatric residents who had passed the Pediatric Advance Life Support course using simulated infant and child scenarios, use of the Glidescope was associated with more failed intubations and similar or prolonged intubation time when compared to DL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial that evaluated airway management by pediatric residents who had passed the Pediatric Advanced Life Support course, use of the Glidescope was associated with a clinically significant longer time to successful intubation (20 to 30 seconds, depending upon the scenario) than DL with a comparable success rate approaching 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these results suggest that video laryngoscopy is not necessarily associated with improved performance of pediatric endotracheal intubation, especially when performed by inexperienced providers. However, practitioners with airway training and experience, even those who are relatively early in their careers (ie, anesthesiology residents), can use these advanced laryngoscopes effectively with little additional training and orientation. In selected patients with limited neck or mouth opening, video laryngoscopy may markedly improve the ability to secure the airway.",
"   </p>",
"   <p>",
"    The technique below describes the use of the GlideScope video laryngoscope. Although use of other indirect video laryngoscopes is similar, the specific descriptions for other types of video laryngoscopes may be obtained from their manufacturers. A comparison of the advantages and disadvantages of pediatric use of the four video laryngoscopes is provided elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Indications",
"      </strong>",
"      &ndash; The GlideScope can be used in patients with difficult or normal airways. Additionally, the shape of its blade allows intubation without neck movement, making it a good choice for intubation of patients with limited neck mobility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This device can be used in conjunction with the intubating introducer. (See",
"      <a class=\"local\" href=\"#H18429511\">",
"       'Intubating introducers (gum elastic bougie)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &ndash; Blood or excessive secretions in the oral cavity or pharynx will make visualization difficult. These should be cleared with suction prior to intubation.",
"     </li>",
"     <li>",
"      <strong>",
"       Technique",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/1,24\">",
"       1,24",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Select an appropriately sized endotracheal tube (ETT), if a cuffed tube is being placed, test its balloon, and insert a lubricated stylet.",
"     </li>",
"     <li>",
"      Bend the tip of the tube so that it forms a 60 to 80 degree angle with the body of the tube.",
"     </li>",
"     <li>",
"      Suction the patient's oral cavity and, if time permits, administer",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      (IV dose 0.02",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      minimum dose: 0.1 mg, maximum dose: 1 mg) or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"       glycopyrrolate",
"      </a>",
"      (IV dose 10",
"      <span class=\"nowrap\">",
"       micrograms/kg,",
"      </span>",
"      maximum dose: 0.2 mg) to control oral secretions.",
"     </li>",
"     <li>",
"      Keeping the patient's head and neck in the neutral position (the curve of the GlideScope blade makes neck extension unnecessary), insert the blade into the midline of the patient's mouth under direct vision.",
"     </li>",
"     <li>",
"      Once the blade is in the mouth, watch the monitor and advance the blade.",
"     </li>",
"     <li>",
"      Once the epiglottis comes into view, either elevate the blade directly (as with a standard straight blade) or place it into the vallecula and use it like a standard curved blade. In either case, lift the blade gently until the vocal cords are seen.",
"     </li>",
"     <li>",
"      Hold the blade in position and insert the ETT into the oral cavity under direct vision.",
"     </li>",
"     <li>",
"      Once the ETT is in the hypopharynx, watch the monitor and advance the ETT until it passes through the cords.",
"     </li>",
"     <li>",
"      Secure the tube in the usual fashion and confirm its location using an end-tidal CO2 detector. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H24#H24\">",
"       \"Emergent endotracheal intubation in children\", section on 'Confirming tube position'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A video demonstrating the use of the GlideScope Cobalt for intubation in an infant can be found elsewhere [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39337/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pitfalls",
"      </strong>",
"      &ndash; The clinician must be careful to look at the patient when initially placing the video laryngoscope blade and when passing the endotracheal tube through the oropharynx to avoid damage to the dentition, palate, and throat. The pitfalls associated with standard intubation also apply to the GlideScope. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H28#H28\">",
"       \"Emergent endotracheal intubation in children\", section on 'During laryngoscopy/intubation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848175\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric causes of a difficult airway include congenital anomalies (",
"      <a class=\"graphic graphic_table graphicRef79504 \" href=\"mobipreview.htm?43/15/44283\">",
"       table 1",
"      </a>",
"      ), epiglottitis, anaphylaxis, airway trauma, and airway foreign bodies. (See",
"      <a class=\"local\" href=\"#H18429469\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link&amp;anchor=H3#H3\">",
"       \"The difficult pediatric airway\", section on 'Causes of the difficult pediatric airway'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whenever possible, a difficult pediatric airway should be identified prior to endotracheal intubation attempts. In any child in whom laryngoscopy and endotracheal intubation is anticipated to be difficult, an alternative plan that involves the use of devices that enhance the clinician&rsquo;s ability to visualize and intubate the trachea should be employed and assistance from specialists (eg, anesthesiologists, otolaryngologists) should be rapidly available (",
"      <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"mobipreview.htm?21/54/22382\">",
"       algorithm 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef63518 \" href=\"mobipreview.htm?33/39/34430\">",
"       algorithm 1B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef73509 \" href=\"mobipreview.htm?24/20/24910\">",
"       algorithm 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18429469\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link&amp;anchor=H12#H12\">",
"       \"The difficult pediatric airway\", section on 'Identification of the difficult pediatric airway'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A contingency plan in the event of a failed endotracheal intubation should be developed for all patients, ideally before rapid sequence intubation is necessary (",
"      <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"mobipreview.htm?12/9/12446\">",
"       algorithm 2",
"      </a>",
"      ). Clinicians should have rescue devices available whenever performing emergent pediatric intubation, especially those children in whom a difficult airway is anticipated. (See",
"      <a class=\"local\" href=\"#H18429469\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of device depends upon the specific obstacles to conventional endotracheal intubation that are encountered or anticipated during direct laryngoscopy and upon the training and experience of the practitioner (see",
"      <a class=\"local\" href=\"#H8355373\">",
"       'Choice of device'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8355596\">",
"       'Training'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Able to see epiglottis but not vocal cords",
"      </strong>",
"      &ndash; Intubating introducer (gum elastic bougie)",
"     </li>",
"     <li>",
"      <strong>",
"       Unable to visualize airway",
"      </strong>",
"      &ndash; Lighted stylet, fiberoptic stylet, flexible fiberoptic bronchoscope, indirect fiberscope, or video laryngoscope",
"     </li>",
"     <li>",
"      <strong>",
"       Limited mouth opening or neck mobility",
"      </strong>",
"      &ndash; Lighted stylet, fiberoptic stylet, flexible fiberoptic bronchoscope, or indirect rigid laryngoscope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of training depends upon the expected frequency with which the clinician will encounter a difficult pediatric airway (see",
"      <a class=\"local\" href=\"#H8355596\">",
"       'Training'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All providers should have training and experience in the use of rescue airway devices. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Providers who are only occasionally exposed to difficult pediatric airways should gain capability with a limited number of relatively easy to use devices (eg, intubating introducers, fiberoptic stylet, or video laryngoscope).",
"     </li>",
"     <li>",
"      Providers whose exposure to difficult pediatric airways is extensive (eg, pediatric anesthesiologists, emergency physicians in busy departments with high acuity, and critical care subspecialists) should develop facility with a wide variety of devices, including those that require repeated use to be most effective (eg, lighted stylet, flexible fiberoptic bronchoscope).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications, contraindications, procedure, and pitfalls are described for a variety of devices designed to facilitate difficult endotracheal intubation in children. (See",
"      <a class=\"local\" href=\"#H8355493\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     King, BR, Hagberg, CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King, C, Henretig, FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/2\">",
"      Semjen F, Bordes M, Cros AM. Intubation of infants with Pierre Robin syndrome: the use of the paraglossal approach combined with a gum-elastic bougie in six consecutive cases. Anaesthesia 2008; 63:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/3\">",
"      Arora MK, Karamchandani K, Trikha A. Use of a gum elastic bougie to facilitate blind nasotracheal intubation in children: a series of three cases. Anaesthesia 2006; 61:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/4\">",
"      Teoh CY, Lim FS. The Proseal laryngeal mask airway in children: a comparison between two insertion techniques. Paediatr Anaesth 2008; 18:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/5\">",
"      Picard N, Lakhnati P, Guillerm AL, et al. [High-risk airway management in pediatric prehospital emergency medicine]. Ann Fr Anesth Reanim 2010; 29:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/6\">",
"      Camkiran A, Pirat A, Akovali NV, Arslan G. Combination of laryngeal mask airway and pediatric Boussignac bougie for difficult tracheal intubation in a newborn with Goldenhar syndrome. Anesth Analg 2012; 115:737.",
"     </a>",
"    </li>",
"    <li>",
"     Hagberg, CA. Current Concepts in the Management of the Difficult Airway. ASA Refresher Courses in Anesthesiology 2001;29:135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/8\">",
"      Holzman RS, Nargozian CD, Florence FB. Lightwand intubation in children with abnormal upper airways. Anesthesiology 1988; 69:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/9\">",
"      Krucylak CP, Schreiner MS. Orotracheal intubation of an infant with hemifacial microsomia using a modified lighted stylet. Anesthesiology 1992; 77:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/10\">",
"      Hung OR, Pytka S, Morris I, et al. Clinical trial of a new lightwand device (Trachlight) to intubate the trachea. Anesthesiology 1995; 83:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/11\">",
"      Davis L, Cook-Sather SD, Schreiner MS. Lighted stylet tracheal intubation: a review. Anesth Analg 2000; 90:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/12\">",
"      Infosino A. Pediatric upper airway and congenital anomalies. Anesthesiol Clin North America 2002; 20:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/13\">",
"      Szigeti CL, Baeuerle JJ, Mongan PD. Arytenoid dislocation with lighted stylet intubation: case report and retrospective review. Anesth Analg 1994; 78:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/14\">",
"      Ellis DG, Jakymec A, Kaplan RM, et al. Guided orotracheal intubation in the operating room using a lighted stylet: a comparison with direct laryngoscopic technique. Anesthesiology 1986; 64:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/15\">",
"      Pfitzner L, Cooper MG, Ho D. The Shikani Seeing Stylet for difficult intubation in children: initial experience. Anaesth Intensive Care 2002; 30:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/16\">",
"      Vlatten A, Aucoin S, Litz S, et al. A comparison of bonfils fiberscope-assisted laryngoscopy and standard direct laryngoscopy in simulated difficult pediatric intubation: a manikin study. Paediatr Anaesth 2010; 20:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/17\">",
"      Shukry M, Hanson RD, Koveleskie JR, Ramadhyani U. Management of the difficult pediatric airway with Shikani Optical Stylet. Paediatr Anaesth 2005; 15:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/18\">",
"      Audenaert SM, Montgomery CL, Stone B, et al. Retrograde-assisted fiberoptic tracheal intubation in children with difficult airways. Anesth Analg 1991; 73:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/19\">",
"      Walker RW, Ellwood J. The management of difficult intubation in children. Paediatr Anaesth 2009; 19 Suppl 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/20\">",
"      Berthelsen P, Prytz S, Jacobsen E. Two-stage fiberoptic nasotracheal intubation in infants: a new approach to difficult pediatric intubation. Anesthesiology 1985; 63:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/21\">",
"      Asai T, Nagata A, Shingu K. Awake tracheal intubation through the laryngeal mask in neonates with upper airway obstruction. Paediatr Anaesth 2008; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/22\">",
"      Gorback MS. Management of the challenging airway with the Bullard laryngoscope. J Clin Anesth 1991; 3:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/23\">",
"      Marshall KA. Complication of Bullard laryngoscope: dislodgment of blade-extender resulting in an upper airway foreign body. Anesthesiology 1998; 89:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/24\">",
"      Holm-Knudsen R. The difficult pediatric airway--a review of new devices for indirect laryngoscopy in children younger than two years of age. Paediatr Anaesth 2011; 21:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/25\">",
"      Cooper RM, Pacey JA, Bishop MJ, McCluskey SA. Early clinical experience with a new videolaryngoscope (GlideScope) in 728 patients. Can J Anaesth 2005; 52:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/26\">",
"      Pediatric Anesthesia 2009; 19:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/27\">",
"      Vanderhal AL, Berci G, Simmons CF Jr, Hagiike M. A videolaryngoscopy technique for the intubation of the newborn: preliminary report. Pediatrics 2009; 124:e339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/28\">",
"      Anesth Analg 2009; 109:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/29\">",
"      Pediatric Anesthesia 2010; 20:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/30\">",
"      Nileshwar A, Garg V. Comparison of Bullard laryngoscope and short-handled Macintosh laryngoscope for orotracheal intubation in pediatric patients with simulated restriction of cervical spine movements. Paediatr Anaesth 2010; 20:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/31\">",
"      White M, Weale N, Nolan J, et al. Comparison of the Cobalt Glidescope video laryngoscope with conventional laryngoscopy in simulated normal and difficult infant airways. Paediatr Anaesth 2009; 19:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/32\">",
"      Kalbhenn J, Boelke AK, Steinmann D. Prospective model-based comparison of different laryngoscopes for difficult intubation in infants. Paediatr Anaesth 2012; 22:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/33\">",
"      Fiadjoe JE, Gurnaney H, Dalesio N, et al. A prospective randomized equivalence trial of the GlideScope Cobalt&reg; video laryngoscope to traditional direct laryngoscopy in neonates and infants. Anesthesiology 2012; 116:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/34\">",
"      Vlatten A, Aucoin S, Litz S, et al. A comparison of the STORZ video laryngoscope and standard direct laryngoscopy for intubation in the Pediatric airway--a randomized clinical trial. Paediatr Anaesth 2009; 19:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/35\">",
"      Fonte M, Oulego-Erroz I, Nadkarni L, et al. A randomized comparison of the GlideScope videolaryngoscope to the standard laryngoscopy for intubation by pediatric residents in simulated easy and difficult infant airway scenarios. Pediatr Emerg Care 2011; 27:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/36\">",
"      Rodriguez-Nunez A, Oulego-Erroz I, Perez-Gay L, Cortinas-Diaz J. Comparison of the GlideScope Videolaryngoscope to the standard Macintosh for intubation by pediatric residents in simulated child airway scenarios. Pediatr Emerg Care 2010; 26:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39337/abstract/37\">",
"      Agr&ograve; F, Barzoi G, Montecchia F. Tracheal intubation using a Macintosh laryngoscope or a GlideScope in 15 patients with cervical spine immobilization. Br J Anaesth 2003; 90:705.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.youtube.com/watch?v=SK3tLEKQGMg&amp;playnext=1&amp;list=PLA09BCBD329F5B88A&amp;index=31 (Accessed on January 10, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13872 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39337=[""].join("\n");
var outline_f38_26_39337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1848175\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18429462\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18429469\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8355373\">",
"      CHOICE OF DEVICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8355596\">",
"      Training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8355493\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15750903\">",
"      Specialized stylets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18429511\">",
"      - Intubating introducers (gum elastic bougie)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15751030\">",
"      - Lighted stylet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15751198\">",
"      - Fiberoptic stylets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13595755\">",
"      - Flexible fiberoptic bronchoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18429730\">",
"      Indirect rigid laryngoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18429737\">",
"      - Bullard rigid fiberoptic laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18429782\">",
"      Video laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1848175\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13872\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13872|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?21/54/22382\" title=\"algorithm 1A\">",
"      Difficult airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/39/34430\" title=\"algorithm 1B\">",
"      Main airway management algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/20/24910\" title=\"algorithm 1C\">",
"      Crash airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/9/12446\" title=\"algorithm 2\">",
"      Failed airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13872|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/2/34863\" title=\"figure 1\">",
"      Cormack Lehane laryngoscopy grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/30/20974\" title=\"figure 2\">",
"      Frova introducer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/24/20864\" title=\"figure 3\">",
"      SunMed bougie",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/0/36870\" title=\"figure 4\">",
"      Endotracheal intubation Shikani optical stylet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/54/38753\" title=\"figure 5\">",
"      Fiberoptic nasotracheal intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/50/31527\" title=\"figure 6\">",
"      Fiberoptic endotracheal intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/4/5187\" title=\"figure 7\">",
"      Bullard laryngoscope insertion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13872|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/21/22872\" title=\"picture 1\">",
"      Laerdal trachlight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/14/15593\" title=\"picture 2\">",
"      Laerdal trachlight handle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/51/7987\" title=\"picture 3\">",
"      Lightwand placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/57/32670\" title=\"picture 4\">",
"      Shikani optical stylet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/26/41390\" title=\"picture 5\">",
"      Bullard rigid fiberoptic laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/18/12576\" title=\"picture 6\">",
"      GlideScope Cobalt video laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/29/15839\" title=\"picture 7\">",
"      Storz pediatric video laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/63/6131\" title=\"picture 8\">",
"      Truview detail photo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/32/14863\" title=\"picture 9\">",
"      Airtraq device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/4/15426\" title=\"picture 10\">",
"      AIRTRAQ pediatric sizes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13872|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?2/2/2085\" title=\"movie 1\">",
"      AIRTRAQ demonstration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13872|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/15/44283\" title=\"table 1\">",
"      Congenital features difficult airway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37593?source=related_link\">",
"      Emergency rescue devices for difficult pediatric airway management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16441?source=related_link\">",
"      Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=related_link\">",
"      Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=related_link\">",
"      Selection of medications for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39338="Management of stable chronic obstructive pulmonary disease";
var content_f38_26_39338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of stable chronic obstructive pulmonary disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     Gary T Ferguson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     Barry Make, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/26/39338/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/26/39338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) is a common condition with a high and continually increasing mortality, affecting men and women equally. It is estimated that approximately 8 percent of all individuals have COPD, including approximately 10 percent of individuals older than 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/1\">",
"     1",
"    </a>",
"    ]. The true prevalence is likely higher because COPD is both under-recognized and under-diagnosed. COPD is the third leading cause of death in the US, sixth leading cause of death worldwide in 1990, and is expected to become the third leading cause of death worldwide by 2020 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of stable COPD will be reviewed here. The diagnosis, natural history, and prognosis of COPD, risk factors for COPD, and treatment of acute exacerbations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35351?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy for COPD is used to decrease dyspnea, reduce the frequency and severity of exacerbations, improve health status, and improve exercise capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/4\">",
"     4",
"    </a>",
"    ]. We share the philosophy of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) that pharmacologic and nonpharmacologic therapies should be added in a stepwise fashion to control symptoms, decrease exacerbations, and improve patient function and quality of life. In the discussion that follows, the various therapies for COPD and clinical evidence for each is reviewed. Finally, an approach to the management of patients with stable COPD is outlined. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mainstays of drug therapy of stable symptomatic COPD are bronchodilators (primarily beta agonists and anticholinergics) and inhaled glucocorticoids given alone or in combination depending upon the severity of disease and response to therapy (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ). These are generally administered via metered dose or dry powder inhalers, and some may be administered by nebulization. The bronchodilator",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , which is only modestly effective and has more side effects than other bronchodilators, is occasionally used for patients with refractory COPD; it is more widely employed in developing countries with limited resources.",
"   </p>",
"   <p>",
"    Education about the purpose and dosing of regularly prescribed and as needed medications, timing of short-acting bronchodilators, and proper inhaler technique is essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some regimens used in the past are now rarely used. These include chronic systemic glucocorticoids and mucoactive agents. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Rarely used medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Smoking cessation is a crucial step in the management of COPD at any stage. Pulmonary rehabilitation and supplemental oxygen therapy also have a major role in the management of COPD, depending of the severity of disease. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Supplemental therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In order to determine whether the patient has achieved an adequate response to therapy, it is necessary to monitor symptoms (dyspnea, exercise tolerance), airflow limitation (ie, spirometry), the amount of as-needed medication use, health status, and the frequency of exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSING DISEASE SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A staging system for COPD severity has been developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) that categorizes disease severity according to airflow limitation (based on forced expiratory volume in one second [FEV",
"    <sub>",
"     1",
"    </sub>",
"    ] and the ratio of forced expiratory volume in one second [FEV",
"    <sub>",
"     1",
"    </sub>",
"    ] to forced vital capacity",
"    <span class=\"nowrap\">",
"     [FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC])",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    ), risk of exacerbations, and symptoms (based on modified Medical Research Council dyspnea scale (",
"    <a class=\"graphic graphic_table graphicRef86426 \" href=\"mobipreview.htm?11/62/12267\">",
"     table 3",
"    </a>",
"    ) or COPD Assessment Tool [CAT]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following categories have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk, less symptoms (A): Typically GOLD 1 or GOLD 2 (mild or moderate airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      0 to 1 exacerbation per year and mMRC grade 0 to 1 or CAT score &lt;10.",
"     </li>",
"     <li>",
"      Low risk, more symptoms (B): Typically GOLD 1 or GOLD 2 (mild or moderate airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      0 to 1 exacerbation per year and mMRC grade &ge;2 or CAT score &ge;10.",
"     </li>",
"     <li>",
"      High risk, less symptoms (C): Typically GOLD 3 or GOLD 4 (severe or very severe airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;2 exacerbations per year and mMRC grade 0 to 1 or CAT score &lt;10.",
"     </li>",
"     <li>",
"      High risk, more symptoms (D): Typically GOLD 3 or GOLD 4 (severe or very severe airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;2 exacerbations per year and mMRC grade &ge;2 or CAT score &ge;10.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This staging system is also used as a guide for the management of patients with stable COPD (",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link&amp;anchor=H15#H15\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The multidimensional BODE index may be used to assess an individual's risk of death or hospitalization due to COPD (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ); however, it is not used to guide therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35351?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\", section on 'BODE index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BRONCHODILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchodilators are the therapeutic mainstay for patients with COPD. They include beta agonists, anticholinergics, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , which is used less often. Bronchodilators have been consistently shown to induce long-term improvements in symptoms, exercise capacity, and airflow limitation, even when there is no spirometric improvement following a single test dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta agonists and anticholinergics are available in short-acting and long-acting inhaled formulations. All symptomatic patients with COPD should be prescribed a short-acting bronchodilator to be used on an as-needed basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/4\">",
"     4",
"    </a>",
"    ]. A regularly scheduled long-acting bronchodilator should be added if symptoms are inadequately controlled with short-acting bronchodilator therapy.",
"   </p>",
"   <p>",
"    Most bronchodilators can be administered by inhalation, orally, subcutaneously, or intravenously. For COPD patients, inhalation is the recommended delivery method because it maximizes the bronchodilator's direct effect on the airways, while minimizing systemic effects. A metered dose inhaler (MDI), dry powder inhaler (DPI), or nebulizer can be used to deliver a bronchodilator medication by inhalation. MDIs (and DPIs) simplify therapy, improve compliance, and may reduce extra medication usage and patient cost. When used correctly, they achieve a bronchodilator response equivalent to that achieved with a nebulizer. However, for some patients, a nebulizer may be easier to use and may be necessary when proper MDI technique is not possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Short-acting bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first decision that most clinicians face when managing a patient with COPD is which short-acting bronchodilator is most appropriate when mild intermittent symptoms begin. Short-acting beta agonists and anticholinergics can be used alone or in combination. All of the short-acting bronchodilators improve lung function and symptoms. The unique advantage of short-acting beta agonists is their rapid onset of action.",
"   </p>",
"   <p>",
"    Combination therapy is generally preferred at this stage because this provides the patient with advantages unique to each medication. In addition, the combination of a short-acting beta agonist plus a short-acting anticholinergic achieves a greater bronchodilator response than either one alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/12\">",
"     12",
"    </a>",
"    ]. However, monotherapy with either agent is acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting beta agonists include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20372?source=see_link\">",
"     pirbuterol",
"    </a>",
"    . They have been proven in randomized, controlled trials and meta-analyses to improve symptoms and lung function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of short-acting beta agonists on an as-needed basis decreases sympathomimetic exposure without significant reduction of benefit. A trial randomly assigned 53 patients with COPD to receive regularly scheduled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or placebo, while continuing a medication regimen that consisted of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide, inhaled glucocorticoid, and as-needed albuterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/14\">",
"     14",
"    </a>",
"    ]. Regularly scheduled albuterol increased the total amount of albuterol received two-fold, without a clinically significant impact on lung function, symptoms, or exercise capacity.",
"   </p>",
"   <p>",
"    Most controlled trials that have compared as-needed versus regularly scheduled dosing have used a similar trial design. Specifically, they compared patients who received regularly scheduled plus as-needed short-acting beta agonist, versus patients who received placebo plus as-needed short-acting beta agonist. This trial design is necessary to alleviate the practical and ethical concerns about having a group without access to short-acting beta agonist for rescue from acute dyspnea.",
"   </p>",
"   <p>",
"    Inhaled short-acting beta agonists are generally felt to be safe when used at the recommended doses. However, in a nested case control study of 76,661 patients with COPD, the rate of severe cardiac arrhythmia was elevated among those with new use of oral or inhaled short-acting beta agonist (RR 1.27, 95% CI 1.03-1.57) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/15\">",
"     15",
"    </a>",
"    ]. Cardiac arrests were characterized as arrhythmia events; among nonfatal arrhythmias, atrial",
"    <span class=\"nowrap\">",
"     fibrillation/flutter",
"    </span>",
"    was most common. Unfortunately, the retrospective design does not allow assessment of confounders such as ongoing cigarette smoking, underlying cardiac disease, and whether the arrhythmia occurred at a time of exacerbation or excess use of the beta agonist.",
"   </p>",
"   <p>",
"    Most recommended doses of beta agonists (both short-acting and long-acting) result in less than maximal bronchodilation. Risks of overuse are possible if an individual attempts to achieve maximal bronchodilation by using higher doses. These risks include tremor and reflex tachycardia due, in part, to peripheral arterial dilation. Hypokalemia can also occur in extreme cases and should be monitored in patients at risk. Oral beta-2 agonists are generally not prescribed because their incidence of side effects is particularly high. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"     \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17898?source=see_link\">",
"     \"Management of the patient with severe COPD and cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/21/8538?source=see_link\">",
"     \"Arrhythmias in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting anticholinergic medications improve lung function and symptoms. As an example, one double-blind trial randomly assigned 183 patients with moderate to severe COPD to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    alone (80 mcg, three times per day),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/16\">",
"     16",
"    </a>",
"    ]. Short-acting beta agonists were permitted as-needed for relief of acute dyspnea. Compared to placebo, ipratropium improved lung function, increased exercise capacity, decreased dyspnea, and decreased cough. As-needed and regularly scheduled dosing regimens of short-acting anticholinergics have not been compared. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33305?source=see_link\">",
"     \"Role of anticholinergic therapy in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     Albuterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    have been compared in randomized, controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/12,17,18\">",
"     12,17,18",
"    </a>",
"    ]. On average, both medications improve lung function to a similar degree. Side effects are unique to each medication class, but are minimal at commonly prescribed doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33305?source=see_link&amp;anchor=H14#H14\">",
"     \"Role of anticholinergic therapy in COPD\", section on 'Potential risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of bronchodilation achieved by short-acting beta agonists and anticholinergics is additive, especially when typically recommended (submaximal) doses of each agent are combined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/4,12,18\">",
"     4,12,18",
"    </a>",
"    ]. As an example, the largest trial randomly assigned 534 patients with COPD to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    alone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    alone, or combination therapy (albuterol plus ipratropium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/12\">",
"     12",
"    </a>",
"    ]. Combination therapy increased the mean peak FEV",
"    <sub>",
"     1",
"    </sub>",
"    more than either agent alone, but did not alter the frequency of exacerbations. A similar study reported that combination therapy decreased the frequency of exacerbation compared to albuterol, but not ipratropium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Long-acting bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting bronchodilators alone or in combination may be insufficient to control symptoms. A regularly scheduled long-acting inhaled bronchodilator (LABA) is added in these patients, who have more advanced disease in the range of GOLD stage II and higher (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. Either a long-acting beta agonist or a long-acting anticholinergic is acceptable. In general, a long-acting anticholinergic is preferred over a long-acting beta agonist because most of the effects of the currently available once daily anticholinergic appear to be superior to the twice daily beta agonists that are available for use.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is another option, although least preferred, because its effects are modest and toxicity is a concern. The use of theophylline is usually limited to an add-on therapy when symptoms continue in patients with more severe disease despite the use of other treatments. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Theophylline'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-acting beta agonists (LABAs) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30500?source=see_link\">",
"     arformoterol",
"    </a>",
"    . Multiple studies have demonstrated their benefit in patients with stable COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/8,20-26\">",
"     8,20-26",
"    </a>",
"    ]. The largest trial of salmeterol, Toward a Revolution in COPD Health (TORCH), randomly assigned 6112 patients with mostly severe COPD (mean FEV",
"    <sub>",
"     1",
"    </sub>",
"    44 percent of predicted (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    )) to one of four treatment arms for three years: salmeterol alone (50 mcg twice daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    alone (500 mcg twice daily), combination therapy (salmeterol plus fluticasone), or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/23\">",
"     23",
"    </a>",
"    ]. Salmeterol significantly decreased exacerbation rates, improved lung function, and improved health-related quality of life compared to placebo. There was a trend toward a decrease in mortality (13.5 versus 15.2 percent), although this reduction did not achieve statistical significance.",
"   </p>",
"   <p>",
"    The true decrease in mortality in TORCH may be larger than the apparent difference noted above because of methodologic issues common to intention-to-treat trials, especially those providing medications with symptomatic relief. The placebo arm had a high discontinuation rate (44 percent) and a lower than expected mortality. This may have occurred because the sickest patients treated with placebo had greater symptoms and left the trial to take therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/27\">",
"     27",
"    </a>",
"    ]. In such a situation, the intention to treat analysis would be expected to underestimate the real benefit of active therapy.",
"   </p>",
"   <p>",
"    The potential association of hospitalization or death due to a cardiac arrhythmia and use of LABAs was examined in a nested case control study of 76,661 patients aged &ge;67 years with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/15\">",
"     15",
"    </a>",
"    ]. The risk of an arrhythmia was increased among those with new use of a LABA (RR 1.27, 95% CI 1.03-1.57), but lost significance when patients with a history of arrhythmia or heart failure were excluded (RR 1.57, 95% CI 0.98-2.54). The observed effects waned with longer term use. As noted above, the study has methodologic flaws related to its retrospective design. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Beta agonists'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"     Indacaterol",
"    </a>",
"    is a once-daily LABA that is approved for the treatment of COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/28-35\">",
"     28-35",
"    </a>",
"    ]. It has both a rapid onset and a long duration of action.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 1683 patients with moderate-to-severe COPD to once daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"       indacaterol",
"      </a>",
"      150 or 300 mcg, placebo, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients who were taking inhaled glucocorticoids at baseline (36 percent) continued on the same dose throughout the study. At week 12, the FEV",
"      <sub>",
"       1",
"      </sub>",
"      at 24 hours post dose (ie, trough) increased by 180 mL over placebo with indacaterol (both 150 and 300 mcg) and by 140 mL over placebo with tiotropium.",
"     </li>",
"     <li>",
"      An extension trial of 415 patients from the above study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/29\">",
"       29",
"      </a>",
"      ] who continued to receive one of the two",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"       indacaterol",
"      </a>",
"      doses or placebo, found that the increased trough FEV",
"      <sub>",
"       1",
"      </sub>",
"      (&ge;170 mL) associated with indacaterol use persisted through week 52 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, both doses of indacaterol were associated with a decrease in the exacerbation rate relative to placebo and a modest decrease in the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      . Approximately 24 percent of those using indacaterol had a transient cough occurring within five minutes of inhalation.",
"     </li>",
"     <li>",
"      In a trial of patients with moderate-to-severe COPD, 838 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"       indacaterol",
"      </a>",
"      150 microg per day or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      50 microg twice daily for 26 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/36\">",
"       36",
"      </a>",
"      ]. The trough value of forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) obtained 24 hours after the last dose of indacaterol and 12 hours after salmeterol was modestly higher in the indacaterol group (70 mL) than the salmeterol group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"     indacaterol",
"    </a>",
"    approved for use in the United States (75 mcg once daily) is lower than the dose approved for Europe (150 and 300 mcg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/37\">",
"     37",
"    </a>",
"    ]. The impact of the different dosages of this medication on long-term outcomes remains unknown.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"     Indacaterol",
"    </a>",
"    is a substrate of CYP3A4 and the P-glycoprotein transporter; however, interactions with agents that inhibit these pathways are not felt to be clinically significant in the prescribed dose range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Anticholinergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-acting anticholinergic medication,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    , improves lung function and decreases dynamic hyperinflation, while also decreasing dyspnea and exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/22,38-43\">",
"     22,38-43",
"    </a>",
"    ]. In addition, it improves trough airflow (ie, 24 hours after the last dose) and reduces hyperinflation, indicating that its effects are long-lasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/44\">",
"     44",
"    </a>",
"    ]. Tiotropium may slow the rate of decline in FEV",
"    <sub>",
"     1",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33305?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of anticholinergic therapy in COPD\", section on 'Tiotropium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conflicting evidence has been reported regarding possible adverse cardiovascular effects of anticholinergic therapy in patients with COPD; however, data from a long-term, randomized trial (Understanding Potential Long-Term Impacts on Function with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     Tiotropium",
"    </a>",
"    [UPLIFT]) support the safety of tiotropium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/48\">",
"     48",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33305?source=see_link&amp;anchor=H14#H14\">",
"     \"Role of anticholinergic therapy in COPD\", section on 'Potential risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;LABAs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    have been compared in a meta-analysis and randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/42,49,50\">",
"     42,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The meta-analysis included seven trials (12,223 participants) comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"       indacaterol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/50\">",
"       50",
"      </a>",
"      ]. No significant difference was noted in improvements in quality of life between tiotropium and the LABAs. Tiotropium was more effective at reducing exacerbations (OR 0.86, 95% CI 0.79-0.93). However, no statistically significant differences were noted in overall hospitalizations or mortality. The meta-analysis concluded that the small number of studies and variability (heterogeneity) in the results prevented determination of which agent would lead to a greater long-term benefit.",
"     </li>",
"     <li>",
"      In the largest comparison trial, 7376 patients with moderate to severe COPD were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      with or without concomitant inhaled glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/49\">",
"       49",
"      </a>",
"      ]. Tiotropium increased the time to the first exacerbation of COPD and reduced the risk of developing an exacerbation by 17 percent (hazard ratio 0.83, 95% CI 0.77 to 0.90).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"       Indacaterol",
"      </a>",
"      , a once daily inhaled beta agonist, has been compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      in subjects with moderate to severe COPD. As an example, a total of 1683 patients were randomly assigned to indacaterol 150 or 300 microg, placebo, or open label tiotropium once daily for 26 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/29\">",
"       29",
"      </a>",
"      ]. Comparable results in forced expiratory volume in one second, dyspnea, and quality of life were obtained in all of the active treatment arms. The incidence of adverse events, such as low serum potassium, high blood glucose, and prolonged QTc interval, was similar across treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    alone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    alone have been compared to the combination of a long-acting bronchodilator plus a glucocorticoid. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Bronchodilators plus inhaled glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Combined therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with GOLD stage II-IV COPD whose symptoms are not well-controlled with a single long-acting bronchodilator, the addition of a second class of long acting bronchodilator may provide additional benefit. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assessing disease severity'",
"    </a>",
"    above.) In this setting, a second long-acting bronchodilator from an alternative bronchodilator class (eg, a long acting muscarinic antagonist [LAMA] or a long-acting beta-agonist [LABA] bronchodilator) is selected when an inhaled glucocorticoid is not desired or felt to not be indicated (",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ). However, data from controlled trials in support of this practice are conflicting with some endpoints showing improvement and others not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. A meta-analysis of five trials (3263 participants) that assessed combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    (LAMA) plus a LABA (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/59/26549?source=see_link\">",
"     indacaterol",
"    </a>",
"    ) and found only a slightly better quality of life and a small increase in the post-bronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    with the combination compared with tiotropium alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/51\">",
"     51",
"    </a>",
"    ]. No difference was noted in other secondary end-points, such as exacerbations, symptom scores, and serious adverse events. &nbsp;",
"   </p>",
"   <p>",
"    Minimal data are available comparing the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    plus a long-acting beta agonist (LABA) with the combination of a LABA plus inhaled glucocorticoid. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Bronchodilators plus inhaled glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INHALED GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;COPD is characterized by both airway and systemic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/54\">",
"     54",
"    </a>",
"    ]. Inhaled glucocorticoids (also known as inhaled corticosteroids or ICS) may reduce this inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. The available data, which are presented in detail separately, suggest that inhaled glucocorticoids decrease exacerbations and modestly slow the progression of respiratory symptoms, but appear to have little impact on lung function and mortality. In COPD, inhaled glucocorticoids are used as part of a combined regimen, but should NOT be used as sole therapy for COPD (ie, without long-acting bronchodilators). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5463?source=see_link\">",
"     \"Role of inhaled glucocorticoid therapy in stable COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects associated with inhaled glucocorticoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids are typically used in combination with a long-acting bronchodilator for patients in GOLD stage III-IV, who have significant symptoms or repeated exacerbations, despite an optimal bronchodilator regimen (",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/19\">",
"     19",
"    </a>",
"    ]. The addition of an inhaled glucocorticoid may be warranted earlier (ie, at the same time that the long-acting inhaled bronchodilator is initiated) if there are signs of inflammation or an asthmatic component to the COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/61\">",
"     61",
"    </a>",
"    ]. Inhaled glucocorticoids are continued in patients whose symptoms, frequency of exacerbations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lung function improve within one month.",
"   </p>",
"   <p>",
"    Combination therapy significantly improves some outcomes compared to placebo, long-acting beta agonists alone, inhaled glucocorticoids alone, or long-acting anticholinergics alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/23,62-65\">",
"     23,62-65",
"    </a>",
"    ]. Support for these conclusions comes from the two largest trials of combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/23,64\">",
"     23,64",
"    </a>",
"    ]. In the TORCH trial described above (6112 patients with moderate to severe COPD),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    significantly improved the secondary end points of lung function, health status, and the rate of exacerbations compared to placebo, salmeterol alone, or fluticasone alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/23\">",
"     23",
"    </a>",
"    ]. Estimates of cost-effectiveness also favored the salmeterol-fluticasone combination over placebo or either of the individual agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Long-acting bronchodilators'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With respect to the primary end point of the TORCH trial, a reduction in mortality rate over three years,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    minimally decreased mortality compared to placebo (10.3 versus 12.6 percent, hazard ratio 0.81, 95% CI, 0.67-0.98). While this is only of borderline statistical significance, the actual effect on mortality may be larger than reported; in the intention to treat analysis sicker patients in the placebo group may have left the trial, seeking active treatment. The risk of death in the combination group did not differ from that in the salmeterol alone group (hazard ratio 0.95), but was significantly lower than the fluticasone alone group (hazard ratio 0.77, 95% CI, 0.64-0.93).",
"   </p>",
"   <p>",
"    The second large trial of combination therapy (Investigating New Standards for Prophylaxis in Reduction of Exacerbations, INSPIRE) included 1323 patients with stable, mostly severe COPD (mean FEV",
"    <sub>",
"     1",
"    </sub>",
"    39 percent of predicted (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    )) who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    (50 and 500",
"    <span class=\"nowrap\">",
"     microg/puff,",
"    </span>",
"    respectively) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    alone for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/64\">",
"     64",
"    </a>",
"    ]. There was no difference in the frequency of exacerbations, which was the primary endpoint, although salmeterol plus fluticasone improved several secondary endpoints, including mortality (HR for time to death 0.48, 95% CI 0.27-0.85) and health status. On the other hand, a subsequent analysis of this trial found that pneumonia was substantially more frequent in the salmeterol plus fluticasone group (HR for time to first pneumonia 1.94, 95% CI 1.19-3.17), despite the lower mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/67\">",
"     67",
"    </a>",
"    ]. Whether a lower strength preparation of fluticasone would have a similarly beneficial effect on mortality without the adverse effect on pneumonia is not known, although a prior study using the 250 microg strength of fluticasone in combination with salmeterol reported a similar increase in the number of pneumonias compared with salmeterol alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/61\">",
"     61",
"    </a>",
"    ]. These data are insufficient to warrant a change in the current guidelines in which the first step is initiation of a long-acting bronchodilator alone rather than the combination of a long-acting beta agonist plus an inhaled glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5463?source=see_link&amp;anchor=H9#H9\">",
"     \"Role of inhaled glucocorticoid therapy in stable COPD\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A question that has been less well studied is whether it would be preferable to add a second long-acting bronchodilator (from the alternate class) or an inhaled glucocorticoid in patients whose disease in not well-controlled with a single long-acting bronchodilator. This was addressed in a randomized trial in which 592 patients with moderate to severe COPD were assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/69\">",
"     69",
"    </a>",
"    ]. After six weeks, lung function was better in the tiotropium-formoterol group as evidenced by an increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    of 103 mL. Rescue medication use did not differ significantly between the groups; other important endpoints, including exacerbations and mortality, were not assessed.",
"   </p>",
"   <p>",
"    The combination of a long-acting anticholinergic plus an inhaled glucocorticoid has not been compared to a long-acting anticholinergic alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients continue to have symptoms or repeated exacerbations of COPD despite therapy with an optimal long-acting inhaled bronchodilator plus an inhaled glucocorticoid (eg, GOLD III or IV) (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ). Evaluating for comorbid conditions that may be contributing to dyspnea (eg, continued smoking, coronary heart disease, heart failure, deconditioning, pulmonary hypertension, thromboembolic disease, respiratory muscle weakness) and poor exercise tolerance may reveal additional therapeutic options.",
"   </p>",
"   <p>",
"    When managing patients with refractory disease, we assess for exercise-related oxygen desaturation using oximetry during a stair climb or six-minute walk; supplemental oxygen is added, if needed. Other nonpharmacologic therapies, including education about proper inhaler technique and use, pulmonary rehabilitation, and smoking cessation should be part of standard management. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Supplemental therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A small number of carefully selected patients may benefit from surgical intervention. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Triple inhaler therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe COPD, triple inhaler therapy with a long-acting beta agonist plus an inhaled glucocorticoid plus a long-acting anticholinergic is often used. The validity of this approach is supported by the following studies that compare triple inhaler therapy to double therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits of triple therapy are suggested by the UPLIFT trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/48\">",
"       48",
"      </a>",
"      ]. In this trial, patients were randomized to receive usual COPD care with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      ; with two-thirds of the patients using an inhaled long acting beta agonist (LABA) and an inhaled glucocorticoid (ICS) as their usual care. The addition of tiotropium to those patients receiving a LABA and an ICS as usual care significantly improved airflows, reduced exacerbations, and improved health related quality of life.",
"     </li>",
"     <li>",
"      A retrospective study of two cohorts of patients with COPD cared for in the Veterans Affairs (VA) system compared a regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      plus inhaled LABA plus ICS to a historic, matched COPD population treated with an inhaled LABA plus ICS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/70\">",
"       70",
"      </a>",
"      ]. The triple combination was associated with a decreased risk of mortality, COPD exacerbations, and hospitalizations. On the other hand, combinations that included tiotropium plus other medications were not associated with these benefits.",
"     </li>",
"     <li>",
"      In a separate retrospective cohort study, 1857 patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      plus ICS plus LABA were compared to 996 taking ICS plus LABA for a mean follow up of 4.6 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/71\">",
"       71",
"      </a>",
"      ]. The group taking triple therapy had a lower mortality (HR 0.65, 95% CI 0.57-0.75), as well as fewer hospital admissions and courses of oral glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have shown a benefit to triple therapy compared with single agent therapy in moderate to severe COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind trial, 449 patients with moderate or severe COPD were randomly assigned to one of three treatment groups:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      plus placebo, tiotropium plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      , or tiotropium plus both salmeterol and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      for one year; the latter two groups were compared with tiotropium alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/72\">",
"       72",
"      </a>",
"      ]. Triple therapy, when compared to tiotropium alone, was associated with significant improvements in lung function and disease-specific quality of life and a reduction in all-cause hospitalizations, but not a reduction in overall exacerbation rate.",
"     </li>",
"     <li>",
"      In a 12 week randomized trial, 660 subjects with moderate to severe COPD were randomly assigned to a regimen of inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      or to inhaled tiotropium alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/73\">",
"       73",
"      </a>",
"      ]. The number of severe exacerbations was significantly lower in the triple therapy group. In addition, statistically significant improvements were noted in prebronchodilator FEV",
"      <sub>",
"       1",
"      </sub>",
"      and morning symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to triple inhaler therapy, another option that may be tried is adding a low dose of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    . Its mechanisms are controversial and numerous, but modest bronchodilation certainly plays a role. A meta-analysis of 20 randomized, controlled trials demonstrated that theophylline improved FEV",
"    <sub>",
"     1",
"    </sub>",
"    , forced vital capacity (FVC), and gas exchange compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/74\">",
"     74",
"    </a>",
"    ]. Improvement in exercise performance depended on the method of testing. Similarly, in a randomized crossover trial of 60 patients with COPD, theophylline decreased dyspnea and improved gas exchange, lung function, and respiratory muscle function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25031?source=see_link\">",
"     \"Role of methylxanthines in the treatment of COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-acting extended-release preparations are available. Use of such a preparation at night may reduce nocturnal decrements in respiratory function and morning respiratory symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    can be toxic. Theophylline is metabolized in the liver and any process that interferes with liver function can rapidly change theophylline levels. In addition, many drugs can interact with theophylline, requiring close monitoring of drug levels and awareness of these issues. In general, patients with COPD can be adequately treated with serum levels in the 8 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    range. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/16/13578?source=see_link\">",
"     \"Theophylline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204741580\">",
"    <span class=\"h2\">",
"     PDE-4 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphodiesterase-4 (PDE-4) inhibition decreases inflammation and may promote airway smooth muscle relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/77-82\">",
"     77-82",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35060?source=see_link\">",
"     Roflumilast",
"    </a>",
"    is an oral, PDE-4 inhibitor that is approved for use in patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. The FDA approved indication is for the reduction of exacerbations in patients with chronic bronchitis, severe or very severe airflow limitation, and a history of exacerbations. The effects of PDE-4 inhibitors have been examined in several randomized trials and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/87-92\">",
"     87-92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 23 randomized trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35060?source=see_link\">",
"       roflumilast",
"      </a>",
"      or cilomilast versus placebo found that treatment with a PDE-4 inhibitor resulted in a modest improvement in the forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) (45.59 mL, 95% CI 39.1 to 52.03) and a reduced likelihood of an exacerbation (OR 0.78, 95% CI 0.72 to 0.85), but had little effect on quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35060?source=see_link\">",
"       Roflumilast",
"      </a>",
"      significantly improved prebronchodilator FEV",
"      <sub>",
"       1",
"      </sub>",
"      and decreased the rate of moderate to severe exacerbations in a 52 week, randomized trial of 3091 patients with COPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/90\">",
"       90",
"      </a>",
"      ]. Compared to placebo, roflumilast decreased exacerbations (17 percent [95%, CI 8-25]).",
"     </li>",
"     <li>",
"      In 24 week trials, 933 patients with moderate to severe COPD were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35060?source=see_link\">",
"       roflumilast",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      or salmeterol alone and 743 patients were randomly assigned to roflumilast plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      or tiotropium alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/92\">",
"       92",
"      </a>",
"      ]. Roflumilast significantly improved the primary endpoint, the prebronchodilator FEV",
"      <sub>",
"       1",
"      </sub>",
"      , in both trials. Side effects of nausea, diarrhea, and weight loss were more frequent in the roflumilast groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35060?source=see_link\">",
"     roflumilast",
"    </a>",
"    is approved in the United States for COPD patients with a history of exacerbations, the magnitude of benefit on lung function is modest. The use of a once daily oral medication in COPD is enticing; however, the medication should be used as a maintenance therapy to prevent exacerbations rather than to improve other COPD outcomes. Whether roflumilast provides additional benefits when combined with other respiratory medications (eg,",
"    <span class=\"nowrap\">",
"     LABA/inhaled",
"    </span>",
"    glucocorticoid combination) that are used to reduce COPD exacerbation frequency remains unknown and is currently under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RARELY USED MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids have long been used to treat exacerbations in patients with COPD; however, chronic use can have significant adverse effects and has been associated with an increase in morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. The roles of systemic glucocorticoids in the treatment of acute exacerbations of COPD and in chronic stable COPD are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10360?source=see_link\">",
"     \"Role of systemic glucocorticoid therapy in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In brief, long-term systemic glucocorticoid therapy is not recommended, even for severe COPD, because of the significant side effects and evidence of increased morbidity and mortality with this therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. In the uncommon circumstance when they are occasionally used, systemic glucocorticoids should be reduced to the lowest dose possible. Also, objective measures of improvement (eg, spirometry, walk test) must be obtained as emotional and euphoric effects of systemic glucocorticoids can cloud a patient's perception of benefit even if no true pulmonary improvement has been obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mucoactive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thick, tenacious secretions can be a major problem in patients with COPD, but there is little evidence that thinning or increasing the clearance of secretions induces clinical improvement. Thus, mucoactive agents are not accepted as routine care for patients with stable COPD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=see_link\">",
"     \"Role of mucoactive agents in the treatment of COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral expectorants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16101?source=see_link\">",
"     guaifenesin",
"    </a>",
"    , iodides) offer little benefit to patients with COPD. As an example, one study demonstrated that iodinated glycerol improved cough and chest discomfort in some patients with chronic bronchitis; however dyspnea and lung function were unaltered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/96\">",
"     96",
"    </a>",
"    ]. This medication is no longer available in the United States.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     Acetylcysteine",
"    </a>",
"    is a mucolytic that purportedly thins the secretions of patients with chronic bronchitis. It has no effect on airflow or sputum volume, and it can induce significant bronchoconstriction when given by inhalation. Studies looking at the value of oral acetylcysteine as an antioxidant therapy for COPD were negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/97\">",
"     97",
"    </a>",
"    ]. Alternative mucolytics include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     dornase alfa",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    ), exogenous surfactant, various proteolytic agents, and various detergents. These agents require additional evaluation prior to their routine use in patients with COPD.",
"   </p>",
"   <p>",
"    Increasing fluid intake is of no value unless a patient is hypovolemic. Nebulized water or hypertonic saline is without documented benefit and may irritate the airways and induce bronchospasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chronic antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic antibiotic therapy is generally not indicated for patients with stable COPD (eg, emphysema, chronic bronchitis). However, certain antibiotics, macrolides in particular, may have antiinflammatory effects in addition to their antibiotic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7866?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of chronic macrolide therapy on COPD exacerbations was assessed in 109 patients with COPD who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    250 mg or placebo twice daily for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/98\">",
"     98",
"    </a>",
"    ]. The erythromycin group had significantly fewer exacerbations than the placebo group. Further studies are needed before considering regular use of chronic macrolide therapy, particularly to assess potential side effects, including selection of resistant organisms.",
"   </p>",
"   <p>",
"    Patients whose COPD is associated with, bronchiectasis may benefit from chronic antibiotic therapy. The treatment of bronchiectasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonimmunized patients with COPD who are at high risk for contracting influenza",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have early acute influenza infections may benefit from antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with stable severe COPD (especially GOLD Stage IV disease) have chronic hypoxemia. It is important that this be detected because long-term oxygen therapy improves survival and quality of life in hypoxemic patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/8,9,100-103\">",
"     8,9,100-103",
"    </a>",
"    ]. Improved survival may be due, in part, to improved pulmonary hemodynamics. Improved quality of life is likely due to reduced dyspnea during exercise, which improves performance of activities of daily living.",
"   </p>",
"   <p>",
"    Long-term oxygen therapy should be prescribed for all patients with COPD who have chronic hypoxemia (PaO",
"    <sub>",
"     2",
"    </sub>",
"    &le;55 mmHg or SpO",
"    <sub>",
"     2",
"    </sub>",
"    &le;88 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/19\">",
"     19",
"    </a>",
"    ]. The benefits, indications, and prescription of supplemental oxygen are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial blood gases and pulse oximetry are the only reliable methods of detecting hypoxemia in patients with COPD because most patients have few if any symptoms that can specifically be related to decreased oxygenation. Arterial blood gas analysis is also helpful in assessing the presence and severity of hypercapnia, which can complicate oxygen therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients can become hypoxemic during airline travel since planes are not always pressurized to sea level. Supplemental oxygen is recommended for individuals whose in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    is expected to fall below 50 mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/22/33122?source=see_link\">",
"     \"Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Secretion clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, there is little evidence that routine thinning or increasing the clearance of secretions induces clinical improvement. However, selected patients who have excessive secretions or an ineffective cough may benefit from techniques such as postural drainage, positive expiratory pressure therapy, forced expiratory technique, and flutter valve therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encouraging smoking cessation is essential because smoking cessation can reduce the rate of FEV",
"    <sub>",
"     1",
"    </sub>",
"    decline that exists in smokers with COPD. As an example, the Lung Health Study reported a decline in postbronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    of 54.2 and 66.1 mL in women and men, respectively, who continued to smoke over an 11 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/107\">",
"     107",
"    </a>",
"    ]. Women and men who were sustained quitters of smoking had an FEV",
"    <sub>",
"     1",
"    </sub>",
"    decline of only 21.5 and 30.2 mL per year, respectively.",
"   </p>",
"   <p>",
"    Interventions that assist smoking cessation include clinician advice and encouragement, nicotine replacement therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    , and counseling. The best cessation rates are achieved when counseling is combined with medication therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"     \"Patient information: Quitting smoking (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a common cause of COPD exacerbation. Vaccinations can prevent some infections and should be offered to patients with stable COPD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       Pneumococcal polysaccharide vaccine",
"      </a>",
"      should be offered to all patients with COPD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An annual influenza vaccine should be given to all patients, particularly those with COPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/109-112\">",
"       109-112",
"      </a>",
"      ]. In a randomized, placebo-controlled trial of 125 patients with COPD, vaccination reduced the incidence of influenza by 76 percent, regardless of the severity of underlying COPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/109\">",
"       109",
"      </a>",
"      ]. The influenza vaccination itself does not increase the risk of acute exacerbation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/113\">",
"       113",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive pulmonary rehabilitation has been shown to improve exercise capacity, improve quality of life, decrease dyspnea, and decrease health care utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/114-118\">",
"     114-118",
"    </a>",
"    ]. In addition, it may reduce mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/118\">",
"     118",
"    </a>",
"    ]. Given these benefits, which have been shown to persist for up to 18 months, pulmonary rehabilitation should be considered as an addition to medication therapy for symptomatic patients who have GOLD Stage II, III, or IV COPD (",
"    <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education is an important part of managing patients with COPD and is a routine component of pulmonary rehabilitation. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Information for patients'",
"    </a>",
"    below.) Topics about which patients should be informed include reducing risk factors, appropriate administration and use of medications, recognizing and treating exacerbations, minimizing dyspnea, recognizing and treating complications, using long-term supplemental oxygen, and making end-of-life decisions. Discussions about advance directives and end-of-life care are an important component of management of COPD, particularly for patients who have advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assessing disease severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patient education encourages self-management by the patient, as well as partnership between the patient and clinician. The effects include enhanced health, better adherence to the treatment plan, fewer hospitalizations, and fewer emergency visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/120-122\">",
"     120-122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 30 percent of patients with severe COPD have protein-calorie malnutrition. This is associated with increased mortality, impaired respiratory muscle function, and diminished immune competence. High caloric dietary supplements and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    (Megace, an appetite stimulant) have been used in an effort to combat malnutrition. However, there is no evidence that either imparts long-term benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/39/43639?source=see_link\">",
"     \"Nutritional support in advanced lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxidative damage due to oxidant-antioxidant imbalance has been proposed as a cause of COPD. Thus, it has been hypothesized that antioxidants may prevent disease progression. However, controlled clinical trials are needed before antioxidant vitamins can be recommended for the routine management of patients with stable COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19097752\">",
"    <span class=\"h2\">",
"     Noninvasive positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive ventilatory support is sometimes useful in the treatment of acute or severe chronic respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link&amp;anchor=H15#H15\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'COPD exacerbation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/39/19063?source=see_link\">",
"     \"Nocturnal ventilatory support in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carefully selected patients may benefit from lung volume reduction surgery (LVRS) or lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Lung volume reduction surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Emphysema Treatment Trial (NETT) enrolled 1218 patients with severe emphysema and compared lung volume reduction surgery (LVRS) to maximal medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/125\">",
"     125",
"    </a>",
"    ]. Following a baseline assessment, the patients underwent six to ten weeks of mandatory pulmonary rehabilitation and were then randomly assigned to LVRS or continued medical therapy. The efficacy of LVRS varied among patient groups, but there was an overall survival advantage that was most marked in patients with upper lobe emphysema and low exercise capacity. On the other hand, safety monitoring detected a marked increase in early mortality in patients with an FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;20 percent predicted and either a DLCO &lt;20 percent predicted or homogeneous changes on chest CT; enrollment of such patients was discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with lung transplantation for severe COPD is complex. Ample evidence suggests that functional capacity is improved following the procedure, but the presence of a survival benefit is less clear (",
"    <a class=\"graphic graphic_figure graphicRef57297 \" href=\"mobipreview.htm?38/5/38992\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/127-129\">",
"     127-129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link&amp;anchor=H9#H9\">",
"     \"Lung transplantation: General guidelines for recipient selection\", section on 'Chronic obstructive pulmonary disease (COPD)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to define disease severity as precisely as possible in order to determine which patients have the most urgent need for lung transplantation and are likely to have the longest survival after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/130\">",
"     130",
"    </a>",
"    ]. Guidelines for timing a referral for a transplant evaluation for patients with COPD and emphysema due to alpha-1 antitrypsin deficiency include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/127\">",
"     127",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      BODE index &gt;5",
"     </li>",
"     <li>",
"      Post-bronchodilator FEV",
"      <sub>",
"       1",
"      </sub>",
"      &lt;25 percent of predicted",
"     </li>",
"     <li>",
"      Resting hypoxemia, defined as PaO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;55 to 60 mmHg",
"     </li>",
"     <li>",
"      Hypercapnia",
"     </li>",
"     <li>",
"      Secondary pulmonary hypertension",
"     </li>",
"     <li>",
"      Accelerated decline in FEV",
"      <sub>",
"       1",
"      </sub>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transplantation is usually deferred until the BODE index is seven or higher, the FEV",
"    <sub>",
"     1",
"    </sub>",
"    is below 20 percent of predicted, the diffusing capacity for carbon monoxide (DLCO) is below 20 percent of predicted, there is a homogeneous distribution of emphysema, or the clinical course becomes more aggressive with life-threatening exacerbations (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/125,127\">",
"     125,127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35351?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\", section on 'BODE index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link&amp;anchor=H17914506#H17914506\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19097853\">",
"    <span class=\"h1\">",
"     PALLIATIVE TREATMENT OF DYSPNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care aims to relieve suffering at all stages of disease and is not limited to end of life care. Opiates may be of benefit for relief of dyspnea in selected patients, such as those with dyspnea unresponsive to the conventional approaches described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. The optimal dose and timing of opiate medication for control of dyspnea in COPD are not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=see_link&amp;anchor=H1646277#H1646277\">",
"     \"Assessment and management of dyspnea in palliative care\", section on 'Opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-eight opiate-na&iuml;ve patients with dyspnea predominantly due to COPD were randomly assigned to oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      20 mg sustained release once daily or placebo for four days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/133\">",
"       133",
"      </a>",
"      ]. Morphine was associated with significant improvements in dyspnea and sleep, although constipation was a substantial adverse effect.",
"     </li>",
"     <li>",
"      In a separate dose-ranging study among 48 patients, oral sustained release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      at 10 mg per day provided relief of dyspnea in 19 patients, 20 mg provided relief in another 5, and 30 mg provided relief in 3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/134\">",
"       134",
"      </a>",
"      ]. Four patients were unable to tolerate adverse effects. Overall, 27 patients continued on a stable dose of morphine without dose escalation, loss of effect, or adverse effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the risks of respiratory depression, relatively low doses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    short acting preparations are preferred for initial therapy. Choices include short-acting preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    for chronic, persistent dyspnea and rapid onset agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    buccal or sublingual tablets for episodic dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/131,135\">",
"     131,135",
"    </a>",
"    ]. Careful monitoring and individual titration is required because of adverse effects, such as excess somnolence, cognitive dysfunction, hallucinations, nausea, and constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anxiety, depression, and dyspnea are often intertwined and attempts to characterize which symptom is the dominant or primary problem for an individual patient can be difficult. Indeed, hyperventilation from anxiety can often accentuate and occasionally overwhelm patients with dyspnea. Pulmonary rehabilitation can lead to a major improvement in patients with dyspnea, anxiety, and depression and should be strongly considered, especially if the use of opiates is being considered. In addition, psychoactive agents and cognitive behavioral therapy can be helpful in selected patients with anxiety or depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/131,136-138\">",
"     131,136-138",
"    </a>",
"    ]. Respiratory stimulants are not beneficial to these patients and can often accentuate dyspnea, even in those with hypercapnic COPD. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Rehabilitation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with advanced COPD may also benefit from hospice care (",
"    <a class=\"graphic graphic_table graphicRef61282 \" href=\"mobipreview.htm?18/51/19262\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several novel therapies for COPD are being investigated. These therapies include anti-proteases and inhibitors of inflammatory signaling pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Antiproteases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of alpha-1 antitrypsin deficiency as a cause of emphysema increased awareness that an imbalance of various proteases and antiproteases can cause COPD. For patients with alpha-1 antitrypsin deficiency, research suggests that infusions of pooled human plasma alpha-1 antitrypsin (so-called augmentation therapy) may slow the rate of disease progression. The use of antiproteases to treat alpha-1 deficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16361?source=see_link\">",
"     \"Treatment of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New antiproteinases are at various stages of development, including compounds designed to block the effects of neutrophil elastase and matrix metalloproteinases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/26/39338/abstract/139\">",
"     139",
"    </a>",
"    ]. However, these agents have not undergone large-scale clinical trials and remain unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/59/5043?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/46/6883?source=see_link\">",
"       \"Patient information: Shortness of breath (dyspnea) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=see_link\">",
"       \"Patient information: How to use your dry powder inhaler (adults) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/11/24755?source=see_link\">",
"       \"Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD) is a common condition with a high mortality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A staging system for COPD severity has been developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). This staging system defines disease severity according to degree of airflow limitation, risk of exacerbation, and symptoms. It can be used as a guide for the management of patients with stable COPD (",
"      <a class=\"graphic graphic_table graphicRef54300 \" href=\"mobipreview.htm?5/62/6126\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessing disease severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with COPD, we recommend that a short-acting bronchodilator (eg, beta-agonist, anticholinergic agent) be prescribed for use as-needed for relief of intermittent increases in dyspnea (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients not on a long-acting anticholinergic agent, a combination short-acting beta-agonist PLUS a short-acting anticholinergic, rather than either alone, may be prescribed to achieve a greater acute bronchodilator benefit. For patients on a long-acting anticholinergic agent, a short-acting beta agonist is generally used for quick relief of COPD symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Short-acting bronchodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with COPD in whom intermittent short-acting bronchodilators are insufficient to control symptoms or who have other high-risk predictors, including severe or very severe airflow obstruction or two or more exacerbations in the previous year, we recommend adding a regularly scheduled long-acting inhaled bronchodilator (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The purpose of the long-acting inhaled bronchodilator is to improve symptoms, improve lung function, and reduce the frequency of exacerbations. In our clinical practice, we prefer the long-acting inhaled anticholinergic agent to the twice daily long-acting beta agonists. However, the once daily long-acting beta agonist is a reasonable alternative depending on the patient&rsquo;s symptoms and potential medication adverse effects.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      is the least preferred long-acting bronchodilator option because its effects are modest and toxicity is a concern. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Long-acting bronchodilators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Theophylline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who continue to have symptoms or have repeated exacerbations despite an optimal long-acting inhaled bronchodilator regimen, we suggest adding an inhaled glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In our clinical practice:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We add an inhaled glucocorticoid alone when the existing long-acting inhaled bronchodilator regimen includes a long-acting inhaled beta agonist.",
"     </li>",
"     <li>",
"      We add the combination of an inhaled glucocorticoid plus a long-acting inhaled beta agonist when the existing long-acting inhaled bronchodilator regimen does not include a long-acting inhaled beta agonist.",
"     </li>",
"     <li>",
"      An inhaled glucocorticoid may be warranted earlier (ie, at the same time that the long-acting inhaled bronchodilator is initiated) if there are signs of inflammation or an asthmatic component to the COPD. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For symptomatic patients with GOLD Stage II, III, or IV COPD, we recommend pulmonary rehabilitation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The purpose of pulmonary rehabilitation is to improve symptoms, exercise capacity, and quality of life. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend long-term oxygen therapy in all patients with COPD who have chronic hypoxemia (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with COPD should be advised to quit smoking, educated about COPD, and given a yearly influenza vaccination. In addition, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      should be given to all patients with COPD. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Smoking cessation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Patient education'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Vaccinations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who continue to have significant symptoms despite the above interventions may be considered for surgical therapy. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/1\">",
"      Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/2\">",
"      Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27:397.",
"     </a>",
"    </li>",
"    <li>",
"     Hoyert DL, Xu J.. Deaths: Preliminary data for 2011. National Vital Statistics Reports; US Department of Health and Human Services, 2012.",
"    </li>",
"    <li>",
"     Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2011. www.goldcopd.org (Accessed on January 24, 2013).",
"    </li>",
"    <li>",
"     COPD Assessment Test (CAT). file://www.catestonline.org (Accessed on October 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/6\">",
"      Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/7\">",
"      Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/8\">",
"      Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/9\">",
"      Man SF, McAlister FA, Anthonisen NR, Sin DD. Contemporary management of chronic obstructive pulmonary disease: clinical applications. JAMA 2003; 290:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/10\">",
"      Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/11\">",
"      Hanania NA, Celli BR, Donohue JF, Martin UJ. Bronchodilator reversibility in COPD. Chest 2011; 140:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/12\">",
"      In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/13\">",
"      Ram FS, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/14\">",
"      Cook D, Guyatt G, Wong E, et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/15\">",
"      Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 2012; 142:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/16\">",
"      Wadbo M, L&ouml;fdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/17\">",
"      Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996; 100:11S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/18\">",
"      Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/19\">",
"      Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/20\">",
"      Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/21\">",
"      Cazzola M, Donner CF. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/22\">",
"      van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/23\">",
"      Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/24\">",
"      Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/25\">",
"      Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/26\">",
"      Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/27\">",
"      Rabe KF. Treating COPD--the TORCH trial, P values, and the Dodo. N Engl J Med 2007; 356:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/28\">",
"      Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting &beta;-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/29\">",
"      Donohue JF, Fogarty C, L&ouml;tvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/30\">",
"      Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/31\">",
"      Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011; 105:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/32\">",
"      Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 &mu;g once daily in patients aged &ge;40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011; 33:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/33\">",
"      Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/34\">",
"      Indacterol (Arcapta Neohaler) for COPD. Med Lett Drugs Ther 2012; 54:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/35\">",
"      Jiang FM, Liang ZA, Zheng QL, et al. Safety and Efficacy of 12-Week or Longer Indacaterol Treatment in Moderate-to-Severe COPD Patients: A Systematic Review. Lung 2013; 191:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/36\">",
"      Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/37\">",
"      Chowdhury BA, Seymour SM, Michele TM, et al. The risks and benefits of indacaterol--the FDA's review. N Engl J Med 2011; 365:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/38\">",
"      Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/39\">",
"      Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/40\">",
"      Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/41\">",
"      Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/42\">",
"      Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/43\">",
"      Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/44\">",
"      O'Donnell DE, Fl&uuml;ge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/45\">",
"      Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/46\">",
"      Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/47\">",
"      Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/48\">",
"      Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/49\">",
"      Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/50\">",
"      Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD009157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/51\">",
"      Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 4:CD008989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/52\">",
"      van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/53\">",
"      Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/54\">",
"      Sin DD, Paul Man SF. Cooling the fire within: inhaled corticosteroids and cardiovascular mortality in COPD. Chest 2006; 130:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/55\">",
"      Pinto-Plata VM, M&uuml;llerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/56\">",
"      Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/57\">",
"      Ozol D, Aysan T, Solak ZA, et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005; 99:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/58\">",
"      Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/59\">",
"      Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/60\">",
"      Bart G. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:218; author reply 218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/61\">",
"      Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/62\">",
"      Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/63\">",
"      Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/64\">",
"      Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/65\">",
"      Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/66\">",
"      Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010; 35:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/67\">",
"      Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/68\">",
"      Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; :CD007891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/69\">",
"      Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/70\">",
"      Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/71\">",
"      Short PM, Williamson PA, Elder DH, et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting &beta;-agonist therapy in COPD. Chest 2012; 141:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/72\">",
"      Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/73\">",
"      Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/74\">",
"      Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; :CD003902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/75\">",
"      Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/76\">",
"      Martin RJ, Pak J. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/77\">",
"      Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/78\">",
"      Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003; 63:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/79\">",
"      Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/80\">",
"      Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/81\">",
"      Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/82\">",
"      Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005; 11:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/83\">",
"      Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001; 10:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/84\">",
"      Reid P. Roflumilast Altana Pharma. Curr Opin Investig Drugs 2002; 3:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/85\">",
"      Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003; 58:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/86\">",
"      Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/87\">",
"      Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006; 129:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/88\">",
"      Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/89\">",
"      Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/90\">",
"      Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/91\">",
"      Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; :CD002309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/92\">",
"      Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/93\">",
"      Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001; 17:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/94\">",
"      Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD005374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/95\">",
"      Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/96\">",
"      Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/97\">",
"      Decramer M, Rutten-van M&ouml;lken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/98\">",
"      Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/99\">",
"      He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010; 80:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/100\">",
"      Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/101\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/102\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/103\">",
"      Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/104\">",
"      Wolkove N, Kamel H, Rotaple M, Baltzan MA Jr. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest 2002; 121:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/105\">",
"      Fagevik Ols&eacute;n M, Westerdahl E. Positive expiratory pressure in patients with chronic obstructive pulmonary disease--a systematic review. Respiration 2009; 77:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/106\">",
"      Fink JB. Forced expiratory technique, directed cough, and autogenic drainage. Respir Care 2007; 52:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/107\">",
"      Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/108\">",
"      Warnier MJ, van Riet EE, Rutten FH, et al. Smoking cessation strategies in patients with COPD. Eur Respir J 2013; 41:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/109\">",
"      Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/110\">",
"      Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/111\">",
"      Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; :CD002733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/112\">",
"      Calder&oacute;n-Larra&ntilde;aga A, Carney L, Soljak M, et al. Association of population and primary healthcare factors with hospital admission rates for chronic obstructive pulmonary disease in England: national cross-sectional study. Thorax 2011; 66:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/113\">",
"      Tata LJ, West J, Harrison T, et al. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003; 58:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/114\">",
"      Narvaez R, Moors K, Miller R, Ramirez M. Risks in using nonrigorous spanish translations of asthma questionnaires. Chest 2007; 131:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/115\">",
"      Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/116\">",
"      Ries AL, Make BJ, Lee SM, et al. The effects of pulmonary rehabilitation in the national emphysema treatment trial. Chest 2005; 128:3799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/117\">",
"      G&uuml;ell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest 2000; 117:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/118\">",
"      Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review. Respir Res 2005; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/119\">",
"      Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J 2008; 32:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/120\">",
"      Make B. Collaborative self-management strategies for patients with respiratory disease. Respir Care 1994; 39:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/121\">",
"      Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/122\">",
"      Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/123\">",
"      Weisberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002; 121:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/124\">",
"      Wouters EF. Management of severe COPD. Lancet 2004; 364:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/125\">",
"      Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/126\">",
"      National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/127\">",
"      Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/128\">",
"      Studer SM, Levy RD, McNeil K, Orens JB. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 2004; 24:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/129\">",
"      de Perrot M, Chaparro C, McRae K, et al. Twenty-year experience of lung transplantation at a single center: Influence of recipient diagnosis on long-term survival. J Thorac Cardiovasc Surg 2004; 127:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/130\">",
"      Nunley DR, Bauldoff GS, Holloman CH, Pope-Harman A. The lung allocation score and survival in lung transplant candidates with chronic obstructive pulmonary disease. Lung 2009; 187:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/131\">",
"      Horton R, Rocker G. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Curr Opin Support Palliat Care 2010; 4:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/132\">",
"      Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009; 64:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/133\">",
"      Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327:523.",
"     </a>",
"    </li>",
"    <li>",
"     Currow DC, Kenny B, McDonald F et al. Multi-site open label dose ranging study to determine the minimum effective dose of sustained release morphine (SRM) for reducing refractory dyspnea. file://www.eapcnet.org/vienna2009/download/Vienna_Abstracts_2009.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/135\">",
"      Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/136\">",
"      Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. Psychol Med 2008; 38:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/137\">",
"      Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134:43S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/138\">",
"      Jordan N, Lee TA, Valenstein M, et al. Effect of depression care on outcomes in COPD patients with depression. Chest 2009; 135:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/26/39338/abstract/139\">",
"      Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364:985.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1447 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39338=[""].join("\n");
var outline_f38_26_39338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSING DISEASE SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BRONCHODILATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Short-acting bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Comparison",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Long-acting bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Anticholinergic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Comparison",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Combined therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Triple inhaler therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H204741580\">",
"      PDE-4 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RARELY USED MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mucoactive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chronic antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUPPLEMENTAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Secretion clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19097752\">",
"      Noninvasive positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Lung volume reduction surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19097853\">",
"      PALLIATIVE TREATMENT OF DYSPNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Antiproteases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1447|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/5/38992\" title=\"figure 1\">",
"      Survival by diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/28/35275\" title=\"table 1\">",
"      Severity of airflow limitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/62/6126\" title=\"table 2\">",
"      Therapy by stage COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/62/12267\" title=\"table 3\">",
"      MMRC dyspnea scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/51/19262\" title=\"table 4\">",
"      Disease specific guidelines for hospice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=related_link\" title=\"calculator 1\">",
"      Calculator: BODE Index for COPD survival prediction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/21/8538?source=related_link\">",
"      Arrhythmias in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30666?source=related_link\">",
"      Assessment and management of dyspnea in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35351?source=related_link\">",
"      Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6089?source=related_link\">",
"      Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17898?source=related_link\">",
"      Management of the patient with severe COPD and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/39/19063?source=related_link\">",
"      Nocturnal ventilatory support in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/39/43639?source=related_link\">",
"      Nutritional support in advanced lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/11/24755?source=related_link\">",
"      Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/22/33122?source=related_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33305?source=related_link\">",
"      Role of anticholinergic therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5463?source=related_link\">",
"      Role of inhaled glucocorticoid therapy in stable COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25031?source=related_link\">",
"      Role of methylxanthines in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=related_link\">",
"      Role of mucoactive agents in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10360?source=related_link\">",
"      Role of systemic glucocorticoid therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16361?source=related_link\">",
"      Treatment of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_26_39339="Diagnostic tests TVL";
var content_f38_26_39339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used diagnostic tests for amaurosis fugax",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnostic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmologic consult",
"       </td>",
"       <td>",
"        All patients with GCA, retinal vein disease, suspected ocular",
"disease, TMVL from suspected thromboembolic disease or uncertain cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ESR and CRP",
"       </td>",
"       <td>",
"        All patients &gt;50 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotid imaging (carotid duplex ultrasound, MRA, CTA)",
"       </td>",
"       <td>",
"        Patients with TMVL &gt;50 years or with risk factors, or suspected dissection, or uncertain cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac evaluation for embolic source",
"       </td>",
"       <td>",
"        Patients with TMVL &gt;50 years or with risk factors, or with suspected VBI, or TMVL of unccertain cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ECG",
"       </td>",
"       <td>",
"        All patients with suspected ischemia (of brain or eye)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercoaguable testing",
"       </td>",
"       <td>",
"        Patients with history or family history of thrombosis or with probable ischemia and negative workup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain MRI",
"       </td>",
"       <td>",
"        Binocular symptoms atypical for migraine, possible optic neuropathy, seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EEG",
"       </td>",
"       <td>",
"        Suspected seizure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GCA: giant cell arteries; TMVL: transient monocular visual loss; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MRA: magnetic resonance angiography; CTA: computed tomography angiography; VBI: vertebrobasilar ischemia; ECG: electrocardiogram; MRI: magnetic resonance imaging; EEG: electroencephalography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39339=[""].join("\n");
var outline_f38_26_39339=null;
var title_f38_26_39340="Risk of HCW acquiring pathogens";
var content_f38_26_39340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of acquisition of bloodborne pathogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        HBV",
"       </td>",
"       <td class=\"subtitle1\">",
"        HCV",
"       </td>",
"       <td class=\"subtitle1\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seroprevalance, general population",
"       </td>",
"       <td>",
"        0.42 percent (95 percent CI, 0.32-0.55)",
"       </td>",
"       <td>",
"        1.8 percent (95 percent CI, 1.5-2.3)",
"       </td>",
"       <td>",
"        0.31-0.42 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seroprevalance in HCW compared to general population",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Similar",
"       </td>",
"       <td>",
"        Similar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral particles/mL of serum or plasma",
"       </td>",
"       <td>",
"        10",
"        <sup>",
"         2",
"        </sup>",
"        -10",
"        <sup>",
"         8",
"        </sup>",
"       </td>",
"       <td>",
"        1-&gt;10",
"        <sup>",
"         6",
"        </sup>",
"       </td>",
"       <td>",
"        1-10",
"        <sup>",
"         7",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Risk of infection by mode of exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Percutaneous",
"       </td>",
"       <td>",
"        6-30 percent",
"       </td>",
"       <td>",
"        1.8 percent (range, 0-7 percent)",
"       </td>",
"       <td>",
"        0.3 percent (95 percent CI, 0.2-0.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucosal",
"       </td>",
"       <td>",
"        Risk not quantified, transmission documented",
"       </td>",
"       <td>",
"        Risk not quantified, transmission documented",
"       </td>",
"       <td>",
"        0.09 percent (95 percent CI, 0.006-0.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonintact skin",
"       </td>",
"       <td>",
"        Risk not quantified, transmission not documented",
"       </td>",
"       <td>",
"        Risk not quantified, transmission not documented",
"       </td>",
"       <td>",
"        &lt;0.1 percent, risk not completely quantified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human bite",
"       </td>",
"       <td>",
"        Risk not quantified, transmission documented",
"       </td>",
"       <td>",
"        Risk not quantified, transmission documented",
"       </td>",
"       <td>",
"        Risk not quantified, possible transmission reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Infective material leading to HCW infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Documented",
"       </td>",
"       <td>",
"        Blood, blood products",
"       </td>",
"       <td>",
"        Blood, immunoglobulin preparations",
"       </td>",
"       <td>",
"        Blood, blood products, bloody fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Possible",
"       </td>",
"       <td>",
"        Semen, vaginal fluid, bloody fluids, saliva",
"       </td>",
"       <td>",
"        Bloody products, bloody fluids, semen, vaginal fluid",
"       </td>",
"       <td>",
"        Semen, vaginal fluid, cerebrospinal fluid, breast milk, exudates, serosal fluids, amniotic fluid, saliva (during dental exams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unlikely",
"       </td>",
"       <td>",
"        Urine, feces",
"       </td>",
"       <td>",
"        Saliva, urine, feces",
"       </td>",
"       <td>",
"        Saliva, urine, feces",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Weber, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39340=[""].join("\n");
var outline_f38_26_39340=null;
var title_f38_26_39341="Regulation of ventilation";
var content_f38_26_39341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Regulation of ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    (left panel) and PO",
"    <sub>",
"     2",
"    </sub>",
"    (right panel) and minute ventilation in normal subjects. Stimulation of ventilation occurs with a small rise in PCO",
"    <sub>",
"     2",
"    </sub>",
"    , but requires a large fall in PO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"    <div class=\"footnotes\">",
"     PCO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial carbon dioxide tension; PO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial oxyen tension.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hudgel DW. Control of breathing. In: Bronchial Asthma: Mechanisms and Therapeutics, 2d ed, Weiss EB, Segal MS, Stein M (Eds), Little, Brown, Boston, 1984, with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39341=[""].join("\n");
var outline_f38_26_39341=null;
var title_f38_26_39342="Retinal vasculitis in toxo";
var content_f38_26_39342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal vasculitis in toxoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorescein angiogram in a patient with toxoplasmosis shows retinal vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39342=[""].join("\n");
var outline_f38_26_39342=null;
var title_f38_26_39343="Refractive error astigmatic eye";
var content_f38_26_39343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Refractive error: An uncorrected astigmatic eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The refractive power of the eye is different in different meridians. Light rays can never be brought to a single point, and objects will appear blurry at any distance. The circle of least confusion is demonstrated on the retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Yanoff M, Duker JS. Ophthalmology, Mosby 1999. Copyright &copy; 1999 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_26_39343=[""].join("\n");
var outline_f38_26_39343=null;
